{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "### Installation"
      ],
      "metadata": {
        "id": "6e1hLapo0Hvx"
      }
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6qXrSjYSuqPR",
        "outputId": "c5809e4a-b1ba-4383-ae8d-d629959c9677"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Collecting pymupdf\n",
            "  Downloading PyMuPDF-1.22.2-cp39-cp39-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (14.1 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m14.1/14.1 MB\u001b[0m \u001b[31m58.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: pymupdf\n",
            "Successfully installed pymupdf-1.22.2\n",
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Collecting Unidecode\n",
            "  Downloading Unidecode-1.3.6-py3-none-any.whl (235 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m235.9/235.9 kB\u001b[0m \u001b[31m5.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: Unidecode\n",
            "Successfully installed Unidecode-1.3.6\n"
          ]
        }
      ],
      "source": [
        "!pip install pymupdf\n",
        "!pip install Unidecode"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/gdrive')\n",
        "\n",
        "!sudo apt-get install unzip\n",
        "!unzip -q \"/content/gdrive/My Drive/CUAD_v1.zip\""
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JKGDxfiewfWY",
        "outputId": "ef8d0c69-29e6-4f9c-be5c-79ebd46f8265"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/gdrive\n",
            "Reading package lists... Done\n",
            "Building dependency tree       \n",
            "Reading state information... Done\n",
            "unzip is already the newest version (6.0-25ubuntu1.1).\n",
            "0 upgraded, 0 newly installed, 0 to remove and 24 not upgraded.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "import pandas as pd"
      ],
      "metadata": {
        "id": "HnGHtZOw2nDc"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from operator import itemgetter\n",
        "import fitz\n",
        "import json"
      ],
      "metadata": {
        "id": "N4a1jX5fyZI8"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import re \n",
        "from unidecode import unidecode "
      ],
      "metadata": {
        "id": "dI3_yzFin_3z"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import nltk\n",
        "nltk.download('punkt')\n",
        "nltk.download('stopwords')\n",
        "from nltk.tokenize import word_tokenize, sent_tokenize\n",
        "import gensim"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-ek6rkICLVmH",
        "outputId": "549448dd-f633-4c62-f5cb-b8ef4e9d0017"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Unzipping tokenizers/punkt.zip.\n",
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Unzipping corpora/stopwords.zip.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def remove_empty(df):\n",
        "  df = df.reset_index(drop=True)\n",
        "\n",
        "  for i in range(len(df)-1):\n",
        "      if df.at[i, 'content'] == '' and df.at[i, 'heading'] != '':\n",
        "          df.at[i+1, 'heading'] = df.at[i, 'heading'] + '. ' + df.at[i+1, 'heading']\n",
        "          df.drop(i, inplace=True)\n",
        "    \n",
        "      elif df.at[i, 'heading'] == '' and df.at[i, 'content'] != '':\n",
        "          df.at[i+1, 'content'] = df.at[i, 'content'] + '. ' + df.at[i+1, 'content']\n",
        "          df.drop(i, inplace=True)\n",
        "\n",
        "  return df"
      ],
      "metadata": {
        "id": "Q8z8IvbbwFRL"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def split_section_num(df):\n",
        "# Define a regex pattern to detect section numbers\n",
        "  section_pattern = re.compile(r'^\\s*(\\d*\\.\\s+|\\d*\\.|M{0,3}(CM|CD|D?C{0,3})(XC|XL|L?X{0,3})(IX|IV|V?I{0,3})\\.\\s+|M{0,3}(CM|CD|D?C{0,3})(XC|XL|L?X{0,3})(IX|IV|V?I{0,3})\\.)+')\n",
        "\n",
        "  # Define an empty list to store the results\n",
        "  result = []\n",
        "\n",
        "  # Iterate over the rows of the dataframe\n",
        "  for _, row in df.iterrows():\n",
        "    \n",
        "      # Split the content column into individual sentences\n",
        "      sentences = row['content'].split('\\n')\n",
        "\n",
        "      # Define a variable to store the heading\n",
        "      heading = None\n",
        "      \n",
        "      # Iterate over the sentences\n",
        "      for sentence in sentences:\n",
        "          # Check if the sentence is a section heading\n",
        "          if section_pattern.match(sentence):\n",
        "              # If it is, set the heading variable to the first sentence\n",
        "              heading = sentence\n",
        "              \n",
        "              # Append the section heading as a new row to the result list\n",
        "              result.append({\n",
        "                  'heading': heading,\n",
        "                  'content': ''\n",
        "              })\n",
        "          elif heading:\n",
        "              # If there is a heading, append the sentence to the content of the previous section\n",
        "              result[-1]['content'] += sentence + '\\n'\n",
        "          \n",
        "          else:\n",
        "              # If there is no heading, keep the original heading and add the sentence to the content\n",
        "              if any(r['heading'] == row['heading'] for r in result):\n",
        "                  # If a row with the same heading already exists, append the content to its existing content\n",
        "                  result[-1]['content'] += '\\n' + sentence\n",
        "              else:\n",
        "                  # Otherwise, create a new row with the original heading and the sentence as the content\n",
        "                  result.append({\n",
        "                      'heading': row['heading'],\n",
        "                      'content': sentence\n",
        "                  })\n",
        "\n",
        "  # Convert the result list to a new dataframe\n",
        "  new_df = pd.DataFrame(result)\n",
        "\n",
        "  return new_df"
      ],
      "metadata": {
        "id": "7zuH8Fkuyf0i"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def extract_segement(doc):\n",
        "  # get the spans from the PDF file\n",
        "  block_dict = {}\n",
        "\n",
        "  page_num = 1\n",
        "  for page in doc: # Iterate all pages in the document\n",
        "        file_dict = page.get_text('dict') # Get the page dictionary \n",
        "        block = file_dict['blocks'] # Get the block information\n",
        "        block_dict[page_num] = block # Store in block dictionary\n",
        "        page_num += 1 # Increase the page value by 1\n",
        "\n",
        "  # create a dictionary containing detailed information of all spans in the document and store in a DataFrame\n",
        "  spans = pd.DataFrame(columns=['xmin', 'ymin', 'xmax', 'ymax', 'text', 'tag'])\n",
        "  rows = []\n",
        "\n",
        "  for page_num, blocks in block_dict.items():\n",
        "      for block in blocks:\n",
        "          if block['type'] == 0:\n",
        "              for line in block['lines']:\n",
        "                  for span in line['spans']:\n",
        "                      xmin, ymin, xmax, ymax = list(span['bbox'])\n",
        "                      font_size = span['size']\n",
        "                      text = unidecode(span['text'])\n",
        "                      span_font = span['font']\n",
        "                      \n",
        "                      is_upper = False\n",
        "                      is_bold = False                     \n",
        "\n",
        "                      if \"bold\" in span_font.lower():\n",
        "                          is_bold = True \n",
        "                      if re.sub(\"[\\(\\[].*?[\\)\\]]\", \"\", text).isupper():\n",
        "                          is_upper = True                 \n",
        "                      if text.replace(\" \",\"\") !=  \"\":\n",
        "                          rows.append((xmin, ymin, xmax, ymax, text, is_upper, is_bold, span_font, font_size))\n",
        "                          \n",
        "  span_df = pd.DataFrame(rows, columns=['xmin','ymin','xmax','ymax', 'text', 'is_upper','is_bold','span_font', 'font_size'])\n",
        "\n",
        "  # create more features\n",
        "  \"\"\"\n",
        "  The ‘h’ tag denotes the text which is bigger and more important than normal paragraphs. (e.g. UPPER CASE and bold style)\n",
        "  The ‘p’ tag stands for paragraph, or the normal content in the document. \n",
        "  The ‘s’ tag will be used for less important text, which is smaller than ‘p’ text.\n",
        "  \"\"\"\n",
        "\n",
        "  span_scores = []\n",
        "  span_num_occur = {}\n",
        "  special = '[(_:/,#%\\=@)]'\n",
        "\n",
        "  for index, span_row in span_df.iterrows():    \n",
        "      score = round(span_row.font_size)\n",
        "      text = span_row.text    \n",
        "      if not re.search(special, text):       \n",
        "          if span_row.is_bold:\n",
        "              score +=1 \n",
        "          if span_row.is_upper:\n",
        "              score +=1\n",
        "      span_scores.append(score)\n",
        "\n",
        "  values, counts = np.unique(span_scores, return_counts=True)\n",
        "  style_dict = {}\n",
        "\n",
        "  for value, count in zip(values, counts):\n",
        "      style_dict[value] = count\n",
        "\n",
        "  sorted(style_dict.items(), key=lambda x: x[1])\n",
        "\n",
        "  p_size = max(style_dict, key=style_dict.get)\n",
        "  idx = 0\n",
        "  tag = {}\n",
        "\n",
        "  for size in sorted(values, reverse = True):\n",
        "      idx += 1\n",
        "      if size == p_size:\n",
        "          idx = 0\n",
        "          tag[size] = 'p'\n",
        "      if size > p_size:\n",
        "          tag[size] = 'h{0}'.format(idx)\n",
        "      if size < p_size:\n",
        "          tag[size] = 's{0}'.format(idx)\n",
        "\n",
        "  span_tags = [tag[score] for score in span_scores]\n",
        "  span_df['tag'] = span_tags\n",
        "\n",
        "  # define headings and paragraphs in the document\n",
        "  headings_list = []\n",
        "  text_list = []\n",
        "  tmp = []\n",
        "  heading = ''                                                                                                                \n",
        "\n",
        "  for index, span_row in span_df.iterrows():\n",
        "      text = span_row.text\n",
        "      tag = span_row.tag\n",
        "      if 'h' in tag:\n",
        "        if len(text) < 70:\n",
        "          headings_list.append(text)\n",
        "          text_list.append('\\n'.join(tmp)) \n",
        "          tmp = []\n",
        "          heading = text\n",
        "        else:\n",
        "          tmp.append(text) \n",
        "      else:\n",
        "          tmp.append(text)\n",
        "\n",
        "  text_list.append('\\n'.join(tmp))\n",
        "  text_list = text_list[1:]\n",
        "  text_df = pd.DataFrame(zip(headings_list, text_list),columns=['heading', 'content'] )\n",
        "\n",
        "  # combine the empty cells\n",
        "  text_df = remove_empty(text_df)\n",
        "\n",
        "  # split the section number out\n",
        "  new_df = split_section_num(text_df)\n",
        "\n",
        "  # combine the empty cells\n",
        "  new_df = remove_empty(new_df)\n",
        "\n",
        "  return(list(new_df['heading'] + \" \" + new_df['content']))"
      ],
      "metadata": {
        "id": "B7xWteN2oXZz"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# load the file\n",
        "my_path = '/content/CUAD_v1/full_contract_pdf/Part_I/Promotion/DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement.pdf'\n",
        "doc = fitz.open(my_path)\n",
        "my_path2 = '/content/CUAD_v1/full_contract_pdf/Part_I/Promotion/ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement.pdf'\n",
        "doc2 = fitz.open(my_path2)"
      ],
      "metadata": {
        "id": "RmXQiwK2MU7G"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "doc_1 = extract_segement(doc)\n",
        "doc_2 = extract_segement(doc2)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "iBSM5QqnMYYb",
        "outputId": "431fd439-2927-4e4b-b827-e5486414ab6b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                               heading  \\\n",
            "0               CO-PROMOTION AGREEMENT. by and between   \n",
            "1       and. VALEANT PHARMACEUTICALS NORTH AMERICA LLC   \n",
            "2       TABLE OF CONTENTS. Page. ARTICLE 1 DEFINITIONS   \n",
            "3                     ARTICLE 2 RIGHTS AND OBLIGATIONS   \n",
            "4    2.1.  Engagement? Grant of Rights.. 8. 2.2.  R...   \n",
            "..                                                 ...   \n",
            "479                                About Bausch Health   \n",
            "480          Bausch Health Forward-looking Statements    \n",
            "481                                     PM-US-DOP-0072   \n",
            "482                                    SAL.0103.USA.18   \n",
            "484  1. Stock Purchase Agreement dated March 29, 20...   \n",
            "\n",
            "                                               content  \n",
            "0                           DOVA PHARMACEUTICALS, INC.  \n",
            "1    September 26, 2018\\n__________________________...  \n",
            "2                                                    1  \n",
            "3                                                    8  \n",
            "4                                                   11  \n",
            "..                                                 ...  \n",
            "479  Bausch Health Companies Inc. (NYSE/TSX: BHC) i...  \n",
            "480  This news release may contain forward-looking ...  \n",
            "481  The Xifaxan 550 mg product and the Xifaxan tra...  \n",
            "482  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR ...  \n",
            "484  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR ...  \n",
            "\n",
            "[357 rows x 2 columns]\n",
            "                                               heading  \\\n",
            "0                                         Exhibit 10.1   \n",
            "1    PROMOTION AGREEMENT. BY AND BETWEEN. EXACT SCI...   \n",
            "2                                    TABLE OF CONTENTS   \n",
            "3                                                  2.1   \n",
            "4                                                  2.2   \n",
            "..                                                 ...   \n",
            "396                     9.13. Independent Contractors.   \n",
            "397                            9.14. No Legal Advice.    \n",
            "398                               9.15. Counterparts.    \n",
            "399            PFIZER INC.. EXACT SCIENCES CORPORATION   \n",
            "400                                     Signature Page   \n",
            "\n",
            "                                               content  \n",
            "0                                         COLOGUARD(r)  \n",
            "1    August 21, 2018\\nSource: EXACT SCIENCES CORP, ...  \n",
            "2                                                 Page  \n",
            "3                       Joint Steering Committee\\n10\\n  \n",
            "4                     Joint Operations Committee\\n13\\n  \n",
            "..                                                 ...  \n",
            "396   Both Parties are independent contractors unde...  \n",
            "397  Each Party acknowledges and agrees that the ot...  \n",
            "398  This Agreement may be executed in two (2) coun...  \n",
            "399  By /s/ Michael Gladstone\\nBy /s/ Kevin Conroy\\...  \n",
            "400        Source: EXACT SCIENCES CORP, 8-K, 8/22/2018  \n",
            "\n",
            "[401 rows x 2 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Use nltk's English stopwords\n",
        "stopwords = nltk.corpus.stopwords.words('english') \n",
        "new_stopwords = ['shall','agreement','contract','party','date','one','may','hundred','time','will','make','term','section','thousand']\n",
        "stopwords.extend('new_stopwords')"
      ],
      "metadata": {
        "id": "RKggh2T7Man3"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def similarity_para(playbook, document):\n",
        "\n",
        "  # exclude stop words and tokenize words of paragraphs (NLTK) and create dictionary of the playbook\n",
        "  gen_docs = [[w.lower() for w in word_tokenize(i) if w not in stopwords] for i in playbook]\n",
        "  dictionary = gensim.corpora.Dictionary(gen_docs)\n",
        "  # create a bag of words and its frequency in each document\n",
        "  corpus = [dictionary.doc2bow(gen_doc) for gen_doc in gen_docs]\n",
        "  # calculate TFIDF\n",
        "  tf_idf = gensim.models.TfidfModel(corpus)\n",
        "  # creating similarity measure object\n",
        "  sims = gensim.similarities.Similarity('/content/Untitled Folder',tf_idf[corpus], num_features=len(dictionary))\n",
        "\n",
        "  # processing paragraphs of the second document\n",
        "  for i in range(len(document)):\n",
        "    query_doc = [w.lower() for w in word_tokenize(document[i]) if w not in stopwords]\n",
        "    query_doc_bow = dictionary.doc2bow(query_doc)\n",
        "    query_doc_tf_idf = tf_idf[query_doc_bow]\n",
        "    # find similarity for each document\n",
        "    score = sims[query_doc_tf_idf]\n",
        "    # print(score)\n",
        "    print(\"Doc2 \", document[i])\n",
        "    # match the paragaphs with the highest score\n",
        "    if np.max(score) != 0:\n",
        "      indices = np.argmax(score)\n",
        "      print(\"Doc1 \", playbook[indices])\n",
        "    else:\n",
        "      print(\"No Section Matched\")\n",
        "    print()"
      ],
      "metadata": {
        "id": "lMZoOdhYMcvO"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "similarity_para(doc_1, doc_2)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qHRJi60tMgai",
        "outputId": "92f07484-2c07-4977-e481-2dd6646bf6cd"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Doc2  Exhibit 10.1 COLOGUARD(r)\n",
            "Doc1  10.1.  Representations and Warranties of Dova.. 35. 10.2.  Representations and Warranties of Valeant.. 37. 10.3.  Disclaimer of Warranty.. 38. 10.4.  Additional Covenants.. 39. ARTICLE 11 INDEMNIFICATION? LIMITATIONS ON LIABILITY 39\n",
            "\n",
            "Doc2  PROMOTION AGREEMENT. BY AND BETWEEN. EXACT SCIENCES CORPORATION. AND. PFIZER INC. August 21, 2018\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Doc1  Effective. Date \") by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"\n",
            "\n",
            "Doc2  TABLE OF CONTENTS Page\n",
            "Doc1  TABLE OF CONTENTS. Page. ARTICLE 1 DEFINITIONS 1\n",
            "\n",
            "Doc2  2.1 Joint Steering Committee\n",
            "10\n",
            "\n",
            "Doc1  2.1.  Engagement? Grant of Rights.. 8. 2.2.  Retention of Rights.. 9. 2.3.  Non-Competition? Non-Solicitation.. 9. 2.4.  Dova Trademarks and Copyrights.. 10. ARTICLE 3 JOINT STEERING COMMITTEE 11\n",
            "\n",
            "Doc2  2.2 Joint Operations Committee\n",
            "13\n",
            "\n",
            "Doc1  2.1.  Engagement? Grant of Rights.. 8. 2.2.  Retention of Rights.. 9. 2.3.  Non-Competition? Non-Solicitation.. 9. 2.4.  Dova Trademarks and Copyrights.. 10. ARTICLE 3 JOINT STEERING COMMITTEE 11\n",
            "\n",
            "Doc2  2.3 Joint Review Committee\n",
            "14\n",
            "\n",
            "Doc1  2.1.  Engagement? Grant of Rights.. 8. 2.2.  Retention of Rights.. 9. 2.3.  Non-Competition? Non-Solicitation.. 9. 2.4.  Dova Trademarks and Copyrights.. 10. ARTICLE 3 JOINT STEERING COMMITTEE 11\n",
            "\n",
            "Doc2  2.4 Finance Representative\n",
            "15\n",
            "\n",
            "Doc1  2.1.  Engagement? Grant of Rights.. 8. 2.2.  Retention of Rights.. 9. 2.3.  Non-Competition? Non-Solicitation.. 9. 2.4.  Dova Trademarks and Copyrights.. 10. ARTICLE 3 JOINT STEERING COMMITTEE 11\n",
            "\n",
            "Doc2  2.5 Alliance Managers\n",
            "15\n",
            "\n",
            "Doc1  Alliance Managers \" shall have the meaning set forth in Section 4.1.4.\n",
            "\n",
            "Doc2  2.6 Compliance Managers\n",
            "16\n",
            "\n",
            "Doc1  4.3.11. . As soon as practicable, but no later than thirty (30) days after the Effective Date, each Party shall appoint a representative to act as its compliance manager under this Agreement, each of which is routinely\n",
            "responsible for advising such Party on compliance matters and has suitable seniority and other relevant experience and expertise\n",
            "(each, a \"\n",
            "\n",
            "\"). From time to time, each Party may change its Compliance Manager by giving written notice to\n",
            "the other Party. The Compliance Managers shall serve as a key point of contact between the Parties for compliance-related\n",
            "matters. Each Compliance Manager shall facilitate the resolution of any compliance issue with the Compliance Manager of the\n",
            "other Party. The Compliance Managers will use good faith efforts to reach consensus on all compliance matters. If the Compliance\n",
            "Managers do not reach consensus on an issue promptly, then such issue shall be submitted to dispute resolution process described\n",
            "in Section 13.6. Upon the reasonable request of Dova from to time, Valeant shall deliver to Dova copies of Valeant's compliance\n",
            "program policies and compliance training materials which are applicable to the Field Force Personnel's promotion of the Product.\n",
            "Other than as expressly stated herein, Valeant shall not be required to modify its compliance policies or practices in connection\n",
            "with the compliance-related provisions herein.\n",
            "\n",
            "Doc2  3.1 Appointment\n",
            "17\n",
            "\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  3.2 Responsibility for Product\n",
            "19\n",
            "\n",
            "Doc1  4.1.  Valeant Activities.. 14. 4.2.  Detailing.. 15. 4.3.  Compliance with Applicable Law.. 17. 4.4.  Field Force Personnel Training? Product Materials.. 19. 4.5.  Provisions Related to Field Force Personnel.. 21. 4.6.  Responsibility for Valeant Activity Costs and Expenses.. 22. 4.7.  Data Sharing.. 22 ARTICLE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL\n",
            "\n",
            "Doc2  3.3 Annual Marketing Plan\n",
            "26\n",
            "\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  3.4 Sales Promotion, Detailing Efforts and IDN Promotion\n",
            "27\n",
            "\n",
            "Doc1  6.1.  Promotion Fee.. 26. 6.2.  Milestone Payment.. 27. 6.3.  Reports? Payments.. 27. 6.4.  Taxes.. 28. 6.5.  Determination of Specialty.. 29. ARTICLE 7 AUDIT RIGHTS 30\n",
            "\n",
            "Doc2  3.5 Pfizer Investment and Support\n",
            "28\n",
            "\n",
            "Doc1  4.3.8 Dova shall ensure that government-insured patients do not receive co-pay support from Dova with respect\n",
            "to the Product.\n",
            "\n",
            "\n",
            "Doc2  3.6 Exact Investment and Support\n",
            "29\n",
            "\n",
            "Doc1  4.3.8 Dova shall ensure that government-insured patients do not receive co-pay support from Dova with respect\n",
            "to the Product.\n",
            "\n",
            "\n",
            "Doc2  3.7 Changes in Shared M&P Expenses\n",
            "30\n",
            "\n",
            "Doc1  7.1.  Recordkeeping. .. 30. 7.2.  Valeant Rights.. 30. 7.3.  Dova Rights.. 31. ARTICLE 8 INTELLECTUAL PROPERTY 32\n",
            "\n",
            "Doc2  4.1 Responsibility for Shared M&P Expenses\n",
            "30\n",
            "\n",
            "Doc1  4.1. .. 4.1.1. . Valeant shall conduct the Valeant Activities for the Product in the Specialty in the Field in the Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "Territory in accordance with this Agreement.\n",
            "\n",
            "\n",
            "Doc2  4.2 Promotion Fee\n",
            "31\n",
            "\n",
            "Doc1  6.3.2. . Within fifteen (15) days of the end of each month within each Calendar Quarter, Dova shall provide to Valeant a written report setting forth Dova's good faith estimate of the Net Sales and the estimated promotion fee\n",
            "payable in respect of such Net Sales for each of such calendar month and the Calendar Quarter-to-date period, together with its\n",
            "good faith estimates of each of the items described in Section 6.3.1 above (assuming there will be no adjustments made to the\n",
            "promotion fee pursuant to Section 6.1.2). The Parties acknowledge and agree that the monthly reports will only set forth Dova's\n",
            "good faith estimates of the items contained therein and are being provided to Valeant for information purposes only and shall not be\n",
            "determinative of the any amounts due hereunder.\n",
            "\n",
            "\n",
            "Doc2  4.3 Fee Statements and Payments\n",
            "33\n",
            "\n",
            "Doc1  About Bausch Health Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our\n",
            "health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter\n",
            "products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our\n",
            "commitments as we build an innovative company dedicated to advancing global health. More information can be found at\n",
            "www.bauschhealth.com.\n",
            "Dova Pharmaceuticals Cautionary Notes Regarding Forward-Looking Statements \n",
            "Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as\n",
            "that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as\n",
            "\"anticipated\", \"believe\", \"expect\", \"may\", \"plan\", \"potential\", \"will\", and similar expressions, and are based on Dova's current\n",
            "beliefs and expectations. These forward-looking statements include the potential benefits of the collaboration, the timing of the\n",
            "Salix sales force beginning to sell DOPTELET and other information relating to the transaction between Dova and Salix. These\n",
            "statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.\n",
            "Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials,\n",
            "increased regulatory requirements, Dova's reliance on third parties over which it may not always have full control, and other risks\n",
            "and uncertainties that are described in Dova's Annual Report on Form 10-K for the year ended December 31, 2017, filed with the\n",
            "U.S. Securities and Exchange Commission (SEC) on February 16, 2018, and Dova's other periodic reports filed with the SEC.\n",
            "Any forward-looking statements speak only as of the date of this press release and are based on information available to Dova as\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "of the date of this release, and Dova assumes no obligation to, and does not intend to, update any forward-looking statements,\n",
            "whether as a result of new information, future events or otherwise.\n",
            "\n",
            "Doc2  4.4 Taxes and Withholding\n",
            "34\n",
            "\n",
            "Doc1  6.4. . To the extent Dova is required to deduct and withhold taxes from any payment to Valeant, Dova shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Valeant an official tax\n",
            "receipt or other evidence of timely payment sufficient to enable Valeant to claim the payment of such taxes as a deduction or tax\n",
            "credit. Valeant may provide to Dova any tax forms that may be reasonably necessary in order for Dova to not withhold tax and\n",
            "Dova shall dispense with withholding, as applicable. Dova shall provide Valeant with reasonable assistance to enable the recovery,\n",
            "as permitted by Applicable Laws, of withholding taxes.\n",
            "\n",
            "\n",
            "Doc2  4.5 No Partnership Provision\n",
            "35\n",
            "\n",
            "Doc1  4.3.4 No employee of Valeant or its Affiliates shall have authority to give any direction, either written or oral,\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "relating to the making of any commitment by Dova or its agents to any Third Party in violation of terms of this or any other\n",
            "provision of this Agreement\n",
            "\n",
            "\n",
            "Doc2  4.6 Payments? Currency\n",
            "35\n",
            "\n",
            "Doc1  9.1.  Confidential Information.. 33. 9.2.  Public Announcements.. 34. ARTICLE 10 REPRESENTATIONS AND WARRANTIES? ADDITIONAL. COVENANTS 35\n",
            "\n",
            "Doc2  4.7 Maintenance of Records? Audits\n",
            "35\n",
            "\n",
            "Doc1  7.1. .  Each Party shall maintain complete and accurate books and records in sufficient detail, in\n",
            "accordance with GAAP (to the extent applicable and in accordance with the Agreement) and all Applicable Law, to enable\n",
            "verification of the performance of such Party's obligations under this Agreement and any payments due to a Party under this\n",
            "Agreement. Unless otherwise specified herein, the books and records for a given Calendar Year of the Term shall be maintained\n",
            "for a period of [***] after the end of such Calendar Year or longer if required by Applicable Law.\n",
            "\n",
            "\n",
            "Doc2  5. REPRESENTATIONS, WARRANTIES AND COVENANTS\n",
            "Doc1  9.1.  Confidential Information.. 33. 9.2.  Public Announcements.. 34. ARTICLE 10 REPRESENTATIONS AND WARRANTIES? ADDITIONAL. COVENANTS 35\n",
            "\n",
            "Doc2  5.1 Mutual Representations and Warranties\n",
            "37\n",
            "\n",
            "Doc1  10.1.  Representations and Warranties of Dova.. 35. 10.2.  Representations and Warranties of Valeant.. 37. 10.3.  Disclaimer of Warranty.. 38. 10.4.  Additional Covenants.. 39. ARTICLE 11 INDEMNIFICATION? LIMITATIONS ON LIABILITY 39\n",
            "\n",
            "Doc2  5.2 Representations and Warranties of Exact\n",
            "38\n",
            "\n",
            "Doc1  10.1.  Representations and Warranties of Dova.. 35. 10.2.  Representations and Warranties of Valeant.. 37. 10.3.  Disclaimer of Warranty.. 38. 10.4.  Additional Covenants.. 39. ARTICLE 11 INDEMNIFICATION? LIMITATIONS ON LIABILITY 39\n",
            "\n",
            "Doc2  5.3 Covenants\n",
            "39\n",
            "\n",
            "Doc1  10.1.  Representations and Warranties of Dova.. 35. 10.2.  Representations and Warranties of Valeant.. 37. 10.3.  Disclaimer of Warranty.. 38. 10.4.  Additional Covenants.. 39. ARTICLE 11 INDEMNIFICATION? LIMITATIONS ON LIABILITY 39\n",
            "\n",
            "Doc2  5.4 Compliance with Law and Ethical Business Practices\n",
            "40\n",
            "\n",
            "Doc1  11.1.  Indemnification by Dova.. 39. 11.2.  Indemnification by Valeant.. 39. 11.3.  Indemnification Procedures.. 40. 11.4.  Limitation of Liability.. 40. 11.5.  Insurance.. 40. ARTICLE 12 TERM AND TERMINATION 41\n",
            "\n",
            "Doc2  5.5 Notice of Investigations\n",
            "43\n",
            "\n",
            "Doc1  12.6.  Survival.. 43. ARTICLE 13 MISCELLANEOUS 43\n",
            "\n",
            "Doc2  5.6 Representation by Legal Counsel\n",
            "43\n",
            "\n",
            "Doc1  12.6.  Survival.. 43. ARTICLE 13 MISCELLANEOUS 43\n",
            "\n",
            "Doc2  5.7 No Inconsistent Agreements\n",
            "43\n",
            "\n",
            "Doc1  12.6.  Survival.. 43. ARTICLE 13 MISCELLANEOUS 43\n",
            "\n",
            "Doc2  5.8 Disclaimer\n",
            "44\n",
            "\n",
            "Doc1  10.1.  Representations and Warranties of Dova.. 35. 10.2.  Representations and Warranties of Valeant.. 37. 10.3.  Disclaimer of Warranty.. 38. 10.4.  Additional Covenants.. 39. ARTICLE 11 INDEMNIFICATION? LIMITATIONS ON LIABILITY 39\n",
            "\n",
            "Doc2  6.1 Indemnification\n",
            "44\n",
            "\n",
            "Doc1  11.1.  Indemnification by Dova.. 39. 11.2.  Indemnification by Valeant.. 39. 11.3.  Indemnification Procedures.. 40. 11.4.  Limitation of Liability.. 40. 11.5.  Insurance.. 40. ARTICLE 12 TERM AND TERMINATION 41\n",
            "\n",
            "Doc2  6.2 Insurance Requirements\n",
            "45\n",
            "\n",
            "Doc1  11.5. . Each Party acknowledges and agrees that during the Term, it shall maintain, through purchase or self- insurance, adequate insurance, including products liability coverage and comprehensive general liability insurance, adequate to\n",
            "cover its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly\n",
            "situated. Each Party shall provide reasonable written proof of the existence of such insurance to the other Party upon request.\n",
            "Dova does not and will not maintain or procure any worker's compensation, healthcare, or other insurance for or on behalf of any\n",
            "Field Force Personnel, all of which shall be Valeant's sole responsibility. For clarity, the insurance requirements of this Section 11.5\n",
            "shall not be construed to create a limit of either Party's liability with respect to its indemnification obligations under this ARTICLE\n",
            "\n",
            "\n",
            "Doc2  6.3 Limitation of Liability\n",
            "46\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "\n",
            "Doc1  13.1.  Force Majeure.. 43. 13.2.  Assignment.. 43. 13.3.  Severability.. 44. 13.4.  Notices.. 44. 13.5.  Governing Law.. 45. 13.6.  Dispute Resolution.. 45. 13.7.  Waiver of Jury Trial.. 45. 13.8.  Entire Agreement? Amendments.. 46. 13.9.  Headings.. 46. 13.10.  Independent Contractors.. 46. 13.11.  Third Party Beneficiaries.. 46. 13.12.  Waiver.. 46. 13.13.  Cumulative Remedies.. 46. 13.14.  Waiver of Rule of Construction.. 46. 13.15.  Use of Names.. 46. 13.16.  Further Actions and Documents.. 47. 13.17.  Certain Conventions.. 47. 13.18.  Counterparts.. 47 iii\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  7.1 Confidentiality\n",
            "46\n",
            "\n",
            "Doc1  13.1.  Force Majeure.. 43. 13.2.  Assignment.. 43. 13.3.  Severability.. 44. 13.4.  Notices.. 44. 13.5.  Governing Law.. 45. 13.6.  Dispute Resolution.. 45. 13.7.  Waiver of Jury Trial.. 45. 13.8.  Entire Agreement? Amendments.. 46. 13.9.  Headings.. 46. 13.10.  Independent Contractors.. 46. 13.11.  Third Party Beneficiaries.. 46. 13.12.  Waiver.. 46. 13.13.  Cumulative Remedies.. 46. 13.14.  Waiver of Rule of Construction.. 46. 13.15.  Use of Names.. 46. 13.16.  Further Actions and Documents.. 47. 13.17.  Certain Conventions.. 47. 13.18.  Counterparts.. 47 iii\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  7.2 Authorized Disclosure and Use\n",
            "47\n",
            "\n",
            "Doc1  9.1.2. . Notwithstanding the obligations set forth in Section 9.1.1, a Party may disclose the other Party's Confidential Information and the terms of this Agreement to the extent:\n",
            "(a)\n",
            "such disclosure is reasonably necessary (x) to comply with the requirements of Governmental\n",
            "Authorities? or (y) for the prosecuting or defending litigation as contemplated by this Agreement?\n",
            "(b)\n",
            "such disclosure is reasonably necessary to its Affiliates, employees, agents, consultants and contractors\n",
            "on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement? provided\n",
            "that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this\n",
            "Agreement and the disclosing Party shall be liable for any failures of such disclosees to abide by such obligations of confidentiality\n",
            "and non-use? or\n",
            "(c)\n",
            "such disclosure is reasonably necessary to comply with Applicable Laws, including regulations\n",
            "promulgated by applicable securities exchanges, court order, administrative subpoena or order.\n",
            "Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party's\n",
            "Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of\n",
            "such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party's cost) in obtaining, a\n",
            "protective order preventing or limiting the required disclosure.\n",
            "\n",
            "\n",
            "Doc2  7.3 Certain Regulatory Filings\n",
            "47\n",
            "\n",
            "Doc1  13.1.  Force Majeure.. 43. 13.2.  Assignment.. 43. 13.3.  Severability.. 44. 13.4.  Notices.. 44. 13.5.  Governing Law.. 45. 13.6.  Dispute Resolution.. 45. 13.7.  Waiver of Jury Trial.. 45. 13.8.  Entire Agreement? Amendments.. 46. 13.9.  Headings.. 46. 13.10.  Independent Contractors.. 46. 13.11.  Third Party Beneficiaries.. 46. 13.12.  Waiver.. 46. 13.13.  Cumulative Remedies.. 46. 13.14.  Waiver of Rule of Construction.. 46. 13.15.  Use of Names.. 46. 13.16.  Further Actions and Documents.. 47. 13.17.  Certain Conventions.. 47. 13.18.  Counterparts.. 47 iii\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  7.4 Public Announcements\n",
            "47\n",
            "\n",
            "Doc1  9.1.  Confidential Information.. 33. 9.2.  Public Announcements.. 34. ARTICLE 10 REPRESENTATIONS AND WARRANTIES? ADDITIONAL. COVENANTS 35\n",
            "\n",
            "Doc2  7.5 Use of Names\n",
            "48\n",
            "\n",
            "Doc1  Dova Trademarks and Copyrights \" shall mean the logos, trade dress, slogans, domain names and housemarks of\n",
            "Dova or any of its Affiliates as may appear on any Product Materials or Product Labeling, in each case, as may be updated from\n",
            "time to time by Dova.\n",
            "\n",
            "Doc2  8.1 Term\n",
            "48\n",
            "\n",
            "Doc1  8.1.  Ownership of Intellectual Property.. 32. 8.2.  Title to Trademarks and Copyrights.. 32. 8.3.  Protection of Trademarks and Copyrights.. 32. 8.4.  Disclosure of Know-How.. 33. ARTICLE 9 CONFIDENTIALITY 33\n",
            "\n",
            "Doc2  8.2 Renewal\n",
            "48\n",
            "\n",
            "Doc1  8.1.  Ownership of Intellectual Property.. 32. 8.2.  Title to Trademarks and Copyrights.. 32. 8.3.  Protection of Trademarks and Copyrights.. 32. 8.4.  Disclosure of Know-How.. 33. ARTICLE 9 CONFIDENTIALITY 33\n",
            "\n",
            "Doc2  8.3 Termination for Cause\n",
            "48\n",
            "\n",
            "Doc1  12.1.  Term.. 41. 12.2.  Early Termination for Cause.. 41 Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  8.4 Termination Without Cause\n",
            "49\n",
            "\n",
            "Doc1  12.1.  Term.. 41. 12.2.  Early Termination for Cause.. 41 Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  8.5 Mutual Termination\n",
            "49\n",
            "\n",
            "Doc1  12.6. . Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Notwithstanding any expiration or termination of this Agreement,\n",
            "such expiration or termination shall not relieve any Party from obligations which are expressly or by implication intended to survive\n",
            "expiration or termination, including Sections 2.3, , 4.4.2, 5.7, 5.9, 6.3.6, 6.3.5, 11.1, 11.2, 11.3, 11.4, 12.4, 12.5 and 12.6,\n",
            "Articles 7, 8, 9 and 13 (to the extent applicable to implementation of the survival of the preceding Sections and Articles) and,\n",
            "solely as it relates to the last Calendar Quarter, Sections 6.1, 6.2 and 6.3, which shall survive and be in full force and effect.\n",
            "\n",
            "\n",
            "Doc2  8.6 Termination for Change of Control\n",
            "49\n",
            "\n",
            "Doc1  12.6. . Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Notwithstanding any expiration or termination of this Agreement,\n",
            "such expiration or termination shall not relieve any Party from obligations which are expressly or by implication intended to survive\n",
            "expiration or termination, including Sections 2.3, , 4.4.2, 5.7, 5.9, 6.3.6, 6.3.5, 11.1, 11.2, 11.3, 11.4, 12.4, 12.5 and 12.6,\n",
            "Articles 7, 8, 9 and 13 (to the extent applicable to implementation of the survival of the preceding Sections and Articles) and,\n",
            "solely as it relates to the last Calendar Quarter, Sections 6.1, 6.2 and 6.3, which shall survive and be in full force and effect.\n",
            "\n",
            "\n",
            "Doc2  8.7 Royalty Upon Expiration\n",
            "49\n",
            "\n",
            "Doc1  12.6. . Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Notwithstanding any expiration or termination of this Agreement,\n",
            "such expiration or termination shall not relieve any Party from obligations which are expressly or by implication intended to survive\n",
            "expiration or termination, including Sections 2.3, , 4.4.2, 5.7, 5.9, 6.3.6, 6.3.5, 11.1, 11.2, 11.3, 11.4, 12.4, 12.5 and 12.6,\n",
            "Articles 7, 8, 9 and 13 (to the extent applicable to implementation of the survival of the preceding Sections and Articles) and,\n",
            "solely as it relates to the last Calendar Quarter, Sections 6.1, 6.2 and 6.3, which shall survive and be in full force and effect.\n",
            "\n",
            "\n",
            "Doc2  8.8 Consequences of Termination\n",
            "50\n",
            "\n",
            "Doc1  4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section. 12.2.2.. 4.1.3. Target Incentive Compensation.  In addition, [***] and continuing throughout the remainder of the Term,\n",
            "Valeant shall ensure the incentive compensation package for each Sales Representatives requires that at least fifty percent (50%) of\n",
            "the target incentive compensation is derived from achieving target sales of the Product. On at least a quarterly basis, the Parties will\n",
            "meet, through the JSC, to review the target incentive compensation and the actual incentive compensation paid out to the Sales\n",
            "Representatives to discuss, in good faith, any appropriate adjustments to the sales targets and goals related to the Product (but not\n",
            "to the above-mentioned fifty percent (50%) threshold of the target incentive compensation), with the intent of achieving, on\n",
            "average, an actual payout to the Sales Representatives of 50% of their incentive compensation relating to sales of the Product.\n",
            "\n",
            "Doc2  8.9 Survival of Certain Obligations\n",
            "50\n",
            "\n",
            "Doc1  12.6.  Survival.. 43. ARTICLE 13 MISCELLANEOUS 43\n",
            "\n",
            "Doc2  9.1 Interpretation\n",
            "51\n",
            "\n",
            "Doc1  9.1.  Confidential Information.. 33. 9.2.  Public Announcements.. 34. ARTICLE 10 REPRESENTATIONS AND WARRANTIES? ADDITIONAL. COVENANTS 35\n",
            "\n",
            "Doc2  9.2 Assignment\n",
            "51\n",
            "\n",
            "Doc1  9.1.  Confidential Information.. 33. 9.2.  Public Announcements.. 34. ARTICLE 10 REPRESENTATIONS AND WARRANTIES? ADDITIONAL. COVENANTS 35\n",
            "\n",
            "Doc2  9.3 Further Actions\n",
            "51\n",
            "\n",
            "Doc1  13.1.  Force Majeure.. 43. 13.2.  Assignment.. 43. 13.3.  Severability.. 44. 13.4.  Notices.. 44. 13.5.  Governing Law.. 45. 13.6.  Dispute Resolution.. 45. 13.7.  Waiver of Jury Trial.. 45. 13.8.  Entire Agreement? Amendments.. 46. 13.9.  Headings.. 46. 13.10.  Independent Contractors.. 46. 13.11.  Third Party Beneficiaries.. 46. 13.12.  Waiver.. 46. 13.13.  Cumulative Remedies.. 46. 13.14.  Waiver of Rule of Construction.. 46. 13.15.  Use of Names.. 46. 13.16.  Further Actions and Documents.. 47. 13.17.  Certain Conventions.. 47. 13.18.  Counterparts.. 47 iii\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  9.4 Force Majeure\n",
            "51\n",
            "\n",
            "Doc1  13.1. . Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "caused by or results from causes beyond the reasonable control of the affected Party, potentially including, embargoes, war, acts of\n",
            "war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor\n",
            "disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any Governmental Authority. The affected\n",
            "Party shall notify the other Party of such force majeure circumstances as soon as reasonably practicable, and shall promptly\n",
            "undertake all reasonable efforts necessary to cure such force majeure circumstances and re-commence its performance hereunder\n",
            "as soon as practicable.\n",
            "\n",
            "\n",
            "Doc2  9.5 Notices\n",
            "52\n",
            "\n",
            "Doc1  13.4. . All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by e-mail (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by\n",
            "nationally-recognized overnight courier, or sent by registered or certified mail, postage prepaid, return receipt requested,\n",
            "addressed as follows:\n",
            "if to Dova, to:\n",
            "Dova Pharmaceuticals, Inc.\n",
            "240 Leigh Farm Road, Suite 245\n",
            "Durham, NC 27707\n",
            "Attention: Chief Executive Officer\n",
            "Email: asapir@dova.com\n",
            "With a copy to:\n",
            "Dova Pharmaceuticals, Inc.\n",
            "240 Leigh Farm Road, Suite 245\n",
            "Durham, NC 27707\n",
            "Attention: General Counsel\n",
            "Email: mbanjak@dova.com\n",
            "if to Valeant, to:\n",
            "Valeant Pharmaceuticals North America LLC\n",
            "400 Somerset Corporate Boulevard\n",
            "Bridgewater, NJ 08807\n",
            "Attention: XXXXXXXXX\n",
            "Email: XXXXXXXX\n",
            "With a copy to\n",
            ":\n",
            "\n",
            "\n",
            "Doc2  9.6 Amendment\n",
            "53\n",
            "\n",
            "Doc1  Applicable Laws \" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind\n",
            "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this\n",
            "Agreement, including, as applicable, the Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. SS 335a et seq.), the Anti-\n",
            "Kickback Statute (42 U.S.C. SS 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal\n",
            "False Claims Act (31 U.S.C. SSSS 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the\n",
            "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for\n",
            "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the\n",
            "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by\n",
            "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)\n",
            "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (iii) governing consumer\n",
            "2\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time\n",
            "to time.\n",
            "\n",
            "Doc2  9.7 Waiver\n",
            "53\n",
            "\n",
            "Doc1  13.12. . The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of\n",
            "such other Party whether of a similar nature or otherwise.\n",
            "\n",
            "\n",
            "Doc2  9.8 Severability\n",
            "53\n",
            "\n",
            "Doc1  13.1.  Force Majeure.. 43. 13.2.  Assignment.. 43. 13.3.  Severability.. 44. 13.4.  Notices.. 44. 13.5.  Governing Law.. 45. 13.6.  Dispute Resolution.. 45. 13.7.  Waiver of Jury Trial.. 45. 13.8.  Entire Agreement? Amendments.. 46. 13.9.  Headings.. 46. 13.10.  Independent Contractors.. 46. 13.11.  Third Party Beneficiaries.. 46. 13.12.  Waiver.. 46. 13.13.  Cumulative Remedies.. 46. 13.14.  Waiver of Rule of Construction.. 46. 13.15.  Use of Names.. 46. 13.16.  Further Actions and Documents.. 47. 13.17.  Certain Conventions.. 47. 13.18.  Counterparts.. 47 iii\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  9.9 Descriptive Headings\n",
            "53\n",
            "\n",
            "Doc1  13.1.  Force Majeure.. 43. 13.2.  Assignment.. 43. 13.3.  Severability.. 44. 13.4.  Notices.. 44. 13.5.  Governing Law.. 45. 13.6.  Dispute Resolution.. 45. 13.7.  Waiver of Jury Trial.. 45. 13.8.  Entire Agreement? Amendments.. 46. 13.9.  Headings.. 46. 13.10.  Independent Contractors.. 46. 13.11.  Third Party Beneficiaries.. 46. 13.12.  Waiver.. 46. 13.13.  Cumulative Remedies.. 46. 13.14.  Waiver of Rule of Construction.. 46. 13.15.  Use of Names.. 46. 13.16.  Further Actions and Documents.. 47. 13.17.  Certain Conventions.. 47. 13.18.  Counterparts.. 47 iii\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  9.10 Governing Law\n",
            "53\n",
            "\n",
            "Doc1  Applicable Laws \" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind\n",
            "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this\n",
            "Agreement, including, as applicable, the Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. SS 335a et seq.), the Anti-\n",
            "Kickback Statute (42 U.S.C. SS 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal\n",
            "False Claims Act (31 U.S.C. SSSS 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the\n",
            "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for\n",
            "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the\n",
            "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by\n",
            "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)\n",
            "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (iii) governing consumer\n",
            "2\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time\n",
            "to time.\n",
            "\n",
            "Doc2  9.11 Dispute Resolution\n",
            "53\n",
            "\n",
            "Doc1  13.6. .. 13.6.1. . Except for disputes resolved by the procedures set forth in Section. 3.4, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a \"\n",
            "\n",
            "\"), then either Party shall have the right to refer such dispute to the Senior Officers\n",
            "who shall confer within [***] after such Dispute was first referred to them to attempt to resolve the Dispute by good faith\n",
            "negotiations. Any final decision mutually agreed to by the Senior Officers in writing shall be conclusive and binding on the Parties. If\n",
            "such Senior Officers do not agree on the resolution of an issue within [***] after such issue was first referred to them, either Party\n",
            "may, by written notice to the other Party, initiate arbitration for resolution of such Dispute pursuant to Section 13.6.2.\n",
            "\n",
            "Doc2  9.12 Entire Agreement of the Parties\n",
            "54\n",
            "\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  9.13 Independent Contractors\n",
            "54\n",
            "\n",
            "Doc1  13.10. . It is expressly agreed that Valeant and Dova shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Valeant nor Dova shall\n",
            "have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be\n",
            "binding on the other Party, without the prior written consent of the other Party.\n",
            "\n",
            "\n",
            "Doc2  9.14 No Legal Advice\n",
            "54\n",
            "\n",
            "Doc1  4.3.4 No employee of Valeant or its Affiliates shall have authority to give any direction, either written or oral,\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "relating to the making of any commitment by Dova or its agents to any Third Party in violation of terms of this or any other\n",
            "provision of this Agreement\n",
            "\n",
            "\n",
            "Doc2  9.15 Counterparts\n",
            "54\n",
            "\n",
            "Doc1  2.2\", and references to \"ARTICLE 2\" or \"Section 2.2\" would refer to material contained in the subsection described as \"Section. 2.2.1\").. 13.18. . This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile or\n",
            "electronic mail (including pdf) and any counterpart so delivered shall be deemed to have been duly and validly delivered and be\n",
            "valid and effective for all purposes and shall have the same force and effect as original signatures.\n",
            "[signature page follows]\n",
            "[\n",
            "Signature page to Co-Promotion Agreement\n",
            "]\n",
            "IN WITNESS WHEREOF, \n",
            "the Parties have executed this Agreement as of the Effective Date.\n",
            "DOVA PHARMACEUTICALS, INC.\n",
            "By: __/s/ Alex C. Sapir______________________\n",
            "Name: Alex C. Sapir\n",
            "Title: CEO\n",
            "\n",
            "\n",
            "Doc2  EXHIBITS Exhibit 1.24\n",
            "-\n",
            "Cost of Sales\n",
            "Exhibit 1.39\n",
            "-\n",
            "Exact Trademarks\n",
            "Exhibit 2.2(c)(iv)\n",
            "-\n",
            "Calendar Quarter Performance Metrics\n",
            "Exhibit 3.2(c)(i)\n",
            "-\n",
            "Sales Deployment Plan\n",
            "Exhibit 3.3(b)\n",
            "-\n",
            "Annual Marketing Plan Outline\n",
            "Exhibit 3.4(a)\n",
            "-\n",
            "Promotion Fee Reduction\n",
            "Exhibit 7.4\n",
            "-\n",
            "Press Release\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Exhibit 8.8(b)\n",
            "-\n",
            "Tail Period Advertising Services\n",
            "ii\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  AGREEMENT This Agreement (the \"\n",
            "Doc1  CO-PROMOTION AGREEMENT This Co-Promotion Agreement (this \"\n",
            "\n",
            "Doc2  Agreement \") is made and entered into as of August 21, 2018 (the \"\n",
            "Doc1  Agreement \") is entered into and dated as of September 26, 2018 (the \"\n",
            "\n",
            "Doc2  Effective Date \"), by and between Pfizer Inc.\n",
            "(\"\n",
            "Doc1  Effective. Date \") by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"\n",
            "\n",
            "Doc2  Pfizer \"), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences\n",
            "Corporation (\"\n",
            "Doc1  Business Day \" means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in\n",
            "New York, New York, USA are closed.\n",
            "\n",
            "Doc2  Exact \"), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and\n",
            "Exact may each be referred to herein individually as a \"\n",
            "Doc1  Valeant \"). Dova and Valeant are each referred to individually as a \"\n",
            "\n",
            "Doc2  Party \" and collectively as the \"\n",
            "Doc1  Field Force Personnel \" shall mean collectively, the Sales Representatives, the members of the institutional account\n",
            "management team described in Section 4.1.5, if any, that are engaged in Detailing the Product and any other employees of Valeant\n",
            "engaged in the Valeant Activities.\n",
            "\n",
            "Doc2  Parties \".\n",
            "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States?\n",
            "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded\n",
            "prescription products? and\n",
            "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and\n",
            "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to\n",
            "invest in Exact's Promotion of the Product in the United States.\n",
            "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,\n",
            "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:\n",
            "Doc1  WHEREAS , the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the\n",
            "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such\n",
            "activities, for the Product in the Territory?\n",
            "NOW, THEREFORE\n",
            ", in consideration of the following mutual promises and obligations, and for other good and valuable\n",
            "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  1.. DEFINITIONS.. 1.1 \"\n",
            "Doc1  1.1 \"\n",
            "\n",
            "\n",
            "Doc2  AdvaMed Code \" shall have the meaning set forth in Section 3.2(c)(ii).\n",
            "Doc1  Compliance Report \" shall have the meaning set forth in Section 4.2.2(c).\n",
            "\n",
            "Doc2  1.2 \"\n",
            "Doc1  1.2 \"\n",
            "\n",
            "\n",
            "Doc2  Advertising \" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device\n",
            "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-\n",
            "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,\n",
            "healthcare institutions and healthcare providers.\n",
            "Doc1  Business Day \" means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in\n",
            "New York, New York, USA are closed.\n",
            "\n",
            "Doc2  1.3 \"\n",
            "Affiliate(s)\n",
            "\" shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control\n",
            "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of\n",
            "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a\n",
            "corporation, for the election of the corresponding managing authority)? \n",
            "provided, however\n",
            ", that the term \"Affiliate\" shall not\n",
            "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to\n",
            "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or\n",
            "otherwise, until such time as such restrictions are no longer in effect.\n",
            "Doc1  Affiliate \" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by\n",
            "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the\n",
            "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of\n",
            "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a\n",
            "particular jurisdiction) of the voting securities of such Person, by contract or otherwise.\n",
            "\n",
            "Doc2  1.4 \"\n",
            "\" shall have the meaning set forth in the preamble.\n",
            "1\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Doc1  1.4 \"\n",
            "\n",
            "\" shall have the meaning set forth in the preamble to this Agreement.\n",
            "\n",
            "Doc2  1.5 \"\n",
            "Doc1  1.5 \"\n",
            "\n",
            "\n",
            "Doc2  Alliance Manager \" shall have the meaning set forth in Section 2.5.\n",
            "Doc1  Compliance Manager \" shall have the meaning set forth in Section 4.3.9.\n",
            "\n",
            "Doc2  1.6 \"\n",
            "Doc1  1.6 \"\n",
            "\n",
            "\n",
            "Doc2  Annual Marketing Plan \" shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial\n",
            "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3.\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  1.7 \"\n",
            "Doc1  1.7 \"\n",
            "\n",
            "\n",
            "Doc2  Annual Supplemental Promotion Fee \" shall have the meaning set forth in Section 4.2(c)(i).\n",
            "Doc1  Compliance Report \" shall have the meaning set forth in Section 4.2.2(c).\n",
            "\n",
            "Doc2  1.8 \"\n",
            "Applicable Compliance/Review Policies\n",
            "\" shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,\n",
            "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures\n",
            "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this\n",
            "Agreement, as the same may be amended from time to time.\n",
            "Doc1  Code \" shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical\n",
            "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.\n",
            "\n",
            "Doc2  1.9 \"\n",
            "Doc1  1.9 \"\n",
            "\n",
            "\n",
            "Doc2  Applicable Law \" shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,\n",
            "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other\n",
            "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed\n",
            "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall\n",
            "be deemed to include all amendments, replacements or successors thereto.\n",
            "Doc1  Governmental Authority \" shall mean any court, agency, authority, department, regulatory body or other\n",
            "instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political\n",
            "subdivision of any such government or any supranational organization of which any such country is a member, which has competent\n",
            "and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this\n",
            "Agreement.\n",
            "4\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  1.10 \"\n",
            "Doc1  1.10 \"\n",
            "\n",
            "\n",
            "Doc2  Audited Party \" shall have the meaning set forth in Section 4.7(b)(i).\n",
            "Doc1  Compensation Report \" shall have the meaning set forth in Section 4.2.2(b).\n",
            "\n",
            "Doc2  1.11 \"\n",
            "Doc1  1.11 \"\n",
            "\n",
            "\n",
            "Doc2  Auditing Party \" shall have the meaning set forth in Section 4.7(b)(i).\n",
            "Doc1  Compensation Report \" shall have the meaning set forth in Section 4.2.2(b).\n",
            "\n",
            "Doc2  1.12 \"\n",
            "Doc1  1.12 \"\n",
            "\n",
            "\n",
            "Doc2  Baseline Laboratory Service Revenue \" shall mean, with respect to a particular Calendar Year during the Term, the amounts set\n",
            "forth in Section 4.2(b).\n",
            "Doc1  Calendar Year \" shall mean each successive period of twelve (12) months commencing on January 1 and ending on\n",
            "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of\n",
            "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in\n",
            "which the Term ends and end on the last day of the Term.\n",
            "\n",
            "Doc2  1.13 \"\n",
            "Doc1  1.13 \"\n",
            "\n",
            "\n",
            "Doc2  Baseline M&P Expense \" shall have the meaning set forth in Section 3.6.\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.14 \"\n",
            "Doc1  1.14 \"\n",
            "\n",
            "\n",
            "Doc2  Business Day \" shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United\n",
            "States.\n",
            "Doc1  Business Day \" means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in\n",
            "New York, New York, USA are closed.\n",
            "\n",
            "Doc2  1.15 \"\n",
            "Doc1  1.15 \"\n",
            "\n",
            "\n",
            "Doc2  Calendar Quarter \" shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,\n",
            "September 30 or December 31.\n",
            "Doc1  Calendar Year \" shall mean each successive period of twelve (12) months commencing on January 1 and ending on\n",
            "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of\n",
            "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in\n",
            "which the Term ends and end on the last day of the Term.\n",
            "\n",
            "Doc2  1.16 \"\n",
            "Doc1  1.16 \"\n",
            "\n",
            "\n",
            "Doc2  Calendar Year \" shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the\n",
            "applicable year for as long as this Agreement is in effect.\n",
            "Doc1  Calendar Year \" shall mean each successive period of twelve (12) months commencing on January 1 and ending on\n",
            "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of\n",
            "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in\n",
            "which the Term ends and end on the last day of the Term.\n",
            "\n",
            "Doc2  1.17 \"\n",
            "Doc1  1.17 \"\n",
            "\n",
            "\n",
            "Doc2  Calendar Year Baseline Laboratory Service Revenue \" shall have the meaning set forth in Section 4.2(b).\n",
            "Doc1  Compensation Report \" shall have the meaning set forth in Section 4.2.2(b).\n",
            "\n",
            "Doc2  1.18 \"\n",
            "Doc1  1.18 \"\n",
            "\n",
            "\n",
            "Doc2  Change of Control \" shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business\n",
            "relating to the subject matter of this Agreement? (b) a merger, reorganization, or consolidation involving such Party in which the\n",
            "holders of voting securities of such Party outstanding immediately\n",
            "2\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "prior thereto cease to hold at least fifty percent (50%) of the combined voting power of the surviving entity or acquiring entity\n",
            "(or its parent) immediately after such merger, reorganization, or consolidation? or (c) the acquisition of more than fifty percent\n",
            "(50%) of the voting equity securities of such Party as a result of a single transaction or a series of related transactions.\n",
            "Doc1  Affiliate \" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by\n",
            "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the\n",
            "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of\n",
            "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a\n",
            "particular jurisdiction) of the voting securities of such Person, by contract or otherwise.\n",
            "\n",
            "Doc2  1.19 \"\n",
            "Doc1  1.19 \"\n",
            "Detail(s)\n",
            "\" shall mean a Product presentation during a face-to-face sales call between a Target Professional and a\n",
            "Sales Representative, during which a presentation of the Product's attributes, benefits, prescribing information and safety\n",
            "information are orally presented, for use in the Field in the Territory. Neither e-details, nor presentations made at conventions,\n",
            "exhibit booths, a sample drop, educational programs or speaker meetings, or similar gatherings, shall constitute a Detail.\n",
            "\n",
            "\n",
            "Doc2  CIA \" shall have the meaning set forth in Section 5.4(j).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.20 \"\n",
            "Doc1  1.20 \"\n",
            "\n",
            "\n",
            "Doc2  Claims \" shall have the meaning set forth in Section 6.1(a).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.21 \"\n",
            "Doc1  1.21 \"\n",
            "\n",
            "\n",
            "Doc2  Compliance Manager \" shall have the meaning set forth in Section 2.6.\n",
            "Doc1  Compliance Manager \" shall have the meaning set forth in Section 4.3.9.\n",
            "\n",
            "Doc2  1.22 \"\n",
            "Doc1  1.22 \"\n",
            "\n",
            "\n",
            "Doc2  Confidential Information \" shall have the meaning set forth in Section 7.1.\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.23 \"\n",
            "Doc1  1.23 \"\n",
            "\n",
            "\n",
            "Doc2  Co-Promote Field \" shall mean those physicians and practices customarily considered primary care or gastroenterology providers\n",
            "and practices and, subject to Sections 3.1(c)(ii) and 4.2(d), the OB/Gyn Field, in the Territory. For clarity, if Exact, either through\n",
            "its own Sales Representative or by agreement with a Third Party, launches the Product in the OB/Gyn Field, the Co-Promote\n",
            "Field shall not include the OB/Gyn Field.\n",
            "Doc1  4.5. .. 4.5.1. . Valeant hereby agrees and acknowledges that the following shall apply with respect to itself and the Field Force Personnel that are engaged in Detailing:\n",
            "(a)\n",
            "Valeant shall instruct and cause the Field Force Personnel that are engaged in Detailing to use only the\n",
            "Product Labeling and, subject to the terms of Section 4.4, Product Materials approved by Dova for the conduct of the Valeant\n",
            "Activities for the Product and consistent with Applicable Laws. Valeant shall instruct the Field Force Personnel that are engaged in\n",
            "Detailing to, and will monitor the Field Force Personnel that are engaged in Detailing to ensure that such Field Force Personnel,\n",
            "limit their claims of efficacy and safety for the Product to those claims which are consistent with and do not exceed the Product\n",
            "Labeling and any Promotional Materials.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "(b)\n",
            "Valeant shall instruct the Field Force Personnel that are engaged in Detailing to conduct the Valeant\n",
            "Activities for the Product, and will monitor and audit (in accordance with Valeant's standard practice) the Field Force Personnel\n",
            "that are engaged in Detailing so that such personnel conduct the Valeant Activities for the Product in adherence in all respects with\n",
            "Applicable Laws.\n",
            "(c)\n",
            "Valeant shall instruct the Field Force Personnel that are engaged in Detailing regarding provisions of this\n",
            "Agreement applicable to Details of the Product, including Section 4.2 and this Section 4.5.1.\n",
            "(d)\n",
            "Valeant acknowledges and agrees that Dova will not maintain or procure any worker's compensation,\n",
            "healthcare, or other insurance for or on behalf of the Field Force Personnel, all of which shall be Valeant's sole responsibility.\n",
            "(e)\n",
            "Valeant acknowledges and agrees that all Field Force Personnel are employees of Valeant and are not,\n",
            "and are not intended to be treated as, employees of Dova or any of its Affiliates, and that such individuals are not, and are not\n",
            "intended to be, eligible to participate in any benefits programs or in any \"employee benefit plans\" (as such term is defined in section\n",
            "3(3) of ERISA) that are sponsored by Dova or any of its Affiliates or that are offered from time to time by Dova or its Affiliates to\n",
            "their own employees. All matters of compensation, benefits and other terms of employment for any such Field Force Personnel\n",
            "shall be solely a matter between Valeant and such individual. Dova shall not be responsible to Valeant, or to the Field Force\n",
            "Personnel, for any compensation, expense reimbursements or benefits (including vacation and holiday remuneration, healthcare\n",
            "coverage or insurance, life insurance, severance or termination of employment benefits, pension or profit-sharing benefits and\n",
            "disability benefits), payroll-related taxes or withholdings, or any governmental charges or benefits (including unemployment and\n",
            "disability insurance contributions or benefits and workmen's compensation contributions or benefits) that may be imposed upon or\n",
            "be related to the performance by Valeant or such individuals of this Agreement, all of which shall be the sole responsibility of\n",
            "Valeant, even if it is subsequently determined by any Governmental Authority that any such individual may be an employee or a\n",
            "common law employee of Dova or any of its Affiliates or is otherwise entitled to such payments and benefits.\n",
            "(f)\n",
            "Valeant shall be solely responsible for the acts or omissions of the Field Force Personnel that are not in\n",
            "compliance with Applicable Law and the terms of this Agreement while performing any of the activities under this Agreement.\n",
            "Valeant shall be solely responsible and liable for all probationary and termination actions taken by it, as well as for the formulation,\n",
            "content and dissemination (including content) of all employment policies and rules (including written probationary and termination\n",
            "policies) applicable to its employees.\n",
            "\n",
            "\n",
            "Doc2  1.24 \"\n",
            "Doc1  1.24 \"\n",
            "\n",
            "\n",
            "Doc2  Cost of Sales \" shall mean the direct and indirect costs attributable to sales of the Product Laboratory Services, as calculated in\n",
            "accordance with Exhibit 1.24, and as consistently determined in accordance with GAAP.\n",
            "Doc1  1.24 \"\n",
            "\n",
            "\n",
            "Doc2  1.25 \"\n",
            "Debarred/Excluded\n",
            "\" shall have the meaning set forth in Section 5.1(g).\n",
            "Doc1  1.25 \"\n",
            "\n",
            "\n",
            "Doc2  1.26 \"\n",
            "Doc1  1.26 \"\n",
            "\n",
            "\n",
            "Doc2  Detail \" shall mean a customary face-to-face or non-face-to-face contact of a Sales Representative of a Party with an Eligible\n",
            "Prescriber during which such Sales Representative makes a presentation of certain of the Product's attributes, such as\n",
            "describing the FDA-approved indicated uses, safety, effectiveness, or other relevant characteristics of the Product, in a fair and\n",
            "balanced manner and in accordance with the requirements of this Agreement and Applicable Law and in a manner that is\n",
            "customary for the purpose of Promoting a prescription medical device subject to pre-market approval, but excluding: (a) any\n",
            "activities performed by any Representative other than a Sales Representative who is not conducting a face-to-face or non-face-\n",
            "to-face sales call, (b) presentations made at conventions or (c) mere delivery of savings cards, coupons or similar items without\n",
            "discussions with an Eligible Prescriber about the Product? \n",
            "provided\n",
            " that, such measurement shall be on the same basis as the\n",
            "recording Party's measurement for its Sales Representatives' detailing of its other medical devices subject to pre-market\n",
            "approval or prescription pharmaceutical products (as applicable), consistently applied throughout the Term. For clarity, non-\n",
            "face-to-face contact shall mean e-detailing, video detailing or other presentation of Promotional Material by a Sales\n",
            "Representative to an Eligible Prescriber via audio, video, internet, using webex or other similar live conference applications, and\n",
            "in all instances that allows for real time, detailed and substantive communication between the Sales Representative and the\n",
            "Eligible Prescriber regarding the Product and would be considered a Detail by Pfizer for its own products under its own\n",
            "guidelines, but shall exclude any such communications, such as telephone calls, during which such detailed and visual\n",
            "3\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "exchanges of information do not occur. \"\n",
            ",\" when used as a verb, and \"\n",
            "Doc1  1.19 \"\n",
            "Detail(s)\n",
            "\" shall mean a Product presentation during a face-to-face sales call between a Target Professional and a\n",
            "Sales Representative, during which a presentation of the Product's attributes, benefits, prescribing information and safety\n",
            "information are orally presented, for use in the Field in the Territory. Neither e-details, nor presentations made at conventions,\n",
            "exhibit booths, a sample drop, educational programs or speaker meetings, or similar gatherings, shall constitute a Detail.\n",
            "\n",
            "\n",
            "Doc2  Detailing \" shall have correlative meanings.\n",
            "Doc1  Valeant Activities \" shall mean any and all promotional activities (including Detailing) conducted by Valeant to\n",
            "encourage the appropriate use of the Product in the Specialty in the Field in the Territory in accordance with the terms of this\n",
            "Agreement.\n",
            "\n",
            "Doc2  1.27 \"\n",
            "Doc1  1.27 \"\n",
            "\n",
            "\n",
            "Doc2  Disclosing Party \" shall have the meaning set forth in Section 7.1.\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.28 \"\n",
            "Doc1  1.28 \"\n",
            "\n",
            "\n",
            "Doc2  Disputed JOC Matter \" shall have the meaning set forth in Section 2.2(d).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.29 \"\n",
            "Doc1  1.29 \"\n",
            "\n",
            "\n",
            "Doc2  Disputed JRC Matter \" shall have the meaning set forth in Section 2.3(d).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.30 \"\n",
            "Doc1  1.30 \"\n",
            "\n",
            "\n",
            "Doc2  Disputed JSC Matter \" shall have the meaning set forth in Section 2.1(e).\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.31 \"\n",
            "\" shall have the meaning set forth in the preamble.\n",
            "Doc1  1.31 \"\n",
            "\n",
            "\n",
            "Doc2  1.32 \"\n",
            "Doc1  1.32 \"\n",
            "\n",
            "\n",
            "Doc2  Eligible Prescriber \" shall mean (a) a health care provider who has the authority to prescribe the Product under Applicable Law\n",
            "and (b) any other health care professional without prescribing authority but who (i) is reasonably believed to assist with patient\n",
            "care and reimbursement for healthcare service in the office of a health care provider who has authority to prescribe the Product\n",
            "under Applicable Law, and (ii) is allowed to receive Promotion.\n",
            "Doc1  About Salix Salix is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of\n",
            "gastrointestinal diseases. For almost 30 years, Salix has licensed, developed, and marketed innovative products to improve\n",
            "patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently\n",
            "markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology,\n",
            "hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey.\n",
            "\n",
            "Doc2  1.33 \"\n",
            "\" shall have the meaning set forth in the preamble.\n",
            "Doc1  1.33 \"\n",
            "\n",
            "\n",
            "Doc2  1.34 \"\n",
            "Doc1  1.34 \"\n",
            "\n",
            "\n",
            "Doc2  Exact Copyrights \" shall mean all statutory and common law copyrights owned by Exact in and to the Promotional Materials,\n",
            "Advertising materials or Product Label used in the Territory.\n",
            "Doc1  2.4.2 Valeant shall follow all instructions and guidelines of Dova (of which Dova has provided Valeant copies) in\n",
            "connection with the use of any Dova Trademarks and Copyrights, and, if Dova reasonably objects to the manner in which any such\n",
            "Dova Trademarks and Copyrights are being used, Valeant shall cease the use of any such Dova Trademarks and Copyrights in\n",
            "such manner upon written notice from Dova thereof. Without limiting the foregoing, Valeant shall also adhere to at least the same\n",
            "quality control provisions as companies in the pharmaceutical industry adhere to for their own trademarks and copyrights. In all\n",
            "cases, Valeant shall use the Dova Trademarks and Copyrights with the necessary trademark (and copyright, as applicable)\n",
            "designations, and shall use the Dova Trademarks and Copyrights in a manner that does not derogate from Dova's rights in the\n",
            "Dova Trademarks and Copyrights. Valeant shall not at any time during the Term knowingly do or allow to be done any act or thing\n",
            "which will in any way impair or diminish the rights of Dova in or to the Dova Trademarks and Copyrights. All goodwill and\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "improved reputation generated by Valeant's use of the Dova Trademarks and Copyrights shall inure to the benefit of Dova, and\n",
            "any use of the Dova Trademarks and Copyrights by Valeant shall cease at the end of the Term. Valeant shall have no rights under\n",
            "this Agreement in or to the Dova Trademarks and Copyrights except as specifically provided herein. During the Term, Valeant will\n",
            "not contest the ownership of the Dova Trademarks and Copyrights, their validity, or the validity of any registration therefor. During\n",
            "the Term, Valeant will not knowingly register and/or use any marks (including in connection with any domain names) that are\n",
            "confusingly similar to the Dova Trademarks and Copyrights.\n",
            "\n",
            "\n",
            "Doc2  1.35 \"\n",
            "Doc1  1.35 \"\n",
            "\n",
            "\n",
            "Doc2  Exact House Marks \" shall mean the Exact trade name and logo, including all registrations and applications for registration of any\n",
            "of the foregoing in the Territory.\n",
            "Doc1  13.15. . Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for\n",
            "any purpose in connection with the performance of this Agreement.\n",
            "\n",
            "\n",
            "Doc2  1.36 \"\n",
            "Doc1  1.36 \"\n",
            "\n",
            "\n",
            "Doc2  Exact Indemnitee \" shall have the meaning set forth in Section 6.1(b).\n",
            "Doc1  Compensation Report \" shall have the meaning set forth in Section 4.2.2(b).\n",
            "\n",
            "Doc2  1.37 \"\n",
            "Doc1  1.37 \"\n",
            "\n",
            "\n",
            "Doc2  Exact JSC Members \" shall have the meaning set forth in Section 2.1(a).\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.38 \"\n",
            "Doc1  1.38 \"\n",
            "\n",
            "\n",
            "Doc2  Exact Patent Rights \" shall mean the Patent Rights owned or controlled by Exact as of the Effective Date.\n",
            "Doc1  2.2. . Except with respect to the exclusive rights granted to Valeant to conduct the Valeant Activities for the Product in the Specialty in the Territory in the Field pursuant to Section 2.1 and, and if agreed upon, outside the Specialty in\n",
            "the Territory in the Field pursuant to Section 4.1.5, Dova retains all rights in and to the Product. Without limiting the generality of\n",
            "the foregoing (and without limiting Dova's retained rights set forth in Section 2.1), Dova specifically retains the following rights (and\n",
            "Valeant and its Affiliates shall have no rights to the following, except as set forth below in this Section 2.2):\n",
            "\n",
            "\n",
            "Doc2  1.39 \"\n",
            "Doc1  1.39 \"\n",
            "\n",
            "\n",
            "Doc2  Exact Sponsorships and Related Activities \" shall have the meaning set forth in Section 3.2(d)(i).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.40 \"\n",
            "Doc1  1.40 \"\n",
            "\n",
            "\n",
            "Doc2  Exact Trademarks \" shall mean (a) the Trademarks listed on Exhibit 1.39 and the registrations thereof, (b) any pending or future\n",
            "trademark registration applications owned or controlled and used in connection with or intended for use in connection with the\n",
            "Product in the Territory, (c) any unregistered trademark rights used in connection with the Product as may exist through use in\n",
            "the Territory, (d) any current or future modifications or variants of any of the foregoing rights, and (e) any future Trademarks\n",
            "adopted by Exact or its Affiliates for use in connection with the Product in the Territory.\n",
            "Doc1  2.4.2 Valeant shall follow all instructions and guidelines of Dova (of which Dova has provided Valeant copies) in\n",
            "connection with the use of any Dova Trademarks and Copyrights, and, if Dova reasonably objects to the manner in which any such\n",
            "Dova Trademarks and Copyrights are being used, Valeant shall cease the use of any such Dova Trademarks and Copyrights in\n",
            "such manner upon written notice from Dova thereof. Without limiting the foregoing, Valeant shall also adhere to at least the same\n",
            "quality control provisions as companies in the pharmaceutical industry adhere to for their own trademarks and copyrights. In all\n",
            "cases, Valeant shall use the Dova Trademarks and Copyrights with the necessary trademark (and copyright, as applicable)\n",
            "designations, and shall use the Dova Trademarks and Copyrights in a manner that does not derogate from Dova's rights in the\n",
            "Dova Trademarks and Copyrights. Valeant shall not at any time during the Term knowingly do or allow to be done any act or thing\n",
            "which will in any way impair or diminish the rights of Dova in or to the Dova Trademarks and Copyrights. All goodwill and\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "improved reputation generated by Valeant's use of the Dova Trademarks and Copyrights shall inure to the benefit of Dova, and\n",
            "any use of the Dova Trademarks and Copyrights by Valeant shall cease at the end of the Term. Valeant shall have no rights under\n",
            "this Agreement in or to the Dova Trademarks and Copyrights except as specifically provided herein. During the Term, Valeant will\n",
            "not contest the ownership of the Dova Trademarks and Copyrights, their validity, or the validity of any registration therefor. During\n",
            "the Term, Valeant will not knowingly register and/or use any marks (including in connection with any domain names) that are\n",
            "confusingly similar to the Dova Trademarks and Copyrights.\n",
            "\n",
            "\n",
            "Doc2  1.41 \"\n",
            "Doc1  1.41 \"\n",
            "\n",
            "\n",
            "Doc2  Excluded Channel \" shall have the meaning set forth in Section 4.2(d).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.42 \"\n",
            "Doc1  1.42 \"\n",
            "\n",
            "\n",
            "Doc2  Ex-US Commercial Rights \" shall have the meaning set forth in Section 3.1(c)(i).\n",
            "4\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.43 \"\n",
            "Doc1  1.43 \"\n",
            "\n",
            "\" shall have the meaning set forth in the preamble to this Agreement.\n",
            "\n",
            "Doc2  Ex-US Commercial Rights Transfer Notice \" shall have the meaning set forth in Section 3.1(c)(i).\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.44 \"\n",
            "Doc1  1.44 \"\n",
            "\n",
            "\n",
            "Doc2  FDA \" shall mean the United States Food and Drug Administration or any successor agency thereto.\n",
            "Doc1  FDA \" shall mean the United States Food and Drug Administration or any successor agency performing comparable\n",
            "functions.\n",
            "\n",
            "Doc2  1.45 \"\n",
            "Doc1  1.45 \"\n",
            "\n",
            "\n",
            "Doc2  FD&C Act \" shall mean the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations\n",
            "promulgated thereunder.\n",
            "Doc1  Act \" shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. SS 301 et seq., as it may be amended from\n",
            "time to time, and the regulations promulgated thereunder.\n",
            "\n",
            "Doc2  1.46 \"\n",
            "Doc1  1.46 \"\n",
            "\n",
            "\n",
            "Doc2  Finance Representative \" shall have the meaning set forth in Section 2.4.\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.47 \"\n",
            "Doc1  1.47 \"\n",
            "\n",
            "\n",
            "Doc2  First Promotion Fee Period \" shall have the meaning set forth in Section 4.2(c)(i).\n",
            "Doc1  Compliance Report \" shall have the meaning set forth in Section 4.2.2(c).\n",
            "\n",
            "Doc2  1.48 \"\n",
            "Doc1  1.48 \"\n",
            "\n",
            "\n",
            "Doc2  First Supplemental Promotion Fee \" shall have the meaning set forth in Section 4.2(c)(i).\n",
            "Doc1  Compliance Report \" shall have the meaning set forth in Section 4.2.2(c).\n",
            "\n",
            "Doc2  1.49 \"\n",
            "Doc1  1.49 \"\n",
            "\n",
            "\n",
            "Doc2  GAAP \" shall mean United States generally accepted accounting principles, consistently applied.\n",
            "Doc1  GAAP \" shall mean United States generally accepted accounting principles.\n",
            "\n",
            "Doc2  1.50 \"\n",
            "Doc1  1.50 \"\n",
            "\n",
            "\n",
            "Doc2  Governmental Authority \" to be broadly interpreted and includes: (a) any national, federal, state, local, regional, or foreign\n",
            "government, or level, branch, or subdivision thereof? (b) any multinational or public international organization or authority? (c)\n",
            "any ministry, department, bureau, division, authority, agency, commission, or body entitled to exercise any administrative,\n",
            "executive, judicial, legislative, police, regulatory, or taxing authority or power? (d) any court, tribunal, or governmental arbitrator\n",
            "or arbitral body? (e) any government-owned or controlled institution or entity? (f) any enterprise or instrumentality performing a\n",
            "governmental function? and (g) any political party.\n",
            "Doc1  Governmental Authority \" shall mean any court, agency, authority, department, regulatory body or other\n",
            "instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political\n",
            "subdivision of any such government or any supranational organization of which any such country is a member, which has competent\n",
            "and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this\n",
            "Agreement.\n",
            "4\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  1.51 \"\n",
            "Doc1  1.51 \"\n",
            "\n",
            "\n",
            "Doc2  Government Official \" to be broadly interpreted, shall mean (a) any elected or appointed government official (\n",
            "e.g.\n",
            ", a member of a\n",
            "ministry of health)? (b) any employee or person acting for or on behalf of a government, government-controlled entity or\n",
            "enterprise performing a governmental function? (c) any political party, candidate for public office, officer, employee, or person\n",
            "acting for or on behalf of a political party or candidate for public office? (d) any employee or person acting for or on behalf of a\n",
            "public international organization (\n",
            "e.g.\n",
            ", the United Nations)? or (e) any individual who holds himself or herself out to be the\n",
            "authorized intermediary of any of the foregoing. For clarity, healthcare providers employed by government-owned hospitals\n",
            "shall be considered Government Officials.\n",
            "Doc1  4.3.3 In performing the activities contemplated by this Agreement, neither Valeant nor Field Force Personnel shall\n",
            "make any payment, either directly or indirectly, of money or other assets to government or political party officials, officials of\n",
            "international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of\n",
            "any of the foregoing where such payment would constitute violation of any Applicable Law. In addition, Valeant shall not make any\n",
            "payment either directly or indirectly to officials if such payment is for the purpose of unlawfully influencing decisions or actions with\n",
            "respect to the subject matter of this Agreement.\n",
            "\n",
            "\n",
            "Doc2  1.52 \"\n",
            "Doc1  1.52. \"Retail Pharmacy \" shall mean an outlet which dispenses the Product directly to a patient in a retail setting or\n",
            "through mail order services.\n",
            "6\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  Gross Margin \" shall mean Laboratory Services Revenue less Cost of Sales.\n",
            "Doc1  Gross to Net Fraction \" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the net\n",
            "sales of the SKU of the Product in the Territory for an applicable period (based on the gross-to-net discounts for all sales of such\n",
            "SKU of the Product (i.e., sales attributable to the Specialty, as well as all other sales of such SKU of the Product), and (ii) the\n",
            "denominator of which is gross sales of such SKU of the Product in the Territory for an applicable period, in each case, as\n",
            "determined in accordance with Dova's revenue recognition policies, which is in accordance with GAAP (on a consistent basis), for\n",
            "quarterly financial reporting purposes, as reported in Dova's quarterly filings with the U.S. Securities Exchange Commission.\n",
            "\n",
            "Doc2  1.53 \"\n",
            "Doc1  1.53 \"\n",
            "\n",
            "\n",
            "Doc2  Gross Margin Percent \" shall mean the percentage as determined by multiplying (a) the fractional value of Gross Margin \n",
            "divided\n",
            "by\n",
            " Laboratory Service Revenue by (b) one hundred percent (100%).\n",
            "Doc1  Applicable Percentage \".\n",
            "(a)\n",
            "If the aggregate actual number of Details for the Product made by the Sales Representatives for a\n",
            "Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due\n",
            "under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\n",
            "(b)\n",
            "If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable\n",
            "Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar\n",
            "Quarter shall be reduced to a new percentage equal to [***].\n",
            "(c)\n",
            "In the event that subsections (a) above and (b) above are both applicable in an applicable Calendar\n",
            "Quarter, then the Applicable Percentage shall be reduced to a new percentage equal to the lower of the percentages calculated\n",
            "under subsections (a) and (b).\n",
            "\n",
            "Doc2  1.54 \"\n",
            "Doc1  1.54 \"\n",
            "\n",
            "\n",
            "Doc2  IDN \" shall mean an integrated healthcare delivery network.\n",
            "Doc1  Non-Retail Institution \" shall mean any institution (other than the Specialty Pharmacies, Retail Pharmacies and\n",
            "Intermediaries) to which Dova (or its Affiliates or its Intermediaries) sells and/or ships units of Product during the Term, which shall\n",
            "include group purchasing organizations (GPOs), hospitals, clinics, long term care facilities and any outlets that are a member of an\n",
            "Integrated Delivery Network (IDN), and with which Dova or its Affiliates do not have data agreements which enables Dova to\n",
            "track shipments of Product from such institution to patients based on the Target Professional prescribing such Product.\n",
            "\n",
            "Doc2  1.55 \"\n",
            "Doc1  1.55 \"\n",
            "\n",
            "\n",
            "Doc2  Incentive Compensation \" shall mean the compensation paid by or under the\n",
            "5\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "authority of Pfizer or any of its Affiliates to a Sales Representative involved in the Promotion of the Product under this\n",
            "Agreement based directly or indirectly on the sales of the products (including the Product) being Promoted by such Sales\n",
            "Representative in the Territory, including any target bonus, award or other incentive, but excluding (i) base salary and (ii) single\n",
            "product \n",
            "ad hoc\n",
            " awards or other similar individual product incentives, such as \"special incentive plans\" that, in the aggregate,\n",
            "do not exceed $2,000 per Calendar Year.\n",
            "Doc1  4.2.1(c). (d)\n",
            "[***]\n",
            "(e)\n",
            "Notwithstanding the terms of this Section 4.2.1, Valeant shall have the right, from time to time, during\n",
            "the Term, to include in the incentive compensation package of all or some of the Sales Representatives a spiff, spiv or other similar\n",
            "incentive bonus that is based on [***], provided that the actual, maximum payout from such incentive bonuses does not exceed, in\n",
            "the aggregate, an amount equal to [***] for each Sales Representative for each Calendar Quarter. Any such spiff, spiv or other\n",
            "similar incentive bonus shall not be included in the calculation of the applicable Sales Representatives incentive compensation\n",
            "package in determining Valeant's compliance with the terms of Section 4.1.3.\n",
            "\n",
            "\n",
            "Doc2  1.56 \"\n",
            "Doc1  1.56 \"\n",
            "\n",
            "\n",
            "Doc2  Included Revenue Percentage \" shall have the meaning set forth in Section 4.2(d).\n",
            "Doc1  Applicable Percentage \".\n",
            "(a)\n",
            "If the aggregate actual number of Details for the Product made by the Sales Representatives for a\n",
            "Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due\n",
            "under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\n",
            "(b)\n",
            "If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable\n",
            "Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar\n",
            "Quarter shall be reduced to a new percentage equal to [***].\n",
            "(c)\n",
            "In the event that subsections (a) above and (b) above are both applicable in an applicable Calendar\n",
            "Quarter, then the Applicable Percentage shall be reduced to a new percentage equal to the lower of the percentages calculated\n",
            "under subsections (a) and (b).\n",
            "\n",
            "Doc2  1.57 \"\n",
            "Doc1  1.57 \"\n",
            "\n",
            "\n",
            "Doc2  Incremental Laboratory Service Revenue \" shall have the meaning set forth in Section 4.2(a).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.58 \"\n",
            "Doc1  1.58 \"\n",
            "\n",
            "\n",
            "Doc2  Indemnified Party \" shall have the meaning set forth in Section 6.1(c)(i).\n",
            "Doc1  Indemnified Party \" shall have the meaning set forth in Section 11.3.\n",
            "\n",
            "Doc2  1.59 \"\n",
            "Doc1  1.59 \"\n",
            "\n",
            "\n",
            "Doc2  Indemnifying Party \" shall have the meaning set forth in Section 6.1(c)(i).\n",
            "Doc1  Indemnifying Party \" shall have the meaning set forth in Section 11.3.\n",
            "\n",
            "Doc2  1.60 \"\n",
            "Doc1  1.60 \"\n",
            "\n",
            "\n",
            "Doc2  JOC \" shall have the meaning set forth in Section 2.2(a)\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.61 \"\n",
            "Doc1  1.61 \"\n",
            "\n",
            "\n",
            "Doc2  JOC Co-Chair \" shall have the meaning set forth in Section 2.2(a).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.62 \"\n",
            "Doc1  1.62 \"\n",
            "\n",
            "\n",
            "Doc2  JRC \" shall have the meaning set forth in Section 2.3(a).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.63 \"\n",
            "Doc1  1.63 \"\n",
            "\n",
            "\n",
            "Doc2  JSC \" shall have the meaning set forth in Section 2.1(a).\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.64 \"\n",
            "Doc1  1.64 \"\n",
            "Third Party(ies)\n",
            "\" shall mean any person or entity other than Dova and Valeant and their respective Affiliates.\n",
            "\n",
            "\n",
            "Doc2  JSC Co-Chair \" shall have the meaning set forth in Section 2.1(b).\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.65 \"\n",
            "Doc1  1.65 \"\n",
            "\n",
            "\n",
            "Doc2  JSC Members \" shall have the meaning set forth in Section 2.1(a).\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.66. \"KAM Team\"  shall have the meaning set forth in Section 3.4(c).\n",
            "Doc1  1.66 \"\n",
            "\n",
            "\n",
            "Doc2  1.67 \"\n",
            "Doc1  1.67 \"\n",
            "\n",
            "\n",
            "Doc2  Laboratory Service Revenue \" shall mean, with respect to a particular Calendar Quarter, as applicable, Exact's revenue earned from\n",
            "performing the Product Laboratory Service in the Territory with regard to patient samples collected in the Territory, subject to\n",
            "Section 4.2(d), as calculated by Exact in accordance with GAAP consistently applied, less the following deductions: (i) trade,\n",
            "quantity or cash discounts, credits, adjustments or allowances, including without limitation those granted in connection with\n",
            "managed care network agreements and those granted on account of price adjustments, billing errors, rejected goods, damaged\n",
            "goods or incomplete tests or other services? (ii) rebates and chargebacks allowed, given or accrued (including, but not limited\n",
            "to, cash, governmental and managed care rebates, hospital or other buying group chargebacks, and governmental taxes in the\n",
            "nature of a rebate based on usage levels or sales of the Product Laboratory Service)? and (iii) patient compliance incentives that\n",
            "are treated as a reduction in revenue in accordance with GAAP, including without limitation gift cards to patients.\n",
            "Doc1  Gross to Net Fraction \" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the net\n",
            "sales of the SKU of the Product in the Territory for an applicable period (based on the gross-to-net discounts for all sales of such\n",
            "SKU of the Product (i.e., sales attributable to the Specialty, as well as all other sales of such SKU of the Product), and (ii) the\n",
            "denominator of which is gross sales of such SKU of the Product in the Territory for an applicable period, in each case, as\n",
            "determined in accordance with Dova's revenue recognition policies, which is in accordance with GAAP (on a consistent basis), for\n",
            "quarterly financial reporting purposes, as reported in Dova's quarterly filings with the U.S. Securities Exchange Commission.\n",
            "\n",
            "Doc2  1.68 \"\n",
            "Doc1  1.68 \"\n",
            "\n",
            "\n",
            "Doc2  Launch Date \" shall mean October 1, 2018.\n",
            "Doc1  Calendar Quarter \" shall mean each successive period of three (3) calendar months commencing on January 1, April\n",
            "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the\n",
            "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar\n",
            "Quarter shall end on the last day of the Term.\n",
            "\n",
            "Doc2  1.69 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Marketing \" shall mean, with respect to a medical device subject to pre-market\n",
            "6\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "approval, Advertising, public relations, medical education activities, market research, creation, development, and distribution of\n",
            "Advertising and Promotional materials, field literature, direct or indirect educational campaigns, and exhibits at seminars and\n",
            "conventions. When used as a verb, \"\n",
            "Doc1  Know-How \" shall mean information, whether or not in written form, including biological, chemical, pharmacological,\n",
            "toxicological, medical or clinical, analytical, quality, manufacturing, research, or sales and marketing information, including\n",
            "processes, methods, procedures, techniques, plans, programs and data.\n",
            "\n",
            "Doc2  Market \" means to engage in Marketing.\n",
            "Doc1  4.7. . Dova shall provide to Valeant certain information relating to the sale, commercialization, marketing and promotion of the Product, as may be mutually agreed by the Parties from time to time, for use by Valeant and the Field Force\n",
            "Personnel in connection with the Valeant Activities. Such information may include data from the applicable reimbursement HUB,\n",
            "specialty data aggregator, market research, and market access contracting and Third Party-provided brand performance data\n",
            "([***]). The timing of the delivery of such information shall be mutually agreed upon by the Parties, acting reasonably.\n",
            "\n",
            "\n",
            "Doc2  1.70 \"\n",
            "OB/Gyn Commercial Rights\n",
            "\" shall have the meaning set forth in Section 3.1(c)(ii).\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.71 \"\n",
            "OB/Gyn Commercial Rights Transfer Notice\n",
            "\" shall have the meaning set forth in Section 3.1(c)(ii).\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.72 \"\n",
            "OB/Gyn Field\n",
            "\" shall mean those healthcare professionals and practices customarily considered OB/Gyn providers and practices.\n",
            "Doc1  Specialty \" shall mean (i) Target Professionals with a primary or secondary specialty designation of\n",
            "Gastroenterology, Colorectal Surgery or Proctology (excluding any such Target Professionals with a primary or secondary\n",
            "specialty designation of Hepatology (including Transplant Hepatology), in each case, as determined by data reported by Dova's\n",
            "Third Party Data Source, subject to any adjustments determined pursuant to the process set out in Section 6.5, and (ii) all\n",
            "healthcare professionals with Nurse or Physician Assistant specialty designations affiliated with the Target Professionals described\n",
            "in subsection (i), as adjusted.\n",
            "\n",
            "Doc2  1.73 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Occurrence \" shall have the meaning set forth in Section 2.6(c).\n",
            "Doc1  Compliance Report \" shall have the meaning set forth in Section 4.2.2(c).\n",
            "\n",
            "Doc2  1.74 \"\n",
            "\" or \"\n",
            "\" shall have the meaning set forth in the preamble.\n",
            "Doc1  1.4 \"\n",
            "\n",
            "\" shall have the meaning set forth in the preamble to this Agreement.\n",
            "\n",
            "Doc2  1.75 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Patent Rights \" shall mean any and all (a) issued patents, (b) pending patent applications, including all provisional applications,\n",
            "substitutions, continuations, continuations-in-part, divisionals, and renewals, and all patents granted thereon, (c) patents of\n",
            "addition, reissues, reexaminations and extensions or restorations by existing or future extension or restorations mechanisms,\n",
            "including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d)\n",
            "inventor's certificates, (e) other forms of government issued rights substantially similar to the foregoing and (f) United States\n",
            "and foreign counterparts of any of the foregoing.\n",
            "Doc1  8.1.2. . Subject to the terms of Section 8.1.1, Dova shall have and retain sole and exclusive right, title and interest in and to all inventions, developments, discoveries, writings, trade secrets, Know-How, methods, practices,\n",
            "procedures, designs, improvements and other technology, whether or not patentable or copyrightable, and any patent applications,\n",
            "patents, or copyrights based thereon (collectively, \"\n",
            "\n",
            "\") relating to the Product that are (i) owned or controlled\n",
            "by Dova as of the Effective Date, (ii) made, discovered, conceived, reduced to practice or generated by Dova (or its employees\n",
            "or representatives) during the Term, or (iii) made, discovered, conceived, reduced to practice or generated by Valeant (or its\n",
            "employees or representatives) in performing its activities pursuant to this Agreement to the extent primarily related to the Product\n",
            "or which is otherwise derived from the Confidential Information of Dova (\"\n",
            "\"). Valeant agrees to assign, and hereby\n",
            "does assign, to Dova (and shall cause its Affiliates and its and their respective employees and other representatives to assign to\n",
            "Dova) any and all right, title and interest that Valeant (or any such Affiliates, employees or other representatives) may have in or to\n",
            "any Invention. For clarity, any and all Inventions and any information contained therein or related thereto shall constitute\n",
            "Confidential Information of Dova.\n",
            "\n",
            "Doc2  1.76 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Payer \" shall mean a Third Party entity that pays a portion or all of the cost of the Product Laboratory Service performed with\n",
            "respect to a given patient using the Product. For clarity, a patient who pays for the cost of his or her own Product Laboratory\n",
            "Service, in whole or in part, shall not be included in this definition of \"Payer\" and a \"Payer\" may include government entities or\n",
            "agencies, managed care organizations, and health or prescription insurance providers.\n",
            "Doc1  Adverse Event \" shall mean any untoward medical occurrence in a patient or clinical investigation subject who is\n",
            "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is\n",
            "used. An \"Adverse Event\" can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or\n",
            "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that\n",
            "worsened in severity after administration of the Product would be considered an \"Adverse Event\".\n",
            "\n",
            "Doc2  1.77 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Person \" shall mean an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation,\n",
            "limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or\n",
            "organization, including a government or political subdivision or department or agency of a government.\n",
            "Doc1  Person \" shall mean any individual, corporation, partnership, limited liability company, association, joint-stock\n",
            "company, trust, unincorporated organization or other entity, or government or political subdivision thereof.\n",
            "\n",
            "Doc2  1.78 \"\n",
            "\" shall have the meaning set forth in the preamble.\n",
            "Doc1  Effective Date \" shall have the meaning set forth in the preamble to this Agreement.\n",
            "\n",
            "Doc2  1.79 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Pfizer Indemnitee \" shall have the meaning set forth in Section 6.1(a).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.80 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Pfizer JSC Members \" shall have the meaning set forth in Section 2.1(a).\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  1.81 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Pfizer Trainers \" shall have the meaning set forth in Section 3.2(e)(i).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.82 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  PhRMA Code \" shall have the meaning set forth in Section 3.2(c)(ii).\n",
            "7\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Doc1  Code \" shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical\n",
            "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.\n",
            "\n",
            "Doc2  1.83 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Pre-Launch Meeting \" shall have the meaning set forth in Section 3.2(e)(v).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.84 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Product \" shall mean the medical device subject to pre-market approval currently commercialized under the brand name\n",
            "\"COLOGUARD\" and indicated for the qualitative detection of colorectal neoplasia associated DNA markers and for the\n",
            "presence of occult hemoglobin in human stool.\n",
            "Doc1  13.17. . Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Exhibit, of or to, as the case\n",
            "may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words of any\n",
            "gender include each other gender, (b) words such as \"herein\", \"hereof\", and \"hereunder\" refer to this Agreement as a whole and\n",
            "not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice\n",
            "versa, (d) whenever any provision of this Agreement uses the term \"including\" (or \"includes\"), such term shall be deemed to mean\n",
            "\"including without limitation\" (or \"includes without limitations\"), and (e) references to any Articles or Sections include Sections and\n",
            "subsections that are part of the references' Article or Section (e.g., a section numbered \"Section 2.2.1\" would be part of \"Section\n",
            "\n",
            "\n",
            "Doc2  1.85 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Product Label \" shall mean the labels and labeling documents approved on August 11, 2014 by the FDA under the Premarket\n",
            "Approval P130017, , and any supplements, extensions or changes thereto.\n",
            "Doc1  Product Labeling \" shall mean the labels and other written, printed or graphic matter upon (a) any container or\n",
            "wrapper utilized with the Product or (b) any written material accompanying the Product, including Product package inserts, in each\n",
            "case as approved by the FDA.\n",
            "\n",
            "Doc2  1.86 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Product Laboratory Service \" shall mean the colorectal cancer screening test performed on a specimen provided by a patient using\n",
            "the Product, including specimen collection, laboratory testing, data handling and analysis, interpretation of results, patient\n",
            "compliance (including call center activity) and billing to be provided by Exact or its Affiliates according to the \"Laboratory\n",
            "Instruction for Use\" in the Product Label, wherein the Laboratory Instructions for Use are further subject to any changes as\n",
            "required by any pre-market approval supplements approved by the FDA.\n",
            "Doc1  Adverse Event \" shall mean any untoward medical occurrence in a patient or clinical investigation subject who is\n",
            "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is\n",
            "used. An \"Adverse Event\" can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or\n",
            "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that\n",
            "worsened in severity after administration of the Product would be considered an \"Adverse Event\".\n",
            "\n",
            "Doc2  1.87 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Product Training \" shall mean, with respect to the Product, the Product-specific training program conducted in accordance with the\n",
            "applicable Annual Marketing Plan and Applicable Laws, which may include training concerning (a) the scientific basis for the\n",
            "Product, (b) permissible communications regarding safety and efficacy claims relating to the Product, (c) permissible\n",
            "communications related to the Product in accordance with the Product Label, (d) use of Promotional Materials by the Sales\n",
            "Representatives, and (e) other appropriate topics relevant to the Promotion of the Product as determined by Exact in\n",
            "consultation with Pfizer.\n",
            "Doc1  4.4. .. 4.4.1 Training, Training Materials and Promotional Materials.\n",
            "(a)\n",
            "Subject to the terms of this Section 4.4.1, Dova shall prepare and control the content of (i) all Product\n",
            "training materials for Field Force Personnel (the \"\n",
            "\n",
            "\") and (ii) all Product marketing and educational\n",
            "materials (the \"\n",
            "\n",
            "Doc2  1.88 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Promotion \" shall mean (a) those activities customarily undertaken by a Party's field sales representatives in the Territory to\n",
            "encourage the approved use of a particular prescription medical device (or prescription pharmaceutical medicine as applicable)\n",
            "subject to pre-market approval (or other regulatory approval, as applicable), including detailing, and (b) any other activities\n",
            "customarily undertaken by a Party aimed at encouraging the approved use of a particular prescription medical device subject to\n",
            "pre-market authorization approval, including without limitation, healthcare professional peer-to-peer communication,\n",
            "communications of product benefits to IDNs, the creation and use of promotional materials, Marketing, meetings and events\n",
            "(including without limitation speaker bureau events), trade shows, advocacy activities, including with respect to guideline\n",
            "organizations, and sponsorships. The terms \"\n",
            "Doc1  Valeant Activities \" shall mean any and all promotional activities (including Detailing) conducted by Valeant to\n",
            "encourage the appropriate use of the Product in the Specialty in the Field in the Territory in accordance with the terms of this\n",
            "Agreement.\n",
            "\n",
            "Doc2  Promote \", \"\n",
            "Doc1  3.3.4 facilitate the flow of information and otherwise promote the communications and collaboration within and\n",
            "among the Parties relating to this Agreement and the promotion of the Product?\n",
            "\n",
            "\n",
            "Doc2  Promoting \" and \"\n",
            "Doc1  2.2.1 responsibility for promoting the Product outside the Specialty?\n",
            "\n",
            "\n",
            "Doc2  Promotional \" shall have corresponding meanings.\n",
            "Doc1  3.3.10 discuss the Promotional Materials matters described in Section 4.4.1(b)?\n",
            "\n",
            "\n",
            "Doc2  1.89 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Promotion Fee \" shall have the meaning set forth in Section 4.2(a).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.90 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Promotional Materials \" shall mean, with respect to the Product, all written, printed, graphic, electronic, audio, video or other\n",
            "materials (such as a journal reprint) other than the Product Label, provided by Exact, with respect to currently\n",
            "8\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "developed materials, or developed by the Parties, in each case, for use by a Party's Sales Representatives during Details or\n",
            "other Representatives in the Territory.\n",
            "Doc1  Promotional Materials \") (the Product Training Materials and the Promotional Materials, collectively, the\n",
            "\"\n",
            "\"). Dova shall be solely responsible for ensuring that the Product Materials prepared and approved by it are\n",
            "in compliance with the Regulatory Approval for the Product, the Product Labeling and Applicable Law. Once approved by Dova,\n",
            "the content of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant\n",
            "to review such content and provide verbal feedback to Dova in advance of use of the Product Materials. Within [***] of receipt of\n",
            "such Product Materials, Valeant shall verbally provide to Dova any comments and/or proposed revisions to such Product\n",
            "Materials, which comments and revisions Dova shall reasonably consider so long as Dova deems such suggestions are acceptable\n",
            "in the promotion of the Product? provided that in any event, to the extent that Dova reasonably believes that such changes are not\n",
            "in compliance with Applicable Law, the Regulatory Approval for the Product or the applicable Product Labeling, then Dova shall\n",
            "not be required to incorporate any such suggestions from Valeant in the Product Materials. In the event of any disagreement\n",
            "between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova shall have the right\n",
            "to conclusively determine such matter. If Valeant has provided comments to Dova on the Product Materials and Dova accepts\n",
            "some or all of such comments, then, once revised, Dova shall provide to Valeant the revised versions of such Product Materials for\n",
            "further review by Valeant, in accordance with the terms and timelines of this Section 4.4.1(a) above. Valeant shall use only Product\n",
            "Materials approved by Dova in the performance of Valeant Activities under this Agreement? provided, however, that Valeant shall\n",
            "not be required to use any Product Materials that have not been approved by Valeant or which have not incorporated comments\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "provided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant\n",
            "reserves the right not to use certain Product Materials. The content of Product Materials shall not be modified or changed by\n",
            "Valeant or Field Force Personnel at any time without the prior written approval of Dova in each instance. Dova shall be\n",
            "responsible for the costs and expenses of creation and development of the Product Materials and Valeant shall be responsible for\n",
            "the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant. The Parties will\n",
            "coordinate the production and delivery of Product Materials to allow sufficient internal and field force review time to accommodate\n",
            "scheduled training meetings and distribution to Field Force Personnel that are engaged in Detailing. In the event that Dova incurs\n",
            "costs and expenses for which Valeant is responsible under this Section 4.4.1, Dova may deduct such amounts from the payments\n",
            "due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3. Promptly after the\n",
            "Effective Date, the Parties will collaborate to finalize the Product Materials in accordance with this Section 4.4.1(a), as soon as\n",
            "reasonably practical.\n",
            "(b)\n",
            "Commencing with the Promotional Materials to be used for Calendar Year 2019 and for the remainder\n",
            "of the Term, Valeant and Dova shall meet to discuss the content of such Promotional Materials in order to ensure that such\n",
            "Promotional Materials appropriately address any messaging that may be desired for the Target Professionals in the Specialty. Such\n",
            "discussions may take place in the forum of the JSC. Dova shall in good faith reasonably consider all comments and suggestions of\n",
            "Valeant regarding the Promotional Materials.\n",
            "(c)\n",
            "Promptly after the Effective Date, the Parties will collaborate to plan and schedule training for the Sales\n",
            "Representatives at a mutually acceptable time(s) and date(s), including a launch meeting for the Sales Representatives at a mutually\n",
            "acceptable location. Dova will lead such initial training and Valeant shall cooperate with any reasonable requests of Dova in order\n",
            "to support such training. The costs and expenses of such launch meeting will be shared equally by the Parties, other than travel and\n",
            "lodging for the Sales Representatives which shall be the responsibility of Valeant. All other training costs and expenses shall be the\n",
            "responsibility of Valeant. After the initial training, the Parties will collaborate to provide additional training at such frequency, times\n",
            "and places as the circumstances warrant and the Parties mutually agree. Valeant shall have the right, but not the obligation, to\n",
            "conduct such additional training itself, provided that the Valeant trainers have been trained by Dova, and provided further that\n",
            "Dova shall have the right to attend such training upon reasonable notice by Valeant to Dova. Valeant will certify in writing to Dova\n",
            "that all Field Force Personnel have completed the training described in this Section 4.4.1(b).\n",
            "(d)\n",
            "Valeant and all Field Force Personnel that are engaged in Valeant Activities shall comply with the\n",
            "applicable provisions of the Code, and shall be trained on Valeant's compliance policies, including those that are consistent with the\n",
            "applicable provisions of Sec. 1128B(b) of the Social Security Act and the American Medical Association Ethical Guidelines for\n",
            "Gifts to Physicians from Industry (which such training may have been accomplished prior to the Term), prior to commencing any\n",
            "Valeant Activities. Valeant agrees that it shall train any employee or agent of Valeant who is involved in performing the activities\n",
            "contemplated by this Agreement on anti-corruption and anti-bribery at its own expense.\n",
            "(e)\n",
            "Field Force Personnel that are engaged in Detailing shall conduct the Valeant Activities only after having\n",
            "undergone the training described in this Section 4.4 and, without limiting the foregoing, no Field Force Personnel member shall\n",
            "Detail the Product without having undergone such training. Subject to the foregoing, Valeant shall have the responsibility for on-\n",
            "going training of its Field Force Personnel that are engaged in Detailing in accordance with customary practice in the\n",
            "pharmaceutical industry.\n",
            "\n",
            "Doc2  1.91 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  QSR \" shall mean the Quality System Regulation, 21 C.F.R. Part 820, as may be amended from time to time and any successor\n",
            "thereto.\n",
            "Doc1  Act \" shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. SS 301 et seq., as it may be amended from\n",
            "time to time, and the regulations promulgated thereunder.\n",
            "\n",
            "Doc2  1.92 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Receiving Party \" shall have the meaning set forth in Section 7.1.\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.93 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Regulatory Approval \" shall mean, with respect to a prescription medical device subject to pre-market authorization approval in any\n",
            "jurisdiction in the Territory for a given indication, all technical, medical and scientific licenses, registrations, authorizations and\n",
            "approvals of pre-market approval application, supplements and amendments, and pre- and post- approvals of the FDA,\n",
            "sufficient for the manufacture, distribution, use and sale of such prescription medical device, including any services associated\n",
            "with such medical device, in such jurisdiction in the Territory for such indication in accordance with Applicable Law, excluding\n",
            "any pricing and reimbursement approvals.\n",
            "Doc1  Regulatory Approval \" shall mean any and all necessary approvals, licenses, registrations or authorizations from\n",
            "any Governmental Authority, in each case, necessary to commercialize the Product in the Territory.\n",
            "\n",
            "Doc2  1.94 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Renewal Term \" shall have the meaning set forth in Section 8.2.\n",
            "Doc1  Term \" shall have the meaning set forth in Section 12.1.\n",
            "\n",
            "Doc2  1.95 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Representatives \" shall mean, with respect to a Party, such Party's employees, agents or independent contractors, and such Party's\n",
            "Affiliates and their respective employees, agents or independent contractors, including Sales Representatives, in each case who\n",
            "are performing services under the Annual Marketing Plan.\n",
            "Doc1  11.2. . Valeant shall defend, indemnify and hold harmless Dova and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims and all\n",
            "associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any\n",
            "misrepresentation or breach of any representations, warranties, agreements or covenants of Valeant under this Agreement, or (b)\n",
            "the negligence, willful misconduct, or violation of Applicable Laws by Valeant (or any of its Affiliates or its and their respective\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "officers, directors, employees, agents or representatives)? except in each case to the extent any such Claims, and all associated\n",
            "Losses, are caused by an item for which Dova is obligated to indemnify Valeant pursuant to Section 11.1.\n",
            "\n",
            "\n",
            "Doc2  1.96 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Sales Deployment Plan \" shall have the meaning set forth in Section 3.2(c)(i).\n",
            "Doc1  Compliance Report \" shall have the meaning set forth in Section 4.2.2(c).\n",
            "\n",
            "Doc2  1.97 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Sales Representative \" shall mean an internal or field sales representative employed by a Party full-time who details products or\n",
            "services for human use in the Territory. For clarity, Sales Representative excludes sales managers such as district business\n",
            "managers and above.\n",
            "Doc1  Sales Representative \" shall mean an individual employed and compensated by Valeant as a full-time employee as\n",
            "part of its sales forces and who engages in Detailing of the Designated Product (or the Alternate Product, as the case may be) in\n",
            "the Territory, and who is also trained with respect to the Product in accordance with this Agreement (including the Product\n",
            "Labeling and the use of the Promotional Materials) to deliver Details for the Product in the Field in the Territory.\n",
            "\n",
            "Doc2  1.98 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Senior Officers \" shall mean, with respect to Exact, the Chief Executive Officer of Exact and, with respect to Pfizer, Regional\n",
            "President, North America, Internal Medicine, Pfizer Innovative Health.\n",
            "Doc1  Senior Officer \" shall mean, with respect to Dova, its President and Chief Executive Officer (or such officer's\n",
            "designee), and with respect to Valeant, its [***] (or such officer's designee). From time to time, each Party may change its Senior\n",
            "Officer by giving written notice to the other Party.\n",
            "\n",
            "Doc2  1.99 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Shared M&P Expense \" shall mean the incremental investment in Promotion expense above the Baseline M&P Expenses agreed to\n",
            "by the Parties, as set forth in Sections 3.5 and 3.6.\n",
            "Doc1  4.6. . Other than as expressly set out herein, Valeant shall be solely responsible for any and all costs and expenses incurred by Valeant or any of its Affiliates in connection with the conduct of\n",
            "the Valeant Activities for the Product hereunder, including all costs and expenses in connection with Sales Representatives,\n",
            "including salaries, travel expenses and other expenses, credentialing, licensing, providing benefits, deducting federal, state and local\n",
            "payroll taxes, and paying workers' compensation premiums, unemployment insurance contributions and any other payments\n",
            "required by Applicable Laws to be made on behalf of employees.\n",
            "\n",
            "\n",
            "Doc2  1.100 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Tail Period \" shall have the meaning set forth in Section 8.7.\n",
            "Doc1  12.5. . Solely in the event that Dova has terminated this Agreement pursuant to Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion services performed by Valeant during the Term, with respect\n",
            "to the Tail Period, Dova shall make payments to Valeant in an amount equal to [***] of the amounts that would have been payable\n",
            "by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had the Agreement not been so terminated. Such\n",
            "payments shall be made within [***] following the end of each calendar quarter in the Tail Period. Sections 6.3, 6.4 and 6.5 shall\n",
            "apply, \n",
            "mutatis mutandis\n",
            ", to such Tail Period payments. For clarity, no tail payment shall be due following any expiration or\n",
            "termination of this Agreement except as set forth in this Section 12.5.\n",
            "\n",
            "\n",
            "Doc2  1.101 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Term \" shall have the meaning set forth in Section 8.1.\n",
            "Doc1  Term \" shall have the meaning set forth in Section 12.1.\n",
            "\n",
            "Doc2  1.102 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Territory \" shall mean the fifty (50) states of the United States and the District of Columbia and includes Puerto Rico.\n",
            "Doc1  $ \" shall mean United States dollar.\n",
            "\n",
            "Doc2  1.103 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Third Party \" shall mean any Person other than Exact, Pfizer or their respective Affiliates.\n",
            "Doc1  1.64 \"\n",
            "Third Party(ies)\n",
            "\" shall mean any person or entity other than Dova and Valeant and their respective Affiliates.\n",
            "\n",
            "\n",
            "Doc2  1.104 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Trademark \" shall mean any registered word, name, symbol, color, designation or\n",
            "9\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "device or any combination thereof, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo\n",
            "or business symbol.\n",
            "Doc1  13.15. . Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for\n",
            "any purpose in connection with the performance of this Agreement.\n",
            "\n",
            "\n",
            "Doc2  1.105 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Training Materials \" shall mean, with respect to the Product, the materials (which may include written or other recorded,\n",
            "videotaped or web-based training materials or online training programs) to be used in Product Training for a Party's Sales\n",
            "Representatives regarding the Product.\n",
            "Doc1  4.4. .. 4.4.1 Training, Training Materials and Promotional Materials.\n",
            "(a)\n",
            "Subject to the terms of this Section 4.4.1, Dova shall prepare and control the content of (i) all Product\n",
            "training materials for Field Force Personnel (the \"\n",
            "\n",
            "\") and (ii) all Product marketing and educational\n",
            "materials (the \"\n",
            "\n",
            "Doc2  1.106 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  VAT \" shall have the meaning set forth in Section 4.4.\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  1.107 \"\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  Violating Party \" shall have the meaning set forth in Section 8.3(d).\n",
            "Doc1  Product Materials \" shall have the meaning set forth in Section 4.4.1(a).\n",
            "\n",
            "Doc2  2.. GOVERNANCE.. 2.1. Joint Steering Committee. (a)\n",
            "Doc1  2.1.  Engagement? Grant of Rights.. 8. 2.2.  Retention of Rights.. 9. 2.3.  Non-Competition? Non-Solicitation.. 9. 2.4.  Dova Trademarks and Copyrights.. 10. ARTICLE 3 JOINT STEERING COMMITTEE 11\n",
            "\n",
            "Doc2  Composition.  Promptly following the Effective Date, the Parties will establish a Joint Steering Committee (\"\n",
            "\"), comprised of\n",
            "three (3) Representatives of Exact and three (3) Representatives of Pfizer. The JSC Representatives for each of Exact and\n",
            "Pfizer will be referred to herein as the \"\n",
            "\" and the \"\n",
            "\", respectively, and the Exact\n",
            "JSC Members and the Pfizer JSC Members will be referred to herein as the \"\n",
            "\". Each Party may replace any\n",
            "of its JSC Members at any time upon notice to the other Party and the Parties may increase or decrease the number of its\n",
            "JSC Members on the JSC? \n",
            "provided\n",
            " that at all times an equal number of JSC Members from each Party are appointed to\n",
            "the JSC.\n",
            "(b)\n",
            "Doc1  3.1. . As soon as practicable, but no later than twenty (20) days after the Effective Date, the Parties shall form a joint steering committee (\"\n",
            "\n",
            "\") whose responsibilities during the Term shall be to oversee the activities set forth in\n",
            "Section 3.3. The JSC shall consist of three (3) representatives from each Party, each with suitable seniority and relevant experience\n",
            "and expertise to enable such person to address matters falling within the purview of the JSC. From time to time, each Party may\n",
            "change any of its representatives on the JSC by giving written notice to the other Party. The meetings of the JSC will be chaired by\n",
            "a representative from Dova or Valeant, on an alternating basis. The JSC shall determine a meeting schedule? provided, that, in any\n",
            "event, meetings shall be conducted no less frequently than quarterly by teleconference or in person, or as otherwise agreed by the\n",
            "Parties. In person meetings shall occur at such places as mutually agreed by the Parties. Employees or consultants of either Party\n",
            "that are not representatives of the Parties on the JSC may attend meetings of the JSC? provided, that such attendees (i) shall not\n",
            "participate in the decision-making process of the JSC, and (ii) are bound by obligations of confidentiality and non-disclosure\n",
            "equivalent to those set forth in ARTICLE 9.\n",
            "\n",
            "Doc2  Committee Chair.  The JSC will be co-chaired by a Pfizer JSC Member and an Exact JSC Member (each, a \"\n",
            "\").\n",
            "Each Party may replace its JSC Co-Chair at any time upon notice to the other Party. The role of secretary of the JSC shall\n",
            "rotate each meeting between the JSC Co-Chairs (or any JSC Member who is appointed, by mutual agreement of both JSC\n",
            "Co-Chairs, as secretary of the JSC). The secretary of the JSC shall:\n",
            "(i)\n",
            "notify each Party at least fifteen (15) days (or as much notice as is reasonably possible) in advance of each JSC\n",
            "meeting?\n",
            "(ii)\n",
            "collect and organize agenda items from each Party for each JSC meeting?\n",
            "(iii)\n",
            "prepare and circulate to JSC Members each JSC meeting agenda no later than five (5) Business Days (or as far in\n",
            "advance as is reasonably possible) prior to the scheduled date for each JSC meeting? and\n",
            "(iv)\n",
            "prepare the written minutes of each JSC meeting and, within fifteen (15) days after such meeting, circulate such\n",
            "minutes for review and approval by the Parties.\n",
            "10\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(c)\n",
            "Doc1  3.2. . Meetings of the JSC may be called by either Party on no less than thirty (30) days' notice during the Term. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to\n",
            "such proposed items at least ten (10) days in advance to the applicable meeting? provided that under exigent circumstances\n",
            "requiring input by the JSC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the\n",
            "meeting, or may propose that there not be a specific agenda for that particular meeting, so long as the other Party consents to such\n",
            "later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably\n",
            "withheld. The chairperson shall prepare and circulate for review and approval of the Parties minutes of each meeting within thirty\n",
            "(30) days after the meeting. Each Party shall bear its own costs for its members to attend such meetings.\n",
            "\n",
            "\n",
            "Doc2  Meetings.  The JSC will meet no less than once each Calendar Quarter (or less frequently upon mutual agreement of the Parties)\n",
            "either in-person or by audio or video teleconference. Meetings of the JSC will occur at such times and places in the\n",
            "Territory as mutually agreed to by the Parties? \n",
            "provided, however\n",
            ", that no more than half of the meetings will be required\n",
            "to be held in-person in any Calendar Year. Meetings of the JSC will only occur if at least one JSC Member of each Party\n",
            "is present at the meeting or participating by teleconference or videoconference. Each Party will be solely responsible for,\n",
            "and will not be entitled to any reimbursement from the other Party with respect to, any and all personnel costs or\n",
            "expenses (including travel expenses) incurred by or on behalf of its Representatives in connection with participation in\n",
            "any JSC meetings or sub-committee or working group meetings, or any other travel required to be undertaken by either\n",
            "Party's personnel in connection with the performance of the Agreement. The Parties will endeavor to schedule meetings\n",
            "of the JSC at least fifteen (15) days in advance. The Parties shall approve the minutes of each meeting promptly, but in\n",
            "no event later than the next meeting of the JSC.\n",
            "(d)\n",
            "Doc1  3.1. . As soon as practicable, but no later than twenty (20) days after the Effective Date, the Parties shall form a joint steering committee (\"\n",
            "\n",
            "\") whose responsibilities during the Term shall be to oversee the activities set forth in\n",
            "Section 3.3. The JSC shall consist of three (3) representatives from each Party, each with suitable seniority and relevant experience\n",
            "and expertise to enable such person to address matters falling within the purview of the JSC. From time to time, each Party may\n",
            "change any of its representatives on the JSC by giving written notice to the other Party. The meetings of the JSC will be chaired by\n",
            "a representative from Dova or Valeant, on an alternating basis. The JSC shall determine a meeting schedule? provided, that, in any\n",
            "event, meetings shall be conducted no less frequently than quarterly by teleconference or in person, or as otherwise agreed by the\n",
            "Parties. In person meetings shall occur at such places as mutually agreed by the Parties. Employees or consultants of either Party\n",
            "that are not representatives of the Parties on the JSC may attend meetings of the JSC? provided, that such attendees (i) shall not\n",
            "participate in the decision-making process of the JSC, and (ii) are bound by obligations of confidentiality and non-disclosure\n",
            "equivalent to those set forth in ARTICLE 9.\n",
            "\n",
            "Doc2  JSC Responsibilities.  The JSC shall:\n",
            "(i)\n",
            "review, discuss, and approve each Annual Marketing Plan for a Calendar Year, including the quarterly baseline budget\n",
            "amounts contained therein, no later than the applicable date set forth in Section 3.3(a)?\n",
            "(ii)\n",
            "oversee the implementation of each Annual Marketing Plan?\n",
            "(iii)\n",
            "review, discuss, and approve any modifications to the Annual Marketing Plan submitted by the JOC?\n",
            "(iv)\n",
            "oversee the JOC and JRC and each committee's activities?\n",
            "(v)\n",
            "act as the first level escalation to resolve disputes between the Parties, any resolution of dispute brought before the\n",
            "JSC shall be by the unanimous consent of both JSC Co-Chairs?\n",
            "(vi)\n",
            "form and oversee any sub-committee or working group in furtherance of activities contemplated in the Annual\n",
            "Marketing Plan?\n",
            "(vii)\n",
            "form and oversee any sub-committee or working group as determined by the JSC to be necessary to review and\n",
            "discuss specific matters related to the subject matter of this Agreement, but not enumerated as a specific\n",
            "responsibility of the JSC, JOC, JRC, or any other properly formed and constituted sub-committee?\n",
            "(viii)\n",
            "review, discuss and approve the allocation of Baseline M&P Expenses and Shared M&P Expenses submitted by the\n",
            "Doc1  3.3.14 form and oversee any sub-committee or working group in furtherance of the activities contemplated by this\n",
            "Agreement?\n",
            "\n",
            "\n",
            "Doc2  JOC? 11\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(ix)\n",
            "review all reports, including sales performance data and other key performance indicators, submitted by the JOC? and\n",
            "(x)\n",
            "escalate any Disputed JSC Matter, as defined in Section 2.1(e), to the Alliance Managers and Senior Officers.\n",
            "(e)\n",
            "Doc1  3.4. . Meetings of the JSC will occur only if at least one representative of each Party is present at the meeting. Each Party shall have one (1) vote. The JSC will use good faith efforts to reach consensus on all matters properly brought\n",
            "before it. If the JSC does not reach unanimous consensus on an issue at a meeting or within a period of [***] thereafter, then the\n",
            "JSC shall submit in writing the respective positions of the Parties to the Senior Officers of the Parties. Such Senior Officers shall\n",
            "use good faith efforts to resolve promptly such matter, which good faith efforts shall include at least one (1) teleconference between\n",
            "such Senior Officers within [***] after the JSC's submission of such matter to them. Any final decision mutually agreed to in\n",
            "writing by the Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are not able to agree on the\n",
            "resolution of any such issue within [***] after such issue was first referred to them, then (i) Valeant shall have the right to\n",
            "conclusively determine all matters related to Valeant Activities and Detailing of the Product, including matters relating to the\n",
            "institutional account manager team, the incentive compensation of the Sales Representatives and targeting for Details, provided that\n",
            "such determination and any related activities comply with the terms and conditions of this Agreement, and (ii) Dova shall have the\n",
            "right to conclusively determine all other matters? provided, however, for clarity any such determination shall not amend, modify or\n",
            "waive any provisions of this Agreement or definitively interpret the provisions of this Agreement.\n",
            "\n",
            "\n",
            "Doc2  Decision Making.  Regardless of the number of Pfizer JSC Members or Exact JSC Members, decisions by the JSC will be made\n",
            "by unanimous agreement. The JSC will use good faith efforts to reach agreement on any and all matters properly\n",
            "brought before it. If, despite such good faith efforts, the JSC is unable to reach a decision on a particular matter within\n",
            "the JSC's responsibilities (each such matter, a \"\n",
            "\"), within five (5) Business Days after the JSC first\n",
            "meets to consider such matter, or such later date as may be mutually agreed by the Parties in writing, then either Party\n",
            "may refer such Disputed JSC Matter for resolution to the Alliance Managers. Within three (3) Business Days after such\n",
            "Disputed JSC Matter is referred to the Alliance Managers, the Alliance Managers shall determine whether the Disputed\n",
            "JSC Matter requires the involvement of the Senior Officers. Should the Alliance Managers refer the Disputed JSC Matter\n",
            "to the Senior Officers, then the Senior Officers will promptly initiate good faith discussions to resolve such Disputed\n",
            "JSC Matter. If the Senior Officers are unable to resolve such Disputed JSC Matter within five (5) Business Days of it\n",
            "being referred to them, then, Exact, after having considered, in good faith, the advice and input from Pfizer, will have final\n",
            "decision-making authority with respect to such Disputed JSC Matter where the subject matter of the Disputed JSC\n",
            "Matter substantially relates to (i) Product pricing, including any rebates or discounts? (ii) manufacturing? (iii) research\n",
            "and development, including any trials? and (iv) engagement with Governmental Authorities? \n",
            "provided, however\n",
            ", that\n",
            "Exact will not have final decision making authority to require Pfizer to conduct any activities that Pfizer, in good faith,\n",
            "believes violate Applicable Law or Pfizer's Applicable Compliance/Review Policies. For all Disputed JSC Matters that are\n",
            "not resolved by the Senior Officers and are not subject to Exact's final decision-making authority, neither Party will take\n",
            "any action on such Disputed JSC Matter until resolution can be reached in accordance with this Section 2.1(e), and,\n",
            "except in the case of a potential violation of Applicable Law, pending such resolution the Parties shall continue to carry\n",
            "out activities under this Agreement in accordance with the then-current Annual Marketing Plan.\n",
            "(f)\n",
            "Doc1  3.4. . Meetings of the JSC will occur only if at least one representative of each Party is present at the meeting. Each Party shall have one (1) vote. The JSC will use good faith efforts to reach consensus on all matters properly brought\n",
            "before it. If the JSC does not reach unanimous consensus on an issue at a meeting or within a period of [***] thereafter, then the\n",
            "JSC shall submit in writing the respective positions of the Parties to the Senior Officers of the Parties. Such Senior Officers shall\n",
            "use good faith efforts to resolve promptly such matter, which good faith efforts shall include at least one (1) teleconference between\n",
            "such Senior Officers within [***] after the JSC's submission of such matter to them. Any final decision mutually agreed to in\n",
            "writing by the Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are not able to agree on the\n",
            "resolution of any such issue within [***] after such issue was first referred to them, then (i) Valeant shall have the right to\n",
            "conclusively determine all matters related to Valeant Activities and Detailing of the Product, including matters relating to the\n",
            "institutional account manager team, the incentive compensation of the Sales Representatives and targeting for Details, provided that\n",
            "such determination and any related activities comply with the terms and conditions of this Agreement, and (ii) Dova shall have the\n",
            "right to conclusively determine all other matters? provided, however, for clarity any such determination shall not amend, modify or\n",
            "waive any provisions of this Agreement or definitively interpret the provisions of this Agreement.\n",
            "\n",
            "\n",
            "Doc2  Limits on JSC Authority.  Notwithstanding any provision of this Section 2.1 to the contrary, (i) each Party will retain the rights,\n",
            "powers and discretion granted to it under this Agreement consistent with Section 3.2(a), and no such rights, powers, or\n",
            "discretion will be delegated to or vested in the JSC unless such delegation or vesting of rights is expressly provided for\n",
            "in this Agreement or the Parties expressly so agree in writing, (ii) the JSC will not have the power to amend this\n",
            "Agreement or terminate or otherwise modify or waive compliance with this Agreement in any manner and (iii) neither\n",
            "Party will require the other Party to (A) breach any obligation or agreement that\n",
            "12\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "such other Party may have with or to a Third Party or (B) perform any activities that are materially different, greater in\n",
            "scope or more costly than those provided for in the Annual Marketing Plan then in effect.\n",
            "Doc1  3.3.16 perform such other responsibilities as may be mutually agreed upon by the Parties in writing from time to\n",
            "time? provided, however, for clarity the JSC shall have no authority to amend or modify any provisions of this Agreement and no\n",
            "authority to waive or definitively interpret the provisions of this Agreement.\n",
            "\n",
            "\n",
            "Doc2  2.2. Joint Operations Committee. (a)\n",
            "Promptly following the Effective Date, the Parties will establish a Joint Operations Committee (\"\n",
            "\"),\n",
            "comprised of marketing, sales, medical, finance, and such other Representatives of each Party as necessary. The JOC\n",
            "shall be co-chaired by each Party's marketing Representative on the JOC, as designated by the JSC Co-Chair of each\n",
            "Party (each, a \"\n",
            "\"). Each JOC Co-Chair shall (i) have knowledge and expertise in the commercialization of\n",
            "prescription products and services in the Territory, (ii) have sufficient seniority within the applicable Party to make\n",
            "decisions arising within the scope of the JOC's responsibilities, and (iii) be authorized under such Party's internal\n",
            "governance procedures to make decisions or carry out the activities given to such Party under this Agreement.\n",
            "(b)\n",
            "Doc1  3.1. . As soon as practicable, but no later than twenty (20) days after the Effective Date, the Parties shall form a joint steering committee (\"\n",
            "\n",
            "\") whose responsibilities during the Term shall be to oversee the activities set forth in\n",
            "Section 3.3. The JSC shall consist of three (3) representatives from each Party, each with suitable seniority and relevant experience\n",
            "and expertise to enable such person to address matters falling within the purview of the JSC. From time to time, each Party may\n",
            "change any of its representatives on the JSC by giving written notice to the other Party. The meetings of the JSC will be chaired by\n",
            "a representative from Dova or Valeant, on an alternating basis. The JSC shall determine a meeting schedule? provided, that, in any\n",
            "event, meetings shall be conducted no less frequently than quarterly by teleconference or in person, or as otherwise agreed by the\n",
            "Parties. In person meetings shall occur at such places as mutually agreed by the Parties. Employees or consultants of either Party\n",
            "that are not representatives of the Parties on the JSC may attend meetings of the JSC? provided, that such attendees (i) shall not\n",
            "participate in the decision-making process of the JSC, and (ii) are bound by obligations of confidentiality and non-disclosure\n",
            "equivalent to those set forth in ARTICLE 9.\n",
            "\n",
            "Doc2  Meetings.  The JOC shall meet once each month (or more or less frequently upon mutual agreement of the Parties) either in-\n",
            "person or by audio or video teleconference. Meetings of the JOC will occur at such times and places in the Territory as\n",
            "mutually agreed to by the Parties. Each Party will be solely responsible for, and will not be entitled to any reimbursement\n",
            "from the other Party with respect to, any and all personnel costs or expenses (including travel expenses) which are\n",
            "incurred by or on behalf of its Representatives in connection with participation in any JOC meetings or sub-committee or\n",
            "working group meetings, or any other travel required to be undertaken by either Party's personnel in connection with\n",
            "the performance of the Agreement.\n",
            "(c)\n",
            "Doc1  3.1. . As soon as practicable, but no later than twenty (20) days after the Effective Date, the Parties shall form a joint steering committee (\"\n",
            "\n",
            "\") whose responsibilities during the Term shall be to oversee the activities set forth in\n",
            "Section 3.3. The JSC shall consist of three (3) representatives from each Party, each with suitable seniority and relevant experience\n",
            "and expertise to enable such person to address matters falling within the purview of the JSC. From time to time, each Party may\n",
            "change any of its representatives on the JSC by giving written notice to the other Party. The meetings of the JSC will be chaired by\n",
            "a representative from Dova or Valeant, on an alternating basis. The JSC shall determine a meeting schedule? provided, that, in any\n",
            "event, meetings shall be conducted no less frequently than quarterly by teleconference or in person, or as otherwise agreed by the\n",
            "Parties. In person meetings shall occur at such places as mutually agreed by the Parties. Employees or consultants of either Party\n",
            "that are not representatives of the Parties on the JSC may attend meetings of the JSC? provided, that such attendees (i) shall not\n",
            "participate in the decision-making process of the JSC, and (ii) are bound by obligations of confidentiality and non-disclosure\n",
            "equivalent to those set forth in ARTICLE 9.\n",
            "\n",
            "Doc2  JOC Responsibilities.  The JOC shall:\n",
            "(i)\n",
            "prepare the Annual Marketing Plan for review and approval by JSC?\n",
            "(ii)\n",
            "prepare and review Product Marketing strategies and tactics?\n",
            "(iii)\n",
            "prepare allocation of Baseline M&P Expenses and Shared M&P Expense for JSC review and approval?\n",
            "(iv)\n",
            "prepare reports, including sales performance data and other key performance indicators for JSC review in accordance\n",
            "with Exhibit 2.2(c)(iv)?\n",
            "(v)\n",
            "execute and monitor the strategies and tactics in the Annual Marketing Plan?\n",
            "13\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(vi)\n",
            "monitor Product supply and Product Laboratory Service capacity to ensure they are sufficient to meet the demand\n",
            "forecast in the Annual Marketing Plan?\n",
            "(vii)\n",
            "establish key supply, capacity, inventory, and such other metrics to inform the JSC?\n",
            "(viii)\n",
            "prepare any revision to the Annual Marketing Plan as directed by the JSC or otherwise proposed pursuant to\n",
            "Section 3.3(a)?\n",
            "(ix)\n",
            "provide consent to materials for reconsideration by the JSC pursuant to Section 2.3(d)? and\n",
            "(x)\n",
            "with respect to the Annual Marketing Plan, ensure that a consultation with the Compliance Managers is completed\n",
            "and appropriate compliance measures are incorporated into the Annual Marketing Plan.\n",
            "(d)\n",
            "Decisions by the JOC will be made by unanimous agreement. If a unanimous decision cannot be reached,\n",
            "then any disputed matter within the JOC's responsibilities (the \"\n",
            "\") may be escalated by either\n",
            "Party to the JSC for resolution in accordance with Section 2.1(e). Unless and until resolved by the JSC in accordance\n",
            "with Section 2.1(e), neither Party shall take any action with respect to such Disputed JOC Matter and, except in the case\n",
            "of a potential violation of Applicable Law, pending such resolution the Parties shall continue to carry out the activities\n",
            "under this Agreement in accordance with the then-current Annual Marketing Plan.\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  2.3. Joint Review Committee. (a)\n",
            "Promptly following the Effective Date (and in any event, within thirty (30) days of the Effective Date), under the\n",
            "supervision of the JSC, the Parties will establish a Joint Review Committee (\"\n",
            "\"), comprised of marketing, medical,\n",
            "legal, and regulatory Representatives of the Parties. Each Party may appoint one medical, legal and regulatory\n",
            "Representative member to the JRC. The marketing Representatives from the Parties shall coordinate administration and\n",
            "operation of the JRC meetings, including setting agendas, recording decisions regarding materials reviewed, and\n",
            "coordinating review to ensure timely review and approval of Promotional Materials. The Representatives from the\n",
            "Parties on the JRC shall coordinate operational support including scheduling of JRC meetings, timely distribution of\n",
            "materials for review, recording and archiving of approved materials, and other such activities to ensure operational\n",
            "efficiency of JRC meetings. It is the expectation of the Parties that the JRC will utilize Exact's review and approval system\n",
            "to review and approve materials, including Promotional Materials that are subject to JRC review under Section 2.3(c).\n",
            "14\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(b)\n",
            " The JRC shall meet no less than once each month (or more frequently upon mutual agreement of the members of the\n",
            "JRC) either in-person or by audio or video teleconference. Meetings of the JRC will occur at such times and places in the\n",
            "Territory as mutually agreed to by the Parties. Each Party will be solely responsible for, and will not be entitled to any\n",
            "reimbursement from the other Party with respect to, any and all personnel costs or expenses (including travel expenses)\n",
            "which are incurred by or on behalf of its Representatives in connection with participation in any JRC meetings, or any\n",
            "other travel required to be undertaken by either Party's personnel in connection with the performance of the Agreement.\n",
            "(c)\n",
            "Doc1  Promotional Materials \") (the Product Training Materials and the Promotional Materials, collectively, the\n",
            "\"\n",
            "\"). Dova shall be solely responsible for ensuring that the Product Materials prepared and approved by it are\n",
            "in compliance with the Regulatory Approval for the Product, the Product Labeling and Applicable Law. Once approved by Dova,\n",
            "the content of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant\n",
            "to review such content and provide verbal feedback to Dova in advance of use of the Product Materials. Within [***] of receipt of\n",
            "such Product Materials, Valeant shall verbally provide to Dova any comments and/or proposed revisions to such Product\n",
            "Materials, which comments and revisions Dova shall reasonably consider so long as Dova deems such suggestions are acceptable\n",
            "in the promotion of the Product? provided that in any event, to the extent that Dova reasonably believes that such changes are not\n",
            "in compliance with Applicable Law, the Regulatory Approval for the Product or the applicable Product Labeling, then Dova shall\n",
            "not be required to incorporate any such suggestions from Valeant in the Product Materials. In the event of any disagreement\n",
            "between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova shall have the right\n",
            "to conclusively determine such matter. If Valeant has provided comments to Dova on the Product Materials and Dova accepts\n",
            "some or all of such comments, then, once revised, Dova shall provide to Valeant the revised versions of such Product Materials for\n",
            "further review by Valeant, in accordance with the terms and timelines of this Section 4.4.1(a) above. Valeant shall use only Product\n",
            "Materials approved by Dova in the performance of Valeant Activities under this Agreement? provided, however, that Valeant shall\n",
            "not be required to use any Product Materials that have not been approved by Valeant or which have not incorporated comments\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "provided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant\n",
            "reserves the right not to use certain Product Materials. The content of Product Materials shall not be modified or changed by\n",
            "Valeant or Field Force Personnel at any time without the prior written approval of Dova in each instance. Dova shall be\n",
            "responsible for the costs and expenses of creation and development of the Product Materials and Valeant shall be responsible for\n",
            "the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant. The Parties will\n",
            "coordinate the production and delivery of Product Materials to allow sufficient internal and field force review time to accommodate\n",
            "scheduled training meetings and distribution to Field Force Personnel that are engaged in Detailing. In the event that Dova incurs\n",
            "costs and expenses for which Valeant is responsible under this Section 4.4.1, Dova may deduct such amounts from the payments\n",
            "due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3. Promptly after the\n",
            "Effective Date, the Parties will collaborate to finalize the Product Materials in accordance with this Section 4.4.1(a), as soon as\n",
            "reasonably practical.\n",
            "(b)\n",
            "Commencing with the Promotional Materials to be used for Calendar Year 2019 and for the remainder\n",
            "of the Term, Valeant and Dova shall meet to discuss the content of such Promotional Materials in order to ensure that such\n",
            "Promotional Materials appropriately address any messaging that may be desired for the Target Professionals in the Specialty. Such\n",
            "discussions may take place in the forum of the JSC. Dova shall in good faith reasonably consider all comments and suggestions of\n",
            "Valeant regarding the Promotional Materials.\n",
            "(c)\n",
            "Promptly after the Effective Date, the Parties will collaborate to plan and schedule training for the Sales\n",
            "Representatives at a mutually acceptable time(s) and date(s), including a launch meeting for the Sales Representatives at a mutually\n",
            "acceptable location. Dova will lead such initial training and Valeant shall cooperate with any reasonable requests of Dova in order\n",
            "to support such training. The costs and expenses of such launch meeting will be shared equally by the Parties, other than travel and\n",
            "lodging for the Sales Representatives which shall be the responsibility of Valeant. All other training costs and expenses shall be the\n",
            "responsibility of Valeant. After the initial training, the Parties will collaborate to provide additional training at such frequency, times\n",
            "and places as the circumstances warrant and the Parties mutually agree. Valeant shall have the right, but not the obligation, to\n",
            "conduct such additional training itself, provided that the Valeant trainers have been trained by Dova, and provided further that\n",
            "Dova shall have the right to attend such training upon reasonable notice by Valeant to Dova. Valeant will certify in writing to Dova\n",
            "that all Field Force Personnel have completed the training described in this Section 4.4.1(b).\n",
            "(d)\n",
            "Valeant and all Field Force Personnel that are engaged in Valeant Activities shall comply with the\n",
            "applicable provisions of the Code, and shall be trained on Valeant's compliance policies, including those that are consistent with the\n",
            "applicable provisions of Sec. 1128B(b) of the Social Security Act and the American Medical Association Ethical Guidelines for\n",
            "Gifts to Physicians from Industry (which such training may have been accomplished prior to the Term), prior to commencing any\n",
            "Valeant Activities. Valeant agrees that it shall train any employee or agent of Valeant who is involved in performing the activities\n",
            "contemplated by this Agreement on anti-corruption and anti-bribery at its own expense.\n",
            "(e)\n",
            "Field Force Personnel that are engaged in Detailing shall conduct the Valeant Activities only after having\n",
            "undergone the training described in this Section 4.4 and, without limiting the foregoing, no Field Force Personnel member shall\n",
            "Detail the Product without having undergone such training. Subject to the foregoing, Valeant shall have the responsibility for on-\n",
            "going training of its Field Force Personnel that are engaged in Detailing in accordance with customary practice in the\n",
            "pharmaceutical industry.\n",
            "\n",
            "Doc2  JRC Responsibilities.  The JRC shall be responsible for review and approval of all Product or related disease education\n",
            "materials, Promotional Materials and other communication to a Third Party, including pharmaco-economic data, that may\n",
            "be used in Promotion, medical to medical communication, patient education, press release or any other form of external\n",
            "communication intended for healthcare professionals, healthcare organized customers (such as IDNs and hospitals), and\n",
            "Payer organizations, patients or others who are reasonably likely to influence the prescription, use, reimbursement, or\n",
            "purchase of the Product. The JRC shall also ensure that all such materials are in compliance with Applicable Law and\n",
            "each Party's Applicable Compliance/Review Policies. Any conflict between the Parties' Applicable Compliance/Review\n",
            "Policies will be discussed by the JRC and the Compliance Managers to determine an appropriate resolution of such\n",
            "conflict.\n",
            "(d)\n",
            "Decisions by the JRC will be made by unanimous agreement. If a unanimous decision cannot be reached,\n",
            "then the disputed matter (the \"\n",
            "\") can be escalated by either Party to the JSC for resolution in\n",
            "accordance with Section 2.1(e). Unless and until resolved by the JSC in accordance with Section 2.1(e), neither Party\n",
            "shall take any action with respect to such Disputed JRC Matter and, except in the case of a legal or ethical issue, the\n",
            "Parties shall continue to carry out the activities under this Agreement in accordance with the then-current Annual\n",
            "Marketing Plan. A Disputed JRC Matter that is substantially similar in subject matter of a prior Disputed JRC Matter\n",
            "shall not be resubmitted for JSC review and resolution under this Section 2.3(d).\n",
            "Doc1  4.3.11. . As soon as practicable, but no later than thirty (30) days after the Effective Date, each Party shall appoint a representative to act as its compliance manager under this Agreement, each of which is routinely\n",
            "responsible for advising such Party on compliance matters and has suitable seniority and other relevant experience and expertise\n",
            "(each, a \"\n",
            "\n",
            "\"). From time to time, each Party may change its Compliance Manager by giving written notice to\n",
            "the other Party. The Compliance Managers shall serve as a key point of contact between the Parties for compliance-related\n",
            "matters. Each Compliance Manager shall facilitate the resolution of any compliance issue with the Compliance Manager of the\n",
            "other Party. The Compliance Managers will use good faith efforts to reach consensus on all compliance matters. If the Compliance\n",
            "Managers do not reach consensus on an issue promptly, then such issue shall be submitted to dispute resolution process described\n",
            "in Section 13.6. Upon the reasonable request of Dova from to time, Valeant shall deliver to Dova copies of Valeant's compliance\n",
            "program policies and compliance training materials which are applicable to the Field Force Personnel's promotion of the Product.\n",
            "Other than as expressly stated herein, Valeant shall not be required to modify its compliance policies or practices in connection\n",
            "with the compliance-related provisions herein.\n",
            "\n",
            "Doc2  2.4. Finance Representative.  Each Party shall appoint a finance contact to oversee all financial reporting and communications under this\n",
            "Agreement during the Term (each, a \"\n",
            "\"). Each Party may change its designated Finance Representative at\n",
            "any time upon written notice to the other Party. Each Finance Representative will coordinate the efforts of its respective Party in\n",
            "conducting finance activities, including all financial reporting and financial communications between the Parties, under this\n",
            "Agreement during the Term.\n",
            "Doc1  4.1.4. . Each Party shall appoint a person who shall oversee interactions between the Parties for all matters related to this Agreement, and any related agreements between the Parties (each an \"\n",
            "\n",
            "\n",
            "Doc2  2.5. Alliance Managers.  Each Party shall appoint an employee of such Party who shall oversee interactions between the Parties for all\n",
            "matters related to this Agreement, the\n",
            "15\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Annual Marketing Plan and any related agreements between the Parties or their Affiliates (each an \"\n",
            "\"). The\n",
            "Alliance Managers shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange\n",
            "of information, and shall serve as a single point of contact for any matters arising under this Agreement. The Alliance Managers\n",
            "shall have the right to attend all JSC and subcommittee meetings as non-voting participants and may bring to the attention of the\n",
            "JSC or subcommittee any matters or issues either of them reasonably believes should be discussed, and shall have such other\n",
            "responsibilities as the Parties may mutually agree in writing. Each Party may designate different Alliance Managers by notice in\n",
            "writing to the other Party.\n",
            "Doc1  Alliance Manager \"). The\n",
            "Alliance Managers shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of\n",
            "information, and shall serve as a single point of contact for all matters arising under this Agreement. The Alliance Managers shall\n",
            "have the right to attend all JSC meetings and if applicable, subcommittee meetings as non-voting participants and may bring to the\n",
            "attention of the JSC or, if applicable, subcommittee any matters or issues either of them reasonably believes should be discussed,\n",
            "and shall have such other responsibilities as the Parties may mutually agree in writing. Each Party may designate different Alliance\n",
            "Mangers by notice in writing to the other Party.\n",
            "\n",
            "Doc2  2.6. Compliance Managers.  Within thirty (30) days after the Effective Date, Pfizer and Exact each agrees to appoint a Representative who\n",
            "(a) has received compliance training by such Party and (b) is routinely responsible for advising such Party on compliance matters\n",
            "to act as its Compliance Manager (each, a \"\n",
            "\"). The Compliance Managers shall support the JSC.\n",
            "(a)\n",
            "Doc1  4.3.11. . As soon as practicable, but no later than thirty (30) days after the Effective Date, each Party shall appoint a representative to act as its compliance manager under this Agreement, each of which is routinely\n",
            "responsible for advising such Party on compliance matters and has suitable seniority and other relevant experience and expertise\n",
            "(each, a \"\n",
            "\n",
            "\"). From time to time, each Party may change its Compliance Manager by giving written notice to\n",
            "the other Party. The Compliance Managers shall serve as a key point of contact between the Parties for compliance-related\n",
            "matters. Each Compliance Manager shall facilitate the resolution of any compliance issue with the Compliance Manager of the\n",
            "other Party. The Compliance Managers will use good faith efforts to reach consensus on all compliance matters. If the Compliance\n",
            "Managers do not reach consensus on an issue promptly, then such issue shall be submitted to dispute resolution process described\n",
            "in Section 13.6. Upon the reasonable request of Dova from to time, Valeant shall deliver to Dova copies of Valeant's compliance\n",
            "program policies and compliance training materials which are applicable to the Field Force Personnel's promotion of the Product.\n",
            "Other than as expressly stated herein, Valeant shall not be required to modify its compliance policies or practices in connection\n",
            "with the compliance-related provisions herein.\n",
            "\n",
            "Doc2  Responsibilities.  Compliance Managers shall resolve discrepancies between the Parties' respective Applicable\n",
            "Compliance/Review Policies, ensure that each Party has a process to monitor the activities under this Agreement for\n",
            "compliance with Applicable Laws and Applicable Compliance/Review Polices, serve as a key point of contact between\n",
            "the Parties for compliance-related matters, and review the Annual Marketing Plan for compliance with Applicable\n",
            "Compliance/Review Policies and shall promptly notify the JSC of any compliance issues in such Annual Marketing Plan.\n",
            "The JOC shall promptly notify the Compliance Managers of any material revisions to the Annual Marketing Plan. Each\n",
            "Compliance Manager shall facilitate the resolution of any compliance issue with the Compliance Manager of the other\n",
            "Party.\n",
            "(b)\n",
            "Doc1  4.3.11. . As soon as practicable, but no later than thirty (30) days after the Effective Date, each Party shall appoint a representative to act as its compliance manager under this Agreement, each of which is routinely\n",
            "responsible for advising such Party on compliance matters and has suitable seniority and other relevant experience and expertise\n",
            "(each, a \"\n",
            "\n",
            "\"). From time to time, each Party may change its Compliance Manager by giving written notice to\n",
            "the other Party. The Compliance Managers shall serve as a key point of contact between the Parties for compliance-related\n",
            "matters. Each Compliance Manager shall facilitate the resolution of any compliance issue with the Compliance Manager of the\n",
            "other Party. The Compliance Managers will use good faith efforts to reach consensus on all compliance matters. If the Compliance\n",
            "Managers do not reach consensus on an issue promptly, then such issue shall be submitted to dispute resolution process described\n",
            "in Section 13.6. Upon the reasonable request of Dova from to time, Valeant shall deliver to Dova copies of Valeant's compliance\n",
            "program policies and compliance training materials which are applicable to the Field Force Personnel's promotion of the Product.\n",
            "Other than as expressly stated herein, Valeant shall not be required to modify its compliance policies or practices in connection\n",
            "with the compliance-related provisions herein.\n",
            "\n",
            "Doc2  Notification.  Subject to the terms of this Agreement, the Compliance Manager of a Party shall promptly notify the other\n",
            "Party's Compliance Manager in the event that it becomes aware of a potential violation by the other Party of: (i) the\n",
            "other Party's policies or procedures? (ii) any criminal, civil, or administrative laws or regulations applicable to any federal\n",
            "health care program or for which penalties or exclusions may be authorized? or (iii) the requirements under the FD&C\n",
            "Act, or relevant FDA guidance documents related to the Products, payments, or services under this Agreement.\n",
            "(c)\n",
            "Doc1  4.3.11. . As soon as practicable, but no later than thirty (30) days after the Effective Date, each Party shall appoint a representative to act as its compliance manager under this Agreement, each of which is routinely\n",
            "responsible for advising such Party on compliance matters and has suitable seniority and other relevant experience and expertise\n",
            "(each, a \"\n",
            "\n",
            "\"). From time to time, each Party may change its Compliance Manager by giving written notice to\n",
            "the other Party. The Compliance Managers shall serve as a key point of contact between the Parties for compliance-related\n",
            "matters. Each Compliance Manager shall facilitate the resolution of any compliance issue with the Compliance Manager of the\n",
            "other Party. The Compliance Managers will use good faith efforts to reach consensus on all compliance matters. If the Compliance\n",
            "Managers do not reach consensus on an issue promptly, then such issue shall be submitted to dispute resolution process described\n",
            "in Section 13.6. Upon the reasonable request of Dova from to time, Valeant shall deliver to Dova copies of Valeant's compliance\n",
            "program policies and compliance training materials which are applicable to the Field Force Personnel's promotion of the Product.\n",
            "Other than as expressly stated herein, Valeant shall not be required to modify its compliance policies or practices in connection\n",
            "with the compliance-related provisions herein.\n",
            "\n",
            "Doc2  Investigations.  If a Party finds, following an investigation, credible evidence of a significant violation of any applicable\n",
            "policies and procedures that are designed to ensure compliance with: (i) any criminal, civil, or administrative laws or\n",
            "regulations applicable to any federal health care program or for which penalties or exclusions may be authorized? or (ii)\n",
            "the requirements under the FD&C Act, or relevant FDA guidance documents related to the Products, payments, or\n",
            "services under this Agreement (an \"\n",
            "\"), the Party's Compliance Manager shall promptly inform the other\n",
            "Party of the Occurrence and steps taken by the Party to remediate the Occurrence, except\n",
            "16\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "to the extent that the disclosing Party's counsel reasonably believes that such disclosure to the other Party could\n",
            "violate Applicable Law (including privacy laws) or have a significant adverse impact on the disclosing Party's legal\n",
            "position or defense (including the loss of attorney-client privilege) with respect to any such Occurrence. In the event\n",
            "that either Party determines that disclosure of relevant factual information regarding an Occurrence could violate\n",
            "Applicable Laws (including privacy laws) or have a significant adverse impact on its legal position or defense (including\n",
            "the loss of attorney-client privilege), the determining Party shall promptly notify the other Party in writing that the\n",
            "determining Party is exercising its right not to disclose relevant factual information regarding an Occurrence.\n",
            "(d)\n",
            "Each Party shall follow its Applicable Compliance/Review Policies subject to specific exceptions explicitly determined by the\n",
            "Compliance Managers.\n",
            "Doc1  9.1.2. . Notwithstanding the obligations set forth in Section 9.1.1, a Party may disclose the other Party's Confidential Information and the terms of this Agreement to the extent:\n",
            "(a)\n",
            "such disclosure is reasonably necessary (x) to comply with the requirements of Governmental\n",
            "Authorities? or (y) for the prosecuting or defending litigation as contemplated by this Agreement?\n",
            "(b)\n",
            "such disclosure is reasonably necessary to its Affiliates, employees, agents, consultants and contractors\n",
            "on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement? provided\n",
            "that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this\n",
            "Agreement and the disclosing Party shall be liable for any failures of such disclosees to abide by such obligations of confidentiality\n",
            "and non-use? or\n",
            "(c)\n",
            "such disclosure is reasonably necessary to comply with Applicable Laws, including regulations\n",
            "promulgated by applicable securities exchanges, court order, administrative subpoena or order.\n",
            "Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party's\n",
            "Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of\n",
            "such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party's cost) in obtaining, a\n",
            "protective order preventing or limiting the required disclosure.\n",
            "\n",
            "\n",
            "Doc2  3.. APPOINTMENT? PRODUCT OWNERSHIP? MARKETING AND SALES.. 3.1. Appointment. (a)\n",
            "Doc1  JSC \" shall have the meaning set forth in Section 3.1.\n",
            "\n",
            "Doc2  Exclusive Arrangement.  Commencing on the Launch Date, Exact and its Affiliates hereby grant to Pfizer and its Affiliates, on\n",
            "an exclusive basis for the Co-Promote Field (except as to Exact and its Affiliates), and Pfizer accepts, the right and\n",
            "obligation to Promote and Detail the Product in the Territory during the Term jointly with Exact, in accordance with the\n",
            "terms and conditions of this Agreement, all Applicable Laws and the applicable Annual Marketing Plan. Except as set\n",
            "forth in this Agreement, such right shall be non-transferable and non-sublicensable. In implementing its obligations\n",
            "under this Agreement, Pfizer, without charge or expense to Exact (other than as expressly set forth in Sections 3.6 and\n",
            "Doc1  2.1. . During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product\n",
            "in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account\n",
            "management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance\n",
            "with the terms and conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the right for Dova and\n",
            "its Affiliates to promote the Product in the Territory including in the Specialty. Valeant shall have no other rights relating to the\n",
            "Product, except as specifically set forth in this Agreement and, without limiting the foregoing, except as set out in Section 4.1.5, if\n",
            "agreed upon, Valeant shall have no right to, and shall not, conduct the Valeant Activities for the Product outside the Specialty or\n",
            "outside the Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant's rights and obligations under this Section\n",
            "\n",
            "\n",
            "Doc2  4.2(c) of this Agreement), shall provide facilities, personnel (including management and Sales Representatives) and other resources as Pfizer, in its reasonable discretion but not inconsistent with the express terms of this Agreement,\n",
            "believes necessary. The Parties specifically agree that Exact shall not use the Pfizer name, logo or any Trademarks of\n",
            "Pfizer on any materials, including Promotional Materials, without the express written consent of Pfizer. Notwithstanding\n",
            "this Section 3.1 to the contrary, Exact retains the right to Promote the Product on its own behalf in the Co-Promote Field\n",
            "and, subject to Section 3.1(c), Pfizer shall not Promote or Detail the Product outside the Territory or outside the Co-\n",
            "Promote Field.\n",
            "(b)\n",
            "\n",
            "Doc1  2.1. . During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product\n",
            "in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account\n",
            "management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance\n",
            "with the terms and conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the right for Dova and\n",
            "its Affiliates to promote the Product in the Territory including in the Specialty. Valeant shall have no other rights relating to the\n",
            "Product, except as specifically set forth in this Agreement and, without limiting the foregoing, except as set out in Section 4.1.5, if\n",
            "agreed upon, Valeant shall have no right to, and shall not, conduct the Valeant Activities for the Product outside the Specialty or\n",
            "outside the Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant's rights and obligations under this Section\n",
            "\n",
            "\n",
            "Doc2  Grant of License to Pfizer.  Subject to the terms of this Agreement, Exact on behalf of itself and its Affiliates, hereby grants to\n",
            "Pfizer a non-exclusive, royalty free license, with the right to sublicense to one or more of its Affiliates, under the Exact\n",
            "House Marks, the Exact Trademarks and the Exact Copyrights, during the Term, to the extent necessary or appropriate to\n",
            "allow Pfizer and its Affiliates to carry out activities under this Agreement including to Promote and Detail the Product in\n",
            "the Co-Promote Field in the Territory. Such license shall be non-transferable and non-sublicensable\n",
            "17\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(except as provided in this Agreement) and shall automatically terminate upon the expiration or earlier termination of this\n",
            "Agreement.\n",
            "(c)\n",
            "Doc1  2.1. . During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product\n",
            "in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account\n",
            "management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance\n",
            "with the terms and conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the right for Dova and\n",
            "its Affiliates to promote the Product in the Territory including in the Specialty. Valeant shall have no other rights relating to the\n",
            "Product, except as specifically set forth in this Agreement and, without limiting the foregoing, except as set out in Section 4.1.5, if\n",
            "agreed upon, Valeant shall have no right to, and shall not, conduct the Valeant Activities for the Product outside the Specialty or\n",
            "outside the Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant's rights and obligations under this Section\n",
            "\n",
            "\n",
            "Doc2  Right of First Negotiation. (i)\n",
            "During the Term, if Exact (i) enters a formal process authorized or directed by its board of directors or CEO to seek and\n",
            "enter into an arrangement or (ii) intends to agree to a term sheet or seeks to sign a letter of intent or similar\n",
            "arrangement to grant an exclusive commercial license to a Third Party solely to promote or sell the Product\n",
            "outside the Territory (\"\n",
            "\"), Exact shall first notify Pfizer of such intent (a \"\n",
            "Doc1  2.1. . During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product\n",
            "in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account\n",
            "management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance\n",
            "with the terms and conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the right for Dova and\n",
            "its Affiliates to promote the Product in the Territory including in the Specialty. Valeant shall have no other rights relating to the\n",
            "Product, except as specifically set forth in this Agreement and, without limiting the foregoing, except as set out in Section 4.1.5, if\n",
            "agreed upon, Valeant shall have no right to, and shall not, conduct the Valeant Activities for the Product outside the Specialty or\n",
            "outside the Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant's rights and obligations under this Section\n",
            "\n",
            "\n",
            "Doc2  Ex-US. Commercial Rights Transfer Notice \") and Pfizer shall have thirty (30) days thereafter to notify Exact of its\n",
            "desire to obtain the Ex-US Commercial Rights that are the subject of the Ex-US Commercial Rights Transfer\n",
            "Notice. Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith\n",
            "negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights. If Pfizer and Exact are\n",
            "unable to reach agreement on the terms of such Product rights within forty-five (45) days of the commencement\n",
            "of negotiations, Exact shall be free to enter into negotiations and consummate an agreement with any Third\n",
            "Party regarding such Ex-US Commercial Rights? \n",
            "provided\n",
            " that the economic terms of such agreement shall be\n",
            "no more favorable to such Third Party than those last offered to Pfizer.\n",
            "(ii)\n",
            "During the Term, if Exact desires to grant an exclusive commercial license to a Third Party solely to Promote or sell the\n",
            "Product in the OB/Gyn Field in the Territory (the \"\n",
            "OB/Gyn Commercial Rights\n",
            "\"), Exact shall first notify Pfizer\n",
            "of such intent (a \"\n",
            "OB/Gyn Commercial Rights Transfer Notice\n",
            "\") and Pfizer shall have thirty (30) days\n",
            "thereafter to notify Exact of its desire to obtain the OB/Gyn Commercial Rights that are the subject of the\n",
            "OB/Gyn Commercial Rights Transfer Notice. Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall\n",
            "engage in exclusive good faith negotiations to enter into a definitive written agreement for the OB/Gyn\n",
            "Commercial Rights. If Pfizer and Exact are unable to reach agreement on the terms of such Product rights within\n",
            "forty-five (45) days of the commencement of negotiations, then Exact shall be free to enter into negotiations\n",
            "and consummate an agreement with any Third Party regarding such OB/Gyn Commercial Rights? \n",
            "provided\n",
            " that\n",
            "the economic terms of such agreement shall be no more favorable to such Third Party than those last offered to\n",
            "Pfizer.\n",
            "(iii)\n",
            "Notwithstanding the foregoing, this Section 3.1(c) shall not apply to (i) any transfer of rights to the Product in the\n",
            "ordinary course of business of Exact, (ii) the sale of the Product within and outside of the Territory, of all or\n",
            "substantially all of the assets of Exact, or sale\n",
            "18\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "of capital stock of Exact, whether in connection with a merger, acquisition or other similar transaction or (iii) any\n",
            "agreements with Third Parties in territories for which Exact has an existing distribution or other similar\n",
            "agreement.\n",
            "Doc1  13.2. . Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other\n",
            "Party (such consent not to be unreasonably withheld)? provided that a merger, sale of stock or comparable transaction shall not\n",
            "constitute an assignment. In the event either Party desires to make such an assignment or other transfer of this Agreement or any\n",
            "rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party's written\n",
            "consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination\n",
            "whether to provide such written consent within [***] following its receipt of such written notice from such Party. Notwithstanding\n",
            "the foregoing, (a) either Party may, without the other Party's consent, assign this Agreement and its rights and obligations hereunder\n",
            "in whole or in part to an Affiliate? and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or\n",
            "other transfer of all or substantially all of Dova's assets or rights relating to the Product? provided that such assignee shall remain\n",
            "subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing\n",
            "before or after such assignment. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.\n",
            "Any attempted assignment not in accordance with this Section 13.2 shall be void. This Agreement shall be binding on, and inure to\n",
            "the benefit of, each Party, and its permitted successors and assigns.\n",
            "\n",
            "\n",
            "Doc2  3.2. Responsibility for Product. (a)\n",
            "Doc1  3.1.  Formation of the JSC.. 11. 3.2.  Meetings and Minutes.. 11. 3.3.  Purpose of the JSC.. 11. 3.4.  Decision Making.. 13. 3.5.  Marketing Sub-Committee.. 13. ARTICLE 4 VALEANT ACTIVITIES FOR THE PRODUCT 14\n",
            "\n",
            "Doc2  . Except as specifically set forth in this Agreement, Pfizer shall have no other rights with respect to the Product, and shall not Promote, Market or otherwise commercialize the Product except as expressly\n",
            "authorized under this Agreement. Exact retains, and at all times during the Term shall retain, all rights in and relating to\n",
            "the Product not expressly granted to Pfizer under this Agreement, including all proprietary and property interests in and\n",
            "to the Product. In furtherance of the foregoing, Exact retains all rights of and responsibility for (i) Product pricing,\n",
            "including any rebates or discounts? (ii) manufacturing? (iii) research and development, including any trials? (iv)\n",
            "intellectual property defense and enforcement related to the Product? (v) product liability claims and related litigation\n",
            "related to the Product? (vi) government investigations related to the Product? (vii) the day-to-day operations and\n",
            "management of Exact's Representatives? and (viii) engagement with Governmental Authorities with respect to the\n",
            "Product. Pfizer will neither have, nor represent that it has, any control over or proprietary or property interests in the\n",
            "Product. Nothing contained in this Agreement shall be deemed to grant to Pfizer or its Affiliates any license, right, title\n",
            "or interest in or to any patent, Trademark, copyright, trade secret or other similar property of Exact, except as provided\n",
            "for in Section 3.1(b), Section 5.3(c) or otherwise authorized in writing by Exact for Pfizer to perform its obligations under\n",
            "this Agreement. Likewise, nothing contained in this Agreement shall be deemed to grant to Exact or its Affiliates any\n",
            "license, right, title or interest in or to any patent, Trademark, copyright, trade secret or other similar property of Pfizer or\n",
            "its Affiliates except as may be authorized in writing by Pfizer for Exact to perform its obligations under this Agreement.\n",
            "(b)\n",
            "\n",
            "Doc1  2.2.6 responsibility for handling all safety related activities related to Product as set forth in ARTICLE 5 (including\n",
            "submitting all safety reports and interacting with Governmental Authorities with respect thereto) and initiating and managing any\n",
            "Product recalls.\n",
            "For clarity, except as provided in Sections 2.1 or 2.4, Valeant shall not acquire any license or other intellectual property interest, by\n",
            "implication or otherwise, in any technology, Know-How or other intellectual property owned or controlled by Dova or any of its\n",
            "Affiliates, and Dova is not providing any such technology, Know-How or other intellectual property, or any assistance related\n",
            "thereto, to Valeant for any use other than for the mutual benefit of the Parties as expressly contemplated hereby.\n",
            "\n",
            "\n",
            "Doc2  Exact Product Responsibilities.  During the Term, as between the Parties, Exact shall remain solely responsible, at its expense ,\n",
            "except as expressly otherwise provided in this Agreement, for all activities and liabilities that the owner and Regulatory\n",
            "Approval holder of an FDA approved medical device would normally have, including, in each case with respect to the\n",
            "Territory, the following:\n",
            "(i)\n",
            "manufacturing, in accordance with the QSR and Applicable Law (including conducting all quality assurance testing)\n",
            "sufficient quantities of Product to meet market demand therefore?\n",
            "(ii)\n",
            "processing and having sufficient laboratory and manufacturing capacity to process Product Laboratory Services to\n",
            "meet demand, including return receipt and laboratory processing of patient samples?\n",
            "19\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(iii)\n",
            "ensuring all laboratory processing of patient samples are conducted in accordance with CLIA Certificate of\n",
            "Accreditation and patient results are provided to ordering healthcare providers in a timely manner?\n",
            "(iv)\n",
            "ensuring that the Product is not misbranded, as defined in the FD&C Act?\n",
            "(v)\n",
            "handling all customer service activities relating to the Product, including responding in an appropriate and timely\n",
            "fashion to all medical and other inquiries and complaints regarding the Product in accordance with its\n",
            "Applicable Compliance/Review Policies?\n",
            "(vi)\n",
            "contracting with Payers, including entering into contracts for reimbursement of the Product Laboratory Services?\n",
            "(vii)\n",
            "using commercially reasonable efforts to maintain the Exact Trademarks listed on Exhibit 1.39?\n",
            "(viii)\n",
            "setting the price of the Product Laboratory Services, including establishing, processing and paying for any rebates,\n",
            "discounts, chargebacks or other sales incentives associated with the sale of the Product Laboratory Services?\n",
            "(ix)\n",
            "subject to Section 6.1, handling all product liability claims or other claims associated with or arising out of the\n",
            "manufacture, distribution, sale or use of the Product, including managing any litigation associated therewith\n",
            "and paying any damages, fines or other compensation that may be awarded by any Government Authority or\n",
            "that are due as a result of any settlement of any such claim?\n",
            "(x)\n",
            "handling, in a timely and appropriate manner, all government inquiries related to the Product Laboratory Services and\n",
            "the manufacture, distribution, Marketing, Promotion, sale or use of the Product? and\n",
            "(xi)\n",
            "preparing and submitting in a timely manner and in a manner consistent with Applicable Law all reports and\n",
            "information that are required to be submitted to any Government Authority relating to the Product and Product\n",
            "Laboratory Services.\n",
            "(c)\n",
            "Doc1  . Dova shall have the sole authority, at its cost, to manufacture, package, label, warehouse, sell and distribute the Product in the Territory. Dova shall use commercially reasonable efforts to cause sufficient\n",
            "quantities of the Product to be available in inventory to promptly fill orders throughout the Territory and otherwise meet the\n",
            "forecasted demand for the Product in the Territory. If, despite such efforts, there is insufficient supply of Product to meet demand,\n",
            "then Dova shall use commercially reasonable efforts to promptly address such insufficiency. Dova shall contractually require (and\n",
            "shall use commercially reasonable efforts to enforce such contractual provisions) that all Product is manufactured, shipped, sold\n",
            "and distributed in accordance with all Product specifications and all Applicable Law and that its contract manufacturers and/or\n",
            "suppliers of Product operate their facilities in accordance with Applicable Law. Dova shall ensure that all Product Labeling\n",
            "complies with the applicable Regulatory Approval for the Product and Applicable Law. Other than as set forth in this Agreement,\n",
            "Dova shall be responsible for all marketing of the Product in the Territory, provided that Dova shall continue to invest in marketing\n",
            "that is targeted towards the Specialty.\n",
            "\n",
            "\n",
            "Doc2  Exact and Pfizer Product Responsibilities.  During the Term, without limiting either Party's other responsibilities under this\n",
            "Agreement, the Parties shall:\n",
            "(i)\n",
            "establish and maintain a sufficient number of Sales Representatives Promoting the Product to perform the obligations\n",
            "hereunder per the Annual Marketing Plan and consistent with the sales deployment plan included in the\n",
            "Annual Marketing Plan, which initial sales deployment plan for the six-month period beginning on and\n",
            "20\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "immediately following the Launch Date, is attached hereto as Exhibit 3.2(c)(i) (the \"\n",
            "\")?\n",
            "(ii)\n",
            "Market, Promote and Detail the Product in the Co-Promote Field in accordance with the Annual Marketing Plan,\n",
            "Applicable Laws, all regulatory and professional requirements including FDA's regulations and guidelines\n",
            "concerning the Advertising of prescription medical devices subject to pre-market approval, and each Party's\n",
            "Applicable Compliance/Review Policies and, with respect to Exact, the AdvaMed Code of Ethics on\n",
            "Interactions with Health Care Professionals (revised as of July 2009 and as further revised from time to time)\n",
            "(the \"\n",
            "\") and, with respect to Pfizer, the Pharmaceutical Research and Manufacturers of America\n",
            "Code on Interactions with Healthcare Professionals (the \"\n",
            "\")? \n",
            "provided\n",
            " that if there is any conflict\n",
            "between the AdvaMed Code and the PhRMA Code in connection with the implementation of the Annual\n",
            "Marketing Plan, the Compliance Managers shall review and use commercially reasonable efforts to resolve\n",
            "such conflict?\n",
            "(iii)\n",
            "review customer target lists for all Sales Representatives in accordance with the Annual Marketing Plan to ensure\n",
            "that their Promotion is directed to those Eligible Prescribers who are likely to prescribe, recommend or purchase\n",
            "the Product consistent with the approved Product Label and all Applicable Laws and its Applicable\n",
            "Compliance/Review Policies? \n",
            "provided\n",
            " that each Party has the sole discretion to select their target customers\n",
            "from the target lists included in the Annual Marketing Plan and the Party's Sales Representatives shall have\n",
            "authority to Promote and Detail to the Eligible Prescribers on the target lists in their reasonable discretion, in\n",
            "accordance with each Party's respective internal policies and practices?\n",
            "(iv)\n",
            "work collaboratively with the other Party in developing, preparing and generating specific tactics and activities in the\n",
            "Annual Marketing Plan, which shall include supporting the development of all Promotional Materials, Training\n",
            "Materials and other materials generated pursuant to any Annual Marketing Plan? and\n",
            "(v)\n",
            "provide investment and support consistent with Sections 3.5, 3.6 and 4.1, as applicable.\n",
            "(d)\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  Advertising. (i)\n",
            "Subject to the provisions of Section 3.2(d)(ii) with respect to the remainder of Calendar Year 2018 and for Calendar\n",
            "Year 2019, Exact and Pfizer shall develop an annual Advertising plan for the Product as part of the Annual\n",
            "Marketing Plan. The annual Advertising plan shall include the targets for such Advertising,\n",
            "21\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "which shall be updated on an annual basis at the same time and in the same manner as the Annual Marketing\n",
            "Plan. In accordance with each such approved Advertising plan, Pfizer shall develop and execute all media\n",
            "planning and buying of Advertising consistent with its practice for its own product portfolio.\n",
            "(ii)\n",
            "The provisions of this Section 3.2(d) shall have no impact on Exact's Advertising plan for the Product for 2018. The\n",
            "Advertising plan for Calendar Year 2019 shall be Exact's Advertising plan? \n",
            "provided, \n",
            "Pfizer may review and\n",
            "make recommendations on such Advertising plan for Calendar Year 2019 and Exact shall consider such\n",
            "recommendations in good faith and use commercially reasonable efforts to incorporate agreed-upon Pfizer\n",
            "recommendations. It is acknowledged by the Parties that as of the Effective Date Pfizer has executed its\n",
            "television/video media buying on its own behalf for broadcast year 2019 (4Q2018-3Q2019). With respect to\n",
            "broadcast year 2019, Pfizer shall use commercially reasonable efforts and in good faith execute the\n",
            "television/video buy plan in the Calendar Year 2019 Advertising plan in the \"scatter\" market. Exact\n",
            "acknowledges that pricing and inventory for buy placement in the scatter market may not have the pricing\n",
            "advantage or delivery guarantees. For media buying of non-television/video in the Calendar Year 2019\n",
            "Advertising plan, Pfizer shall in good faith integrate the Product into Pfizer portfolio media planning and\n",
            "buying for non-television/video.\n",
            "(iii)\n",
            "The cost of all media buying of Advertising for the Product by or through Pfizer shall be equal to the actual cost of\n",
            "such activities billed to Pfizer (including any third party service fees incurred by Pfizer) and shall not include\n",
            "any markup, administrative fee or service charge.\n",
            "(iv)\n",
            "Subject to compliance by Pfizer with the terms of this Section 3.2(d), during the Term, Exact agrees (A) not to enter\n",
            "into any new binding arrangement with any media vendor for Advertising of the Product without the written\n",
            "consent of Pfizer, which consent shall not be unreasonably withheld, (B) not to meet with any advertising\n",
            "agency or media vendor to discuss any Advertising proposals for content development and creative direction\n",
            "of the Product, without providing Pfizer with a reasonable opportunity for a representative of Pfizer present\n",
            "and participate and (C) to promptly inform Pfizer if it enters into any arrangement with any advertising agency\n",
            "with respect to the Product.\n",
            "(v)\n",
            "Exact agrees that any binding commitment made by Pfizer pursuant to this Section 3.2(d) for media buying for the\n",
            "Product shall also be binding to Exact? \n",
            "provided\n",
            " that such commitment is consistent with the applicable\n",
            "Annual Marketing Plan and the\n",
            "22\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "budget included therein.\n",
            "(vi)\n",
            "After the Effective Date, the Parties will mutually agree to a process by which Pfizer will interact with Exact with\n",
            "respect to the activities undertaken by Pfizer pursuant to this Section 3.2(d).\n",
            "(vii)\n",
            "Notwithstanding the foregoing, Exact may continue any binding commitments as of the Effective Date, including\n",
            "Advertising purchasing and placement activities, related to and in connection with the sponsorship of\n",
            "sporting events (e.g., golf tournaments), celebrity sponsorships (e.g., Harry Connick serving as a Product\n",
            "spokesperson) and those other activities set forth in the Annual Marketing Plan (the \"\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  Exact Sponsorships. and Related Activities \")? \n",
            "provided\n",
            ", that Pfizer shall use commercially reasonable efforts to take responsibility\n",
            "of television/video and media buying related to such Exact Sponsorships and Related Activities following the\n",
            "Effective Date. The Exact Sponsorships and Related Activities may, as mutually agreed by the Parties, be\n",
            "included in the applicable annual Advertising plan.\n",
            "(viii)\n",
            "Following the Term and during the Tail Period subject to Sections 8.7 and 8.8(b), at the request of Exact, Pfizer\n",
            "shall, based on an agreed Advertising plan, plan and execute the media planning and buying plan in a\n",
            "substantially similar manner as it did during the Term, as such plan is updated on an annual basis during the\n",
            "Tail Period. Pfizer shall provide Exact with invoicing of Advertising buying during the Tail Period consistent\n",
            "with its invoicing practice during the Term. This invoice shall be provided within five (5) days of the end of\n",
            "each month during the Tail Period and shall set forth all Advertising costs, including any Pfizer's internal and\n",
            "overhead costs attributable to media buying for the Product, during month preceding the month that the\n",
            "invoice is delivered. Exact shall pay the invoice provided by Pfizer within five (5) days of the date that it\n",
            "receives the invoice.\n",
            "(ix)\n",
            "Within forty-five (45) calendar days after the end of each Calendar Quarter, Pfizer will deliver to Exact a report\n",
            "describing in reasonable detail the media buying activities for the just completed Calendar Quarter and any\n",
            "material deviations from the approved Advertising plan that occurred during such Calendar Quarter.\n",
            "(x)\n",
            "Except for Calendar Year 2018 and 2019 Advertising plan, the Parties shall mutually agree to the Advertising plan\n",
            "and any dispute with respect to such Advertising plan or arising out of material deviation of media buying by\n",
            "Pfizer shall be considered a Disputed JOC Matter and subject to escalation to the JSC under Section 2.3(d).\n",
            "Until such Disputed JOC Matter is resolved, the Parties will continue to operate under the then-current\n",
            "Advertising plan. Without limiting the foregoing, a deviation from the media\n",
            "23\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "buying obligations under an Advertising plan by twenty percent (20%) or more shall be deemed to be\n",
            "material.\n",
            "(e)\n",
            "Doc1  12.5. . Solely in the event that Dova has terminated this Agreement pursuant to Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion services performed by Valeant during the Term, with respect\n",
            "to the Tail Period, Dova shall make payments to Valeant in an amount equal to [***] of the amounts that would have been payable\n",
            "by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had the Agreement not been so terminated. Such\n",
            "payments shall be made within [***] following the end of each calendar quarter in the Tail Period. Sections 6.3, 6.4 and 6.5 shall\n",
            "apply, \n",
            "mutatis mutandis\n",
            ", to such Tail Period payments. For clarity, no tail payment shall be due following any expiration or\n",
            "termination of this Agreement except as set forth in this Section 12.5.\n",
            "\n",
            "\n",
            "Doc2  Product Training. (i)\n",
            "Promptly (and in any event within twenty (20) days) following the Effective Date, Exact shall be responsible for\n",
            "providing Product Training and Training Materials to Pfizer sales trainers (the \"\n",
            "\") who shall\n",
            "then train Pfizer's Sales Representatives who shall Promote the Product using a training program relating solely\n",
            "to the Product and the Product Laboratory Service (including Training Materials). After the initial training,\n",
            "Exact shall periodically provide additional Product Training and the Parties shall agree to the frequency, time\n",
            "and place such additional Product Training will be rolled out to Sales Representatives.\n",
            "(ii)\n",
            "Exact shall bear all costs and expenses of training its Sales Representatives, its training facilities and the cost of\n",
            "developing Training Materials and the training of Pfizer Trainers with respect to the Product and the Product\n",
            "Laboratory Service. Pfizer shall be responsible for all travel, lodging, meal and other expenses and out-of-\n",
            "pocket expenses incurred by Pfizer's Sales Representatives in connection with such Product Training.\n",
            "(iii)\n",
            "Upon termination or expiration of this Agreement, at Exact's election, Pfizer either shall (A) return to Exact or (B)\n",
            "destroy and certify to the Exact such destruction, all Training Materials in the possession of, or under the\n",
            "control of, Pfizer.\n",
            "(iv)\n",
            "Pfizer shall ensure that no Pfizer Representative shall Promote the Product or Product Laboratory Service unless he\n",
            "or she demonstrates sufficient knowledge by meeting the validation requirements of Exact. Pfizer shall maintain,\n",
            "and make available upon request by Exact, records of all testing or certification results, including copies\n",
            "thereof.\n",
            "(v)\n",
            "The Parties shall cooperate in good faith to schedule, plan and conduct a pre-launch meeting for all Sales\n",
            "Representatives Detailing the Product (the \"\n",
            "\"), which shall occur promptly following\n",
            "training of the Pfizer Sales Representatives in accordance with this Section 3.2(e). The Parties shall use\n",
            "commercially reasonable efforts to conduct the Pre-Launch Meeting as an in-person meeting by the first week\n",
            "of October 2018.\n",
            "(f)\n",
            "Doc1  Promotional Materials \") (the Product Training Materials and the Promotional Materials, collectively, the\n",
            "\"\n",
            "\"). Dova shall be solely responsible for ensuring that the Product Materials prepared and approved by it are\n",
            "in compliance with the Regulatory Approval for the Product, the Product Labeling and Applicable Law. Once approved by Dova,\n",
            "the content of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant\n",
            "to review such content and provide verbal feedback to Dova in advance of use of the Product Materials. Within [***] of receipt of\n",
            "such Product Materials, Valeant shall verbally provide to Dova any comments and/or proposed revisions to such Product\n",
            "Materials, which comments and revisions Dova shall reasonably consider so long as Dova deems such suggestions are acceptable\n",
            "in the promotion of the Product? provided that in any event, to the extent that Dova reasonably believes that such changes are not\n",
            "in compliance with Applicable Law, the Regulatory Approval for the Product or the applicable Product Labeling, then Dova shall\n",
            "not be required to incorporate any such suggestions from Valeant in the Product Materials. In the event of any disagreement\n",
            "between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova shall have the right\n",
            "to conclusively determine such matter. If Valeant has provided comments to Dova on the Product Materials and Dova accepts\n",
            "some or all of such comments, then, once revised, Dova shall provide to Valeant the revised versions of such Product Materials for\n",
            "further review by Valeant, in accordance with the terms and timelines of this Section 4.4.1(a) above. Valeant shall use only Product\n",
            "Materials approved by Dova in the performance of Valeant Activities under this Agreement? provided, however, that Valeant shall\n",
            "not be required to use any Product Materials that have not been approved by Valeant or which have not incorporated comments\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "provided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant\n",
            "reserves the right not to use certain Product Materials. The content of Product Materials shall not be modified or changed by\n",
            "Valeant or Field Force Personnel at any time without the prior written approval of Dova in each instance. Dova shall be\n",
            "responsible for the costs and expenses of creation and development of the Product Materials and Valeant shall be responsible for\n",
            "the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant. The Parties will\n",
            "coordinate the production and delivery of Product Materials to allow sufficient internal and field force review time to accommodate\n",
            "scheduled training meetings and distribution to Field Force Personnel that are engaged in Detailing. In the event that Dova incurs\n",
            "costs and expenses for which Valeant is responsible under this Section 4.4.1, Dova may deduct such amounts from the payments\n",
            "due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3. Promptly after the\n",
            "Effective Date, the Parties will collaborate to finalize the Product Materials in accordance with this Section 4.4.1(a), as soon as\n",
            "reasonably practical.\n",
            "(b)\n",
            "Commencing with the Promotional Materials to be used for Calendar Year 2019 and for the remainder\n",
            "of the Term, Valeant and Dova shall meet to discuss the content of such Promotional Materials in order to ensure that such\n",
            "Promotional Materials appropriately address any messaging that may be desired for the Target Professionals in the Specialty. Such\n",
            "discussions may take place in the forum of the JSC. Dova shall in good faith reasonably consider all comments and suggestions of\n",
            "Valeant regarding the Promotional Materials.\n",
            "(c)\n",
            "Promptly after the Effective Date, the Parties will collaborate to plan and schedule training for the Sales\n",
            "Representatives at a mutually acceptable time(s) and date(s), including a launch meeting for the Sales Representatives at a mutually\n",
            "acceptable location. Dova will lead such initial training and Valeant shall cooperate with any reasonable requests of Dova in order\n",
            "to support such training. The costs and expenses of such launch meeting will be shared equally by the Parties, other than travel and\n",
            "lodging for the Sales Representatives which shall be the responsibility of Valeant. All other training costs and expenses shall be the\n",
            "responsibility of Valeant. After the initial training, the Parties will collaborate to provide additional training at such frequency, times\n",
            "and places as the circumstances warrant and the Parties mutually agree. Valeant shall have the right, but not the obligation, to\n",
            "conduct such additional training itself, provided that the Valeant trainers have been trained by Dova, and provided further that\n",
            "Dova shall have the right to attend such training upon reasonable notice by Valeant to Dova. Valeant will certify in writing to Dova\n",
            "that all Field Force Personnel have completed the training described in this Section 4.4.1(b).\n",
            "(d)\n",
            "Valeant and all Field Force Personnel that are engaged in Valeant Activities shall comply with the\n",
            "applicable provisions of the Code, and shall be trained on Valeant's compliance policies, including those that are consistent with the\n",
            "applicable provisions of Sec. 1128B(b) of the Social Security Act and the American Medical Association Ethical Guidelines for\n",
            "Gifts to Physicians from Industry (which such training may have been accomplished prior to the Term), prior to commencing any\n",
            "Valeant Activities. Valeant agrees that it shall train any employee or agent of Valeant who is involved in performing the activities\n",
            "contemplated by this Agreement on anti-corruption and anti-bribery at its own expense.\n",
            "(e)\n",
            "Field Force Personnel that are engaged in Detailing shall conduct the Valeant Activities only after having\n",
            "undergone the training described in this Section 4.4 and, without limiting the foregoing, no Field Force Personnel member shall\n",
            "Detail the Product without having undergone such training. Subject to the foregoing, Valeant shall have the responsibility for on-\n",
            "going training of its Field Force Personnel that are engaged in Detailing in accordance with customary practice in the\n",
            "pharmaceutical industry.\n",
            "\n",
            "Doc2  Promotional Materials.  During the Term, the Parties agree to develop Promotional Materials together in accordance with the\n",
            "Annual Marketing Plan for use in Promoting the Product in the Territory. Each Party shall:\n",
            "24\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(i)\n",
            "only use and distribute the Promotional Materials for use in Promoting the Product? \n",
            "provided\n",
            ", \n",
            "however\n",
            ", that Exact\n",
            "may continue to utilize any remaining promotional materials for the Product created prior to the Effective Date,\n",
            "but Exact will not create any new promotional materials other than the Promotional Materials?\n",
            "(ii)\n",
            "instruct its Representatives to use, and will use commercially reasonable efforts to train and monitor its\n",
            "Representatives to ensure that such Representatives use, only Promotional Materials approved by the JRC?\n",
            "(iii)\n",
            "not, and shall ensure that its Affiliates and agents do not, change or alter any Promotional Materials in any way prior\n",
            "to their distribution or use by such Party or its Sales Representatives without JRC approval? and\n",
            "(iv)\n",
            "(A) use commercially reasonable efforts to train its Representatives with respect to, (B) instruct its Representatives\n",
            "to, and (C) establish appropriate internal systems, policies and procedures for the monitoring of its\n",
            "Representatives with the goal of ensuring that such Representatives will:\n",
            "(A)\n",
            "limit claims of efficacy and safety for the Product to those that are (1) consistent with approved Promotional\n",
            "claims in, and not add, delete or modify claims of efficacy and safety in the Promotion of the Product\n",
            "in any respect from those claims of efficacy and safety that are contained in, the then-effective Annual\n",
            "Marketing Plan, (2) consistent with Applicable Law and (3) consistent with the Product Label?\n",
            "(B)\n",
            "not make any changes or alterations to Promotional Materials? and\n",
            "(C)\n",
            "use Promotional Materials only in a manner that is consistent with this Agreement, Applicable Law and the\n",
            "Product Label.\n",
            "For clarity, the foregoing restrictions shall not apply to Exact Sciences Laboratories, LLC or any Representative of Exact\n",
            "or any of its Affiliates on the customer care team or market access team.\n",
            "(g)\n",
            "Doc1  Promotional Materials \") (the Product Training Materials and the Promotional Materials, collectively, the\n",
            "\"\n",
            "\"). Dova shall be solely responsible for ensuring that the Product Materials prepared and approved by it are\n",
            "in compliance with the Regulatory Approval for the Product, the Product Labeling and Applicable Law. Once approved by Dova,\n",
            "the content of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant\n",
            "to review such content and provide verbal feedback to Dova in advance of use of the Product Materials. Within [***] of receipt of\n",
            "such Product Materials, Valeant shall verbally provide to Dova any comments and/or proposed revisions to such Product\n",
            "Materials, which comments and revisions Dova shall reasonably consider so long as Dova deems such suggestions are acceptable\n",
            "in the promotion of the Product? provided that in any event, to the extent that Dova reasonably believes that such changes are not\n",
            "in compliance with Applicable Law, the Regulatory Approval for the Product or the applicable Product Labeling, then Dova shall\n",
            "not be required to incorporate any such suggestions from Valeant in the Product Materials. In the event of any disagreement\n",
            "between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova shall have the right\n",
            "to conclusively determine such matter. If Valeant has provided comments to Dova on the Product Materials and Dova accepts\n",
            "some or all of such comments, then, once revised, Dova shall provide to Valeant the revised versions of such Product Materials for\n",
            "further review by Valeant, in accordance with the terms and timelines of this Section 4.4.1(a) above. Valeant shall use only Product\n",
            "Materials approved by Dova in the performance of Valeant Activities under this Agreement? provided, however, that Valeant shall\n",
            "not be required to use any Product Materials that have not been approved by Valeant or which have not incorporated comments\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "provided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant\n",
            "reserves the right not to use certain Product Materials. The content of Product Materials shall not be modified or changed by\n",
            "Valeant or Field Force Personnel at any time without the prior written approval of Dova in each instance. Dova shall be\n",
            "responsible for the costs and expenses of creation and development of the Product Materials and Valeant shall be responsible for\n",
            "the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant. The Parties will\n",
            "coordinate the production and delivery of Product Materials to allow sufficient internal and field force review time to accommodate\n",
            "scheduled training meetings and distribution to Field Force Personnel that are engaged in Detailing. In the event that Dova incurs\n",
            "costs and expenses for which Valeant is responsible under this Section 4.4.1, Dova may deduct such amounts from the payments\n",
            "due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3. Promptly after the\n",
            "Effective Date, the Parties will collaborate to finalize the Product Materials in accordance with this Section 4.4.1(a), as soon as\n",
            "reasonably practical.\n",
            "(b)\n",
            "Commencing with the Promotional Materials to be used for Calendar Year 2019 and for the remainder\n",
            "of the Term, Valeant and Dova shall meet to discuss the content of such Promotional Materials in order to ensure that such\n",
            "Promotional Materials appropriately address any messaging that may be desired for the Target Professionals in the Specialty. Such\n",
            "discussions may take place in the forum of the JSC. Dova shall in good faith reasonably consider all comments and suggestions of\n",
            "Valeant regarding the Promotional Materials.\n",
            "(c)\n",
            "Promptly after the Effective Date, the Parties will collaborate to plan and schedule training for the Sales\n",
            "Representatives at a mutually acceptable time(s) and date(s), including a launch meeting for the Sales Representatives at a mutually\n",
            "acceptable location. Dova will lead such initial training and Valeant shall cooperate with any reasonable requests of Dova in order\n",
            "to support such training. The costs and expenses of such launch meeting will be shared equally by the Parties, other than travel and\n",
            "lodging for the Sales Representatives which shall be the responsibility of Valeant. All other training costs and expenses shall be the\n",
            "responsibility of Valeant. After the initial training, the Parties will collaborate to provide additional training at such frequency, times\n",
            "and places as the circumstances warrant and the Parties mutually agree. Valeant shall have the right, but not the obligation, to\n",
            "conduct such additional training itself, provided that the Valeant trainers have been trained by Dova, and provided further that\n",
            "Dova shall have the right to attend such training upon reasonable notice by Valeant to Dova. Valeant will certify in writing to Dova\n",
            "that all Field Force Personnel have completed the training described in this Section 4.4.1(b).\n",
            "(d)\n",
            "Valeant and all Field Force Personnel that are engaged in Valeant Activities shall comply with the\n",
            "applicable provisions of the Code, and shall be trained on Valeant's compliance policies, including those that are consistent with the\n",
            "applicable provisions of Sec. 1128B(b) of the Social Security Act and the American Medical Association Ethical Guidelines for\n",
            "Gifts to Physicians from Industry (which such training may have been accomplished prior to the Term), prior to commencing any\n",
            "Valeant Activities. Valeant agrees that it shall train any employee or agent of Valeant who is involved in performing the activities\n",
            "contemplated by this Agreement on anti-corruption and anti-bribery at its own expense.\n",
            "(e)\n",
            "Field Force Personnel that are engaged in Detailing shall conduct the Valeant Activities only after having\n",
            "undergone the training described in this Section 4.4 and, without limiting the foregoing, no Field Force Personnel member shall\n",
            "Detail the Product without having undergone such training. Subject to the foregoing, Valeant shall have the responsibility for on-\n",
            "going training of its Field Force Personnel that are engaged in Detailing in accordance with customary practice in the\n",
            "pharmaceutical industry.\n",
            "\n",
            "Doc2  Representatives.  Each Party shall be legally responsible and liable for the actions, omissions and conduct of their respective\n",
            "Sales Representatives and other Representatives performing activities hereunder. Each Party shall ensure that all\n",
            "Persons for whom they have legal responsibility and liability in accordance with the foregoing sentence comply with all\n",
            "Applicable Laws, the AdvaMed Code or the PhRMA Code, as applicable, Applicable Compliance/Review Polices, and\n",
            "all requirements of this Agreement, and shall implement and maintain policies and procedures to ensure such\n",
            "compliance.\n",
            "25\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(h)\n",
            "Doc1  Code \" shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical\n",
            "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.\n",
            "\n",
            "Doc2  Marketing Authorization.  Exact shall have the sole right and responsibility between the Parties to take, and shall take, all\n",
            "actions with respect to the Product reasonably necessary in order to maintain the Regulatory Approvals permitting the\n",
            "Marketing and sale of the Product in the Territory throughout the Term.\n",
            "(i)\n",
            "Doc1  5.1. . As between the Parties, except as expressly set out herein, all regulatory matters regarding the Product shall be the responsibility of Dova, including responsibility for all communications with Governmental Authorities, including\n",
            "but not limited to FDA, related to the Product, and Dova shall have sole responsibility to seek and/or obtain any necessary\n",
            "approvals of any Product Labeling and the Promotional Materials used in connection with the Product, and for determining\n",
            "whether the same requires approval. As between the Parties, Dova shall be responsible for any reporting of matters regarding the\n",
            "manufacture, sale or promotion of the Product (including Adverse Events) to or with the FDA and other relevant regulatory\n",
            "authorities, in accordance with Applicable Laws. Dova shall maintain, at its cost, the Regulatory Approvals for the Product and\n",
            "shall comply with all Applicable Law relevant to the conduct of Dova's business with respect to the Product or pursuant to this\n",
            "Agreement, including, without limitation, all applicable requirements under the Act.\n",
            "\n",
            "\n",
            "Doc2  Withdrawal.  Exact shall have sole authority to determine whether to recall or withdraw any Product in the Territory? \n",
            "provided,\n",
            "however, \n",
            "Exact shall notify Pfizer of its decision, including the reasons therefore, regarding any such recall or withdrawal\n",
            "promptly after such decision is made. Exact shall be solely responsible for and shall bear all costs associated, directly or\n",
            "indirectly, with any recalls or withdrawals of the Product.\n",
            "(j)\n",
            "Doc1  5.6. . As between the Parties, Dova shall have the sole right to determine whether to\n",
            "implement, and to implement, a recall, field alert, withdrawal or other corrective action related to the Product. Dova shall bear the\n",
            "cost and expense of any such recall, field alert, withdrawal or other corrective action. Each Party shall promptly (but in any case,\n",
            "not later than [***]) notify the other Party in writing of any order, request or directive of a court or other Governmental Authority\n",
            "to recall or withdraw the Product.\n",
            "\n",
            "\n",
            "Doc2  Customer Service Activities? Safety Reporting.  Exact shall have sole authority to handle all customer service activities\n",
            "regarding the Product in accordance with Section 3.2(b)(v). Promptly upon receipt (and in any event within one\n",
            "Business Day), Pfizer shall refer all customer service inquiries regarding the Product, including all medical and other\n",
            "inquiries and complaints, to Exact for resolution. Following the Effective Date but before the Launch Date, the Parties\n",
            "shall discuss and agree to a procedure by which Product inquiries to, or by, Pfizer will be sent to Exact to comply with\n",
            "applicable safety reporting requirements and obligations for the Product.\n",
            "Doc1  Pharmacovigilance Agreement \"). These responsibilities shall include\n",
            "mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication and exchange (as\n",
            "between the Parties) of safety information such as Adverse Events, lack of efficacy, misuse/abuse, and any other information\n",
            "concerning the safety of the Product. Such guidelines and procedures will be in accordance with, and enable the Parties and their\n",
            "Affiliates to fulfill, regulatory reporting obligations to Governmental Authorities. The Pharmacovigilance Agreement shall provide\n",
            "that: (i) Dova shall be responsible for all pharmacovigilance activities regarding the Product, including signal detection, medical\n",
            "surveillance, risk management, medical literature review and monitoring, Adverse Event reporting and responses to Governmental\n",
            "Authority requests or enquiries, and shall provide information related thereto to Valeant, and (ii) in the event Valeant receives safety\n",
            "information regarding the Product, or information regarding any safety-related regulatory request or inquiry, Valeant shall notify\n",
            "Dova as soon as practicable, but, in any event, within the timelines set forth in the Pharmacovigilance Agreement.\n",
            "\n",
            "Doc2  3.3. Annual Marketing Plan. (a)\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  General.  Promptly following the Effective Date, Exact and Pfizer shall develop an Annual Marketing Plan for the Product.\n",
            "Unless otherwise agreed by the Parties, the JOC shall prepare each Annual Marketing Plan and submit it for review and\n",
            "approval by the JSC by no later than October 1  of the then-current Calendar Year so that the JSC shall have a\n",
            "reasonable opportunity to review, revise and approve such Annual Marketing Plan by no later than October 31  of the\n",
            "Calendar Year preceding the Calendar Year to which such Annual Marketing Plan relates? \n",
            "provided\n",
            " that the Annual\n",
            "Marketing Plan for the 2019 Calendar Year shall be finalized by the JOC and submitted to the JSC promptly following the\n",
            "Effective Date, and in any event no later than December 1, 2018. It is the intent of the Parties that the Annual Marketing\n",
            "Plan for the remainder of 2018 will be approved by the JSC no later than October 1, 2018. If either Party desires to revise\n",
            "or update an approved Annual Marketing Plan prior to the end of a Calendar Year, it shall notify the JOC of such desired\n",
            "revision, and the JOC shall review any such proposed revision and determine whether to submit such revision to the\n",
            "JSC for review and approval.\n",
            "(b)\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  Plan Contents.  The Annual Marketing Plan for each Calendar Year beginning with the 2019 Calendar Year shall contain at a\n",
            "minimum the categories set forth in Exhibit 3.3(b) and such other information that the JOC or JSC believes is necessary.\n",
            "The 2018 Annual Marketing Plan shall contain\n",
            "26\n",
            "st\n",
            "st\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "a high-level summary of the Sales Deployment Plan and use of Shared M&P Expenses for the remainder of 2018.\n",
            "Sales Promotion, Detailing Efforts and IDN Promotion.\n",
            "(a)\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  Sales Promotion.  Commencing on the Launch Date, each of Exact and Pfizer shall implement the sales Detailing plan set forth\n",
            "in the applicable Annual Marketing Plan and the Sales Deployment Plan. In the case of Pfizer, Pfizer shall ensure that (i)\n",
            "the number of Details in a Calendar Year by Pfizer Sales Representatives is not less than six hundred twenty-five\n",
            "thousand (625,000) Details (for the remainder of 2018 Calendar Year following the Launch Date, Pfizer shall deliver one\n",
            "hundred forty thousand (140,000) Details) and (ii) if the Product is Promoted by Pfizer Sales Representatives (A) in\n",
            "position 2 or higher, the Incentive Compensation weighting directly tied to the Product shall not be less than thirty\n",
            "percent (30%) of Incentive Compensation available to be earned by such Sales Representative in the applicable\n",
            "Calendar Quarter and (B) in position 3 or lower, the Incentive Compensation weighting directly tied to the Product shall\n",
            "not be less than twenty-five percent (25%) of Incentive Compensation available to be earned by such Sales\n",
            "Representative in the applicable Calendar Quarter. If Pfizer delivers less than five hundred sixty-two thousand five\n",
            "hundred (562,500) Details in a Calendar Year, then the Promotion Fee due Pfizer for such Calendar Year shall be reduced\n",
            "by the applicable percentage set forth in the table on Exhibit 3.4(a), with such reduction to be deducted from remittance\n",
            "of the Promotion Fee for the last Calendar Quarter of such Calendar Year? \n",
            "provided\n",
            " that if such deduction exceeds the\n",
            "amount payable for such Calendar Quarter then Exact shall apply any such remaining deduction to the Promotion Fee\n",
            "for the next Calendar Quarter or Calendar Quarters, as necessary until the total deduction has been applied. If Pfizer\n",
            "delivers less than four hundred fifty thousand (450,000) Details in a Calendar Year, in addition to percentage reduction\n",
            "of the Promotion Fee set forth in the table on Exhibit 3.4(a), Exact shall have the right to terminate this Agreement\n",
            "under Section 8.3(b), which termination shall not be subject to the right of Pfizer to cure such breach. In no event shall\n",
            "Pfizer owe any monies to Exact for Detail shortfalls under this Agreement other than to refund the Promotion Fee owed\n",
            "to Exact due to Detail shortfall in accordance with this Section 3.4(a).\n",
            "Each Party shall be responsible for its own Sales Representatives costs attributable to the Product, including base salary\n",
            "and Incentive Compensation, normal travel and entertainment expenses, cost of fleet vehicles and other expenses\n",
            "normally associated with Promotion of products and services similar to the Product.\n",
            "(b)\n",
            "Doc1  Applicable Percentage \".\n",
            "(a)\n",
            "If the aggregate actual number of Details for the Product made by the Sales Representatives for a\n",
            "Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due\n",
            "under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\n",
            "(b)\n",
            "If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable\n",
            "Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar\n",
            "Quarter shall be reduced to a new percentage equal to [***].\n",
            "(c)\n",
            "In the event that subsections (a) above and (b) above are both applicable in an applicable Calendar\n",
            "Quarter, then the Applicable Percentage shall be reduced to a new percentage equal to the lower of the percentages calculated\n",
            "under subsections (a) and (b).\n",
            "\n",
            "Doc2  Detailing Efforts and Costs.  Each Party shall have sole and exclusive control of all Detailing efforts and activities by its Sales\n",
            "Representative and Representatives, and shall be solely responsible for the costs thereof. Notwithstanding anything to\n",
            "the contrary in this Agreement or the\n",
            "27\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Annual Marketing Plan, any Detailing costs incurred by a Party or its Affiliates in delivering the Details assigned to\n",
            "such Party shall be the sole responsibility of such Party or Affiliate and shall not be a Baseline M&P Expense or Shared\n",
            "M&P Expense or otherwise a shared cost pursuant to this Agreement.\n",
            "(c)\n",
            "Doc1  Confidential Information \" shall mean all secret, confidential, non-public or proprietary Know-How, whether\n",
            "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party\n",
            "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development\n",
            "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made\n",
            "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a\n",
            "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such\n",
            "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all\n",
            "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this\n",
            "Agreement shall be considered Confidential Information of both Parties.\n",
            "\n",
            "Doc2  IDN Promotion.  As part of this Agreement, Pfizer agrees to deploy its IDN Key Account Managers (or successor team with\n",
            "similar responsibilities, the \"\n",
            "Doc1  4.1.5. Institutional Account Management Team.  Upon prior mutual agreement of the Parties in writing, Valeant\n",
            "may maintain a team of institutional account managers who, among other products, promote the Product in the Territory at liver\n",
            "transplant centers and large academic institutions only, and for purposes of this Section 4.1.5 only, both inside and outside the\n",
            "Specialty. Prior to any promotion of the Product by any institutional account managers, the Parties will discuss in good faith (acting\n",
            "reasonably) the number of institutional account managers that will promote the Product in the Territory, the appropriate portion of\n",
            "such institutional account managers' target incentive compensation to be derived from sales of the Product and the liver transplant\n",
            "centers or large academic institutions such institutional account managers will be responsible for. Such institutional account\n",
            "managers shall not be counted for purposes of determining the Quarterly Average Sales Force Size or the Quarterly Minimum\n",
            "Details. The Parties agree that these institutional account managers shall not be required to achieve any minimum number of Details.\n",
            "The Parties agree that such team may be added or removed by the mutual written agreement of the Parties without the need to\n",
            "amend this Agreement in accordance with Section 13.8.\n",
            "\n",
            "Doc2  KAM Team \") to support understanding and uptake of the Product by IDN customers in\n",
            "accordance with the Annual Marketing Plan. In furtherance, prior to the beginning of each Calendar Year, Pfizer shall\n",
            "discuss and agree with Exact on the defined goals and key performance indicators for the KAM Team. Pfizer and Exact\n",
            "shall agree to execution goals and deliverables of resources, subject to review and approval of the JRC, to be used by\n",
            "the KAM Team with IDN customers, and the tracking of such execution goals and deliverables using a scorecard.\n",
            "(d)\n",
            "Doc1  3.3.7 decide on the acceptable form of and review and discuss the Compensation Reports and the incentive\n",
            "compensation matters described in Section 4.1.3, including any applicable adjustments to the Product-related sales goals and\n",
            "targets of the Sales Representatives?\n",
            "\n",
            "\n",
            "Doc2  Reporting.  Within fifteen (15) Business Days after the end of each month during the Term, each Party shall provide to the\n",
            "other Party a written report setting forth (i) the number of Details completed during such month and (ii) any changes to\n",
            "Incentive Compensation or selling position of the Product by Sales Representatives during such month. Exact shall\n",
            "provide to Pfizer a weekly report detailing, on an Eligible Prescriber-by-Eligible Prescriber basis, the Product Laboratory\n",
            "Services activity, including but not limited to, the number of orders received, number of shipments sent to patients, and\n",
            "number of results sent back to prescriber.\n",
            "Doc1  4.2.2 Records and Reports.\n",
            "(a)\n",
            "Valeant shall keep accurate and complete records, consistent with pharmaceutical industry standards,\n",
            "of each Detail and its obligations hereunder in connection therewith. Such records shall be kept for the longer of (i) [***] after the\n",
            "end of the Calendar Year to which they relate and (ii) such period of time as required by Applicable Laws. Within [***] following\n",
            "the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"\n",
            "\n",
            "\"),\n",
            "setting out (i) the quarterly average number of Sales Representatives during such Calendar Quarter (calculated by taking the sum of\n",
            "the number of Sales Representatives employed by Valeant (or its affiliates) that have incentive compensation packages that comply\n",
            "with the terms of Section 4.1.3 on each Business Day of the Calendar Quarter divided by the number of Business Days in such\n",
            "Calendar Quarter) (the \"\n",
            "\"), and (ii) the aggregate actual number of Details for the Product\n",
            "made by its Sales Representatives during such Calendar Quarter, and the number of Details broken down by the name of the\n",
            "Target Professionals,. Through the JSC, the Parties shall agree on a mutually acceptable form of Detail Report.\n",
            "(b)\n",
            "Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova\n",
            "with a written report (each a \"\n",
            "\"), which describes (i) the details of the incentive compensation package of\n",
            "each Sales Representative as it relates to the Product and the Designated Product (or Alternate Product, as the case may be) (but,\n",
            "in the case of the Designated Product or Alternate Product, such details shall be limited to information regarding what portion of\n",
            "the Sales Representatives' target incentive compensation package is derived from achieving sales targets or goals of the Designated\n",
            "Product (or Alternate Product) , but shall not include any sales targets or goals for the Designated Product (or Alternate Product)),\n",
            "and (ii) the actual incentive compensation payouts for each Sales Representatives as described in Section 4.1.3. Through the JSC,\n",
            "the Parties shall agree on a mutually acceptable form of Compensation Report.\n",
            "(c)\n",
            "Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova\n",
            "with a written report (each a \"\n",
            "\"), which sets out a summary of Valeant's compliance monitoring and auditing\n",
            "of the Field Force Personnel that are engaged in Detailing (as such monitoring is further described in Section 4.5.1(b)), a summary\n",
            "of any compliance-related disciplinary actions relating to any Field Force Personnel that are engaged in Detailing and any\n",
            "associated remedial actions, a summary of all compliance investigations conducted by Valeant of any of the Field Force Personnel\n",
            "that are engaged in Detailing and any associated outcome, and, for the fourth Calendar Quarter only, a summary of the\n",
            "compliance-related training (including a reasonable description of each training topic) received by each Field Force Personnel that\n",
            "are engaged in Detailing during the Calendar Year. Through the JSC, the Parties shall agree on a mutually acceptable form of\n",
            "Compliance Report.\n",
            "\n",
            "Doc2  3.5. Pfizer Investment and Support.  Pfizer shall make financial investment in Marketing and Promoting the Product in accordance with and\n",
            "in all cases subject to the budget in the applicable Annual Marketing Plan (as the same may be adjusted as provided in Section\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  3.3) and shall be equal to fifty percent (50%) of Shared M&P Expense, in the amounts set forth in the chart below. Pfizer, at its own expense, shall use commercially reasonable efforts to carry out Pfizer's responsibilities under the Annual Marketing Plan, which\n",
            "commercially reasonable efforts shall include committing the appropriate resources to assist in the implementation of the Annual\n",
            "Marketing Plan and to carry out the activities Pfizer is responsible for thereunder and hereunder. Pfizer will make investments as\n",
            "set forth in the chart below. Notwithstanding the above, Pfizer agrees to invest its portion of Shared M&P Expense each Calendar\n",
            "Year subject to, (a) Exact spending at least twelve million dollars ($12,000,000) in Baseline M&P Expense each Calendar Quarter\n",
            "(\n",
            "provided\n",
            ", that notwithstanding Exact's quarterly spend for Baseline M&P Expense, Exact shall spend a total of eighty million\n",
            "dollars ($80,000,000) in Baseline M&P Expense each Calendar Year measured as of the end of each Calendar Year), (b) an amount\n",
            "equal to the total Shared M&P Expense contributed by both Parties is used for Marketing and Promotion and (c) a total sum of\n",
            "not less than eighty million dollars ($80,000,000) of Baseline M&P Expense is used for Marketing and Promotional activities,\n",
            "including the costs of Exact Sponsorships and Related Activities? \n",
            "provided, however, \n",
            "the Parties may agree to reallocate Shared\n",
            "M&P Expenses by\n",
            "28\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "mutual written consent. Pfizer agrees to match dollar for dollar Exact's Shared M&P Expense for a Calendar Year to up to the\n",
            "amounts specified in the chart below.\n",
            "Calendar Year\n",
            "Pfizer's Shared M&P Expense\n",
            "2018\n",
            "$24 million\n",
            "2019\n",
            "$22 million\n",
            "2020\n",
            "$21 million\n",
            "2021\n",
            "$20 million\n",
            "For any investment period less than a full Calendar Year (other than 2018), Pfizer's Shared M&P Expense investment shall be\n",
            "adjusted pro rata based on the number of months remaining until the end of the Calendar Year. For Calendar Year 2018, Pfizer's\n",
            "Shared M&P Expense shall be adjusted to equal the number of months remaining from the Launch Date to December 31, 2018\n",
            "divided by twelve (12) multiplied by twenty-four million dollars ($24,000,000)? \n",
            "provided\n",
            " the requirements of this Section 3.5 are\n",
            "satisfied. Pfizer shall have no obligation to incur Shared M&P Expenses in excess of the amount in the above chart for the given\n",
            "Calendar Year, unless the Parties mutually agree to increase their portion of the Shared M&P Expense.\n",
            "\n",
            "Doc1  6.2. . In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand\n",
            "Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the\n",
            "Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\n",
            "\n",
            "\n",
            "Doc2  3.6. Exact Investment and Support.  Exact shall commit, at its sole cost and expense and not subject to reimbursement by Pfizer, to\n",
            "maintaining its originally planned out-of-pocket Marketing and Promotional spends of eighty million dollars ($80,000,000) in each\n",
            "of the 2018, 2019, 2020, and 2021 Calendar Years, including the Exact Sponsorships and Related Activities (the \"\n",
            "Doc1  6.2. . In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand\n",
            "Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the\n",
            "Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\n",
            "\n",
            "\n",
            "Doc2  Baseline M&P. Expense \"). In addition to Baseline M&P Expense, Exact shall invest Shared M&P Expense in amounts to be matched by Pfizer\n",
            "pursuant to Section 3.5 above. Exact, at its own expense, shall use its commercially reasonable efforts to carry out Exact's\n",
            "responsibilities under the Annual Marketing Plan, which commercially reasonable efforts shall include committing the appropriate\n",
            "resources to assist in the implementation of the Annual Marketing Plan and to carry out the activities Exact is responsible for\n",
            "thereunder. In addition, except as provided for in Section 3.2(d), Exact shall be responsible for contracting with agencies and\n",
            "vendors who are or will be providing services (including the development of Promotional Materials and Training Materials)\n",
            "associated with the execution of the Annual Marketing Plan, shall timely pay all amounts due to such agencies and vendors for\n",
            "such services and shall authorize Pfizer to interact directly with and instruct such agencies and vendors in connection with such\n",
            "services as necessary and appropriate under this Agreement.\n",
            "Calendar\n",
            "Year\n",
            "Exact's Baseline M&P\n",
            "Expense\n",
            "Exact's Shared M&P\n",
            "Expense\n",
            "2018\n",
            "$80 million\n",
            "$24 million\n",
            "2019\n",
            "$80 million\n",
            "$22 million\n",
            "2020\n",
            "$80 million\n",
            "$21 million\n",
            "2021\n",
            "$80 million\n",
            "$20 million\n",
            "29\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "For any investment period less than a full Calendar Year (other than 2018), Exact's Baseline M&P Expense and Shared M&P\n",
            "Expense investment shall be adjusted pro rata based on the number of months remaining until the end of the Calendar Year. For\n",
            "Calendar Year 2018, Exact's Baseline M&P Expense and Shared M&P Expense shall be adjusted to equal the number of months\n",
            "remaining from the Launch Date to December 31, 2018 divided by twelve (12) multiplied by eighty million dollars ($80,000,000) or\n",
            "twenty-four million dollars ($24,000,000), as applicable? \n",
            "provided\n",
            " that the requirements of this Section 3.6 are satisfied. Exact\n",
            "shall have no obligation to incur Shared M&P Expenses in excess of the amount in the above chart for the given Calendar Year,\n",
            "unless the Parties each agree to increase their portion of the Shared M&P Expense.\n",
            "Doc1  6.2. . In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand\n",
            "Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the\n",
            "Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\n",
            "\n",
            "\n",
            "Doc2  3.7. Changes in Shared M&P Expenses.  In the event the Parties agree to not implement or to discontinue implementation of a strategy or\n",
            "tactic included in any Annual Marketing Plan, the applicable Shared M&P Expense investment set forth above shall be either (a)\n",
            "adjusted if, during good faith discussions at the JSC, the Parties agree on the implementation of a substitute strategy or tactic in\n",
            "place of the strategy or tactic that was not implemented or was discontinued, which adjustment will reflect any difference in cost\n",
            "of such substitute strategy or tactic or (b) reduced by the amount(s) allocated in the applicable budget for such strategy or tactic\n",
            "under the applicable Annual Marketing Plan, if the Parties, during good faith discussions at the JSC, agree not to implement a\n",
            "substitute strategy or tactic in place of the strategy or tactic that was not implemented or which was discontinued. Any amount\n",
            "saved as result of this Section 3.7 shall be re-deployed to other expenses associated with the Marketing of the Product, unless\n",
            "otherwise determined by the JSC.\n",
            "Doc1  3.5. .. 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee\n",
            "comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss,\n",
            "among other things:\n",
            "(a)\n",
            "the number of speaker programs for the Product to be conducted by Dova in each Calendar Year?\n",
            "(b)\n",
            "the Promotional Materials and quantities thereof?\n",
            "(c)\n",
            "the annual brand plan? and\n",
            "(d)\n",
            "the annual conference strategy.\n",
            "\n",
            "\n",
            "Doc2  4.. ACCOUNTING.. 4.1. Responsibility for Shared M&P Expenses. (a)\n",
            "Shared M&P Expenses contributed by Exact and Pfizer pursuant to Sections 3.5 and 3.6 shall be used solely to fund\n",
            "activities pursuant to the Annual Marketing Plan. The Parties shall agree to Calendar Quarter phasing of Baseline M&P\n",
            "Expenses and Shared M&P Expenses for budgeting purposes. The Parties will spend amounts contributed to Baseline\n",
            "M&P Expenses and Shared M&P Expenses simultaneously throughout each Calendar Year, in a manner consistent with\n",
            "the approved budget set forth in the Annual Marketing Plan. Any Baseline M&P Expenses and Shared M&P Expenses\n",
            "budgeted but not spent in Calendar Quarter may be rolled over into the next Calendar Quarter. For the avoidance of\n",
            "doubt, Pfizer will match dollar for dollar Exact's Shared M&P Expense for a Calendar Year to up to the amounts set forth\n",
            "in Section 3.5.\n",
            "(b)\n",
            "Doc1  4.6. . Other than as expressly set out herein, Valeant shall be solely responsible for any and all costs and expenses incurred by Valeant or any of its Affiliates in connection with the conduct of\n",
            "the Valeant Activities for the Product hereunder, including all costs and expenses in connection with Sales Representatives,\n",
            "including salaries, travel expenses and other expenses, credentialing, licensing, providing benefits, deducting federal, state and local\n",
            "payroll taxes, and paying workers' compensation premiums, unemployment insurance contributions and any other payments\n",
            "required by Applicable Laws to be made on behalf of employees.\n",
            "\n",
            "\n",
            "Doc2  Remainder of 2018.  Promptly after the Effective Date, Exact shall discuss with Pfizer its planned Marketing and Promotional\n",
            "spend associated with the Product for the period beginning on the Effective Date and ending on December 31, 2018, so\n",
            "that Pfizer may understand and recommend\n",
            "30\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "reallocation of all or any portion of such planned Marketing and Promotional spend associated with the Product. Budget\n",
            "phasing of 2018 pro-rated Baseline M&P Expenses and pro-rated Shared M&P Expenses shall be done on the Calendar\n",
            "Quarter basis. Exact agrees it shall spend at least eighty million dollars ($80,000,000) toward Marketing and Promotion\n",
            "(including any amounts spent between January 1, 2018 and the Effective Date) and the pro-rated Shared M&P Expense\n",
            "for 2018.\n",
            "(c)\n",
            "Within fifteen (15) Business Days after the end of each month during the Term beginning with October, 2018, Exact\n",
            "shall provide to Pfizer a written report setting forth the amount of Baseline M&P Expenses and Shared M&P Expenses\n",
            "incurred and paid for by Exact during such month, which report shall also provide sufficient itemization and detail related\n",
            "to such expenses in order for Pfizer to confirm that such Baseline M&P Expenses and Shared M&P Expenses were\n",
            "incurred pursuant to the Annual Marketing Plan. Pfizer, within fifteen (15) Business Days after the end of each month\n",
            "during the Term, beginning with October, 2018, shall prepare and provide to Exact a written report setting forth the\n",
            "aggregate amount of Shared M&P Expenses incurred and paid for by Pfizer during such month, along with sufficient\n",
            "itemization and detail related to such expenses in order for Exact to confirm that such Shared M&P Expenses were\n",
            "incurred pursuant to the Annual Marketing Plan.\n",
            "Doc1  4.6. . Other than as expressly set out herein, Valeant shall be solely responsible for any and all costs and expenses incurred by Valeant or any of its Affiliates in connection with the conduct of\n",
            "the Valeant Activities for the Product hereunder, including all costs and expenses in connection with Sales Representatives,\n",
            "including salaries, travel expenses and other expenses, credentialing, licensing, providing benefits, deducting federal, state and local\n",
            "payroll taxes, and paying workers' compensation premiums, unemployment insurance contributions and any other payments\n",
            "required by Applicable Laws to be made on behalf of employees.\n",
            "\n",
            "\n",
            "Doc2  4.2. Promotion Fee. (a)\n",
            "Doc1  6.3.2. . Within fifteen (15) days of the end of each month within each Calendar Quarter, Dova shall provide to Valeant a written report setting forth Dova's good faith estimate of the Net Sales and the estimated promotion fee\n",
            "payable in respect of such Net Sales for each of such calendar month and the Calendar Quarter-to-date period, together with its\n",
            "good faith estimates of each of the items described in Section 6.3.1 above (assuming there will be no adjustments made to the\n",
            "promotion fee pursuant to Section 6.1.2). The Parties acknowledge and agree that the monthly reports will only set forth Dova's\n",
            "good faith estimates of the items contained therein and are being provided to Valeant for information purposes only and shall not be\n",
            "determinative of the any amounts due hereunder.\n",
            "\n",
            "\n",
            "Doc2  Calculation of Promotion Fee.  From the Launch Date and ending on the last day of the next Calendar Quarter and each\n",
            "subsequent Calendar Quarter during the Term, Exact shall owe Pfizer a service fee equal to fifty percent (50%) of the\n",
            "product of: Laboratory Service Revenue minus Baseline Laboratory Service Revenue (\"\n",
            "Doc1  6.3. .. 6.3.1. . Within [***] after the end of each Calendar Quarter during the Term, Dova shall provide to Valeant a written report setting forth in reasonable detail the calculation of the Net Sales for such Calendar\n",
            "Quarter and the promotion fee payable in respect of such Net Sales in accordance with Section 6.1, including (i) the number of\n",
            "units of the Product shipped from Specialty Pharmacies to patients in the Territory during such Calendar Quarter, together with an\n",
            "itemized list of such units by Target Professional writing the applicable prescription, (ii) the number of units of the Product shipped\n",
            "from Specialty Pharmacies to patients in the Territory based on prescriptions written by the Specialty only during such Calendar\n",
            "Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription (iii)\n",
            "the number of units per shipment of Products (and the number of such shipments) sold by Dova (or its Affiliates or Intermediaries)\n",
            "to the Non-Retail Institutions during such Calendar Quarter, including details respecting which shipments are based on initial orders\n",
            "from such Non-Retail Institutions and which Non-Retail Institutions ordered the Product, (iv) the number of units of the Product\n",
            "shipped from Retail Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units\n",
            "by Target Professional writing the applicable prescription, (v) the number of units shipped from Retail Pharmacies to patients based\n",
            "on prescriptions written by the Specialty in the Territory during such Calendar Quarter, together with an itemized list of such units\n",
            "by Target Professional in the Specialty writing the applicable prescription, (vi) the applicable Specialty Fraction for such Calendar\n",
            "Quarter, (vii) the WAC applicable to each dispensable unit, (ix) the Gross to Net Fraction for the applicable period, together with\n",
            "the details respecting the calculation thereof (including details regarding each of the categories of the deductions to gross sales for\n",
            "such Calendar Quarter). Within sixty (60)\n",
            "days after the end of each Calendar Quarter during the Term, Dova shall pay to Valeant\n",
            "the undisputed portion of the promotion fee payable in respect of such Net Sales in accordance with Section 6.1. If this Agreement\n",
            "terminates or expires during a Calendar Quarter, the promotion fee payable to Valeant under Section 6.1 will be calculated only on\n",
            "the Net Sales that occurred during such Calendar Quarter prior to the effective date of such termination or expiration.\n",
            "\n",
            "\n",
            "Doc2  Incremental Laboratory Service. Revenue \") for the Calendar Quarter multiplied by Gross Margin Percent for the Calendar Quarter (such product, the\n",
            "\"\n",
            "\"). In no event shall the Gross Margin Percent used in the calculation of the Promotion Fee be less than\n",
            "sixty-eight percent (68%) or more than seventy-four percent (74%). The calculation of the Promotion Fee pursuant to\n",
            "this Section 4.2(a) is subject to Section 4.2(c) below. Promotion Fee(s) and all compensation paid by Exact to Pfizer under\n",
            "this Agreement, even where calculated as a percentage of sales, is intended to compensate Pfizer a fair market value for\n",
            "the entirety of services that Pfizer is providing to Exact hereunder.\n",
            "The formula for the calculation of the Promotion Fee is as follows:\n",
            "A = Laboratory Service Revenue\n",
            "B = Baseline Laboratory Service Revenue\n",
            "C = Gross Margin Percent\n",
            "Promotion Fee = 0.5 * (A-B) * C\n",
            "31\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(b)\n",
            "Doc1  Applicable Percentage \".\n",
            "(a)\n",
            "If the aggregate actual number of Details for the Product made by the Sales Representatives for a\n",
            "Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due\n",
            "under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\n",
            "(b)\n",
            "If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable\n",
            "Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar\n",
            "Quarter shall be reduced to a new percentage equal to [***].\n",
            "(c)\n",
            "In the event that subsections (a) above and (b) above are both applicable in an applicable Calendar\n",
            "Quarter, then the Applicable Percentage shall be reduced to a new percentage equal to the lower of the percentages calculated\n",
            "under subsections (a) and (b).\n",
            "\n",
            "Doc2  Baseline Laboratory Service Revenue.  The chart below sets forth the Baseline Laboratory Service Revenue for the Product\n",
            "for each Calendar Year during the Term (the \"\n",
            "\"). In the Annual\n",
            "Marketing Plan the appropriate Calendar Year Baseline Laboratory Service Revenue shall be allocated among each\n",
            "Calendar Quarter during such Calendar Year, taking into consideration seasonality or other sales demand variables. For\n",
            "2018, the first Calendar Quarter shall be from the Launch Date to December 31, 2018 and the Calendar Year Baseline\n",
            "Laboratory Service Revenue allocated to that Calendar Quarter shall be $130 million.\n",
            "Calendar Year\n",
            "Baseline Laboratory Service\n",
            "Revenue\n",
            "2018\n",
            "$441 million\n",
            "2019\n",
            "$622 million\n",
            "2020\n",
            "$861 million\n",
            "2021\n",
            "$1.191 billion\n",
            "(c)\n",
            "Doc1  6.2. . In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand\n",
            "Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the\n",
            "Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\n",
            "\n",
            "\n",
            "Doc2  Supplemental Promotion Fee. (i)\n",
            "Subject to Pfizer's compliance with Sections 3.4(a)(i) and 3.4(a)(ii), (A) Exact shall pay Pfizer the amount, if any, by\n",
            "which the aggregate amount of the Promotion Fee incurred by Exact to Pfizer during the remainder of 2018\n",
            "Calendar Year and 2019 Calendar Year (the \"\n",
            "\") is less than $37.5 million (the \"\n",
            "Doc1  6.2. . In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand\n",
            "Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the\n",
            "Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\n",
            "\n",
            "\n",
            "Doc2  First. Supplemental Promotion Fee \"), and (B) Exact shall pay Pfizer the amount, if any, by which the aggregate\n",
            "Promotion Fee incurred by Exact to Pfizer during each of Calendar Year 2020 and 2021 is less than $30 million\n",
            "(\"\n",
            "\"), in each case to compensate Pfizer for the sales, Marketing and other\n",
            "performance provided by Pfizer under this Agreement.\n",
            "(ii)\n",
            "As of June 30 of each Calendar Year during the Term, Exact shall calculate a partial-period amount to be paid toward\n",
            "the potential First Supplemental Promotion Fee or the potential Annual Supplemental Promotion Fee, as the\n",
            "case may be. With regard to the First Supplemental Promotion Fee, the partial-period payment shall be equal to\n",
            "the amount by which the Promotion Fee for 2018, and the first six (6) months of Calendar Year 2019, is less than\n",
            "$22.5 million, and with regard to each Annual Supplemental Promotion Fee, the partial-period payment shall be\n",
            "equal to the amount by which the Promotion Fee for the six-month (6-month) period through June 30 is less\n",
            "than $15 million.\n",
            "(iii)\n",
            "As of December 31 of each Calendar Year during the Term, Exact shall calculate the First Supplemental Promotion Fee\n",
            "or the Annual Supplemental Promotion Fee, as the case may be, if any, for the entirety of the applicable period.\n",
            "Exact shall pay Pfizer the First\n",
            "32\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Supplemental Promotion Fee or the Annual Supplemental Promotion Fee, as the case may be, if any, less any\n",
            "partial-period payment made by Exact during the applicable period pursuant to Section 4.2(c)(ii).\n",
            "(iv)\n",
            "To the extent the amount of the Promotion Fee for the First Promotion Fee Period exceeds the First Supplemental\n",
            "Promotion Fee, Exact shall be entitled to a credit of such excess amount up to the amount of any partial-period\n",
            "payment made by Exact during such First Promotion Fee Period pursuant to Section 4.2(c)(ii), and Exact shall\n",
            "apply such credit toward the Promotion Fee payment due Pfizer for the fourth Calendar Quarter of 2019 (or due\n",
            "for subsequent Calendar Quarters until such credit is fully exhausted). To the extent the amount of the\n",
            "Promotion Fee for any Calendar Year after 2019 exceeds the Annual Supplemental Promotion Fee for such\n",
            "Calendar Year, Exact shall be entitled to a credit of such excess amount up to the amount of any partial-period\n",
            "payment made by Exact during such Calendar Year pursuant to Section 4.2(c)(ii), and Exact shall apply such\n",
            "credit toward the Promotion Fee payment due Pfizer for the fourth Calendar Quarter of such Calendar Year (or\n",
            "due for subsequent Calendar Quarters until such credit is fully exhausted).\n",
            "(v)\n",
            "Any amounts due under Sections 4.2(c)(i) and (ii) shall be payable within thirty (30) days after each of June 30 , and\n",
            "December 31  of each Calendar Year, beginning with June 30, 2019, as applicable.\n",
            "(d)\n",
            "OB/Gyn Sales.\n",
            " If Exact (i) grants OB/Gyn Commercial Rights to a Third Party in accordance with Section 3.1(c) or (ii) launches\n",
            "its own sales channel in the OB/Gyn Field (as applicable, the \"\n",
            "\"), then the Laboratory Service\n",
            "Revenue used to perform the calculation set forth in Section 4.2(a) and to determine royalty payments pursuant to\n",
            "Section 8.7 shall exclude all Laboratory Service Revenue attributable to the Excluded Channel except a mutually agreed\n",
            "percentage of Laboratory Service Revenue during the applicable period attributable to such Excluded Channel (the\n",
            "\"\n",
            "\")? \n",
            "provided\n",
            ", that (A) such Included Revenue Percentage will reflect the anticipated\n",
            "relative contribution of the Parties with regard to the Excluded Channel after such launch, and (B) the Included Revenue\n",
            "Percentage shall not be less than the revenue percentage attributable to the OB/Gyn Field as of the date of such launch,\n",
            "calculated on the same basis that revenue from the OB/Gyn Field is calculated by Exact on the Effective Date.\n",
            "Doc1  6.2. . In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand\n",
            "Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the\n",
            "Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\n",
            "\n",
            "\n",
            "Doc2  4.3. Fee Statements and Payments. (a)\n",
            "Doc1  About Bausch Health Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our\n",
            "health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter\n",
            "products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our\n",
            "commitments as we build an innovative company dedicated to advancing global health. More information can be found at\n",
            "www.bauschhealth.com.\n",
            "Dova Pharmaceuticals Cautionary Notes Regarding Forward-Looking Statements \n",
            "Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as\n",
            "that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as\n",
            "\"anticipated\", \"believe\", \"expect\", \"may\", \"plan\", \"potential\", \"will\", and similar expressions, and are based on Dova's current\n",
            "beliefs and expectations. These forward-looking statements include the potential benefits of the collaboration, the timing of the\n",
            "Salix sales force beginning to sell DOPTELET and other information relating to the transaction between Dova and Salix. These\n",
            "statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.\n",
            "Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials,\n",
            "increased regulatory requirements, Dova's reliance on third parties over which it may not always have full control, and other risks\n",
            "and uncertainties that are described in Dova's Annual Report on Form 10-K for the year ended December 31, 2017, filed with the\n",
            "U.S. Securities and Exchange Commission (SEC) on February 16, 2018, and Dova's other periodic reports filed with the SEC.\n",
            "Any forward-looking statements speak only as of the date of this press release and are based on information available to Dova as\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "of the date of this release, and Dova assumes no obligation to, and does not intend to, update any forward-looking statements,\n",
            "whether as a result of new information, future events or otherwise.\n",
            "\n",
            "Doc2  Monthly and Quarterly Financial Deliverables.  Exact shall on a monthly basis, not later than fifteen (15) Business Days after\n",
            "the end of the month, deliver to Pfizer a full suite of performance data, including Product Laboratory Services completed,\n",
            "average selling price per unit, Laboratory Service Revenue, rebates, net revenue and a detailed Cost of Sales schedule\n",
            "33\n",
            "th\n",
            "st\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(consisting of collection kits distributed to patients, royalties paid, shipping costs, lab operating expenses and reagent\n",
            "costs). Not later than fifteen (15) Business Days after the end of the Calendar Quarter, Exact shall deliver to Pfizer a\n",
            "rolling sales forecast and an estimate, for the remaining Calendar Quarters in the Calendar Year, of the Promotion Fee as\n",
            "set forth in Section 4.2.\n",
            "(b)\n",
            "Doc1  6.3.2. . Within fifteen (15) days of the end of each month within each Calendar Quarter, Dova shall provide to Valeant a written report setting forth Dova's good faith estimate of the Net Sales and the estimated promotion fee\n",
            "payable in respect of such Net Sales for each of such calendar month and the Calendar Quarter-to-date period, together with its\n",
            "good faith estimates of each of the items described in Section 6.3.1 above (assuming there will be no adjustments made to the\n",
            "promotion fee pursuant to Section 6.1.2). The Parties acknowledge and agree that the monthly reports will only set forth Dova's\n",
            "good faith estimates of the items contained therein and are being provided to Valeant for information purposes only and shall not be\n",
            "determinative of the any amounts due hereunder.\n",
            "\n",
            "\n",
            "Doc2  . Exact, within thirty (30) days after the end of each Calendar Quarter of the Term, shall deliver to Pfizer a consolidated report in the form of and containing the information necessary to confirm the calculation of the\n",
            "Promotion Fee for such Calendar Quarter, together with the underlying spreadsheets with respect to such Calendar\n",
            "Quarter. The Promotion Fee due with respect to such Calendar Quarter and reflected on the consolidated report shall be\n",
            "remitted at the time such report is made.\n",
            "\n",
            "Doc1  6.3. .. 6.3.1. . Within [***] after the end of each Calendar Quarter during the Term, Dova shall provide to Valeant a written report setting forth in reasonable detail the calculation of the Net Sales for such Calendar\n",
            "Quarter and the promotion fee payable in respect of such Net Sales in accordance with Section 6.1, including (i) the number of\n",
            "units of the Product shipped from Specialty Pharmacies to patients in the Territory during such Calendar Quarter, together with an\n",
            "itemized list of such units by Target Professional writing the applicable prescription, (ii) the number of units of the Product shipped\n",
            "from Specialty Pharmacies to patients in the Territory based on prescriptions written by the Specialty only during such Calendar\n",
            "Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription (iii)\n",
            "the number of units per shipment of Products (and the number of such shipments) sold by Dova (or its Affiliates or Intermediaries)\n",
            "to the Non-Retail Institutions during such Calendar Quarter, including details respecting which shipments are based on initial orders\n",
            "from such Non-Retail Institutions and which Non-Retail Institutions ordered the Product, (iv) the number of units of the Product\n",
            "shipped from Retail Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units\n",
            "by Target Professional writing the applicable prescription, (v) the number of units shipped from Retail Pharmacies to patients based\n",
            "on prescriptions written by the Specialty in the Territory during such Calendar Quarter, together with an itemized list of such units\n",
            "by Target Professional in the Specialty writing the applicable prescription, (vi) the applicable Specialty Fraction for such Calendar\n",
            "Quarter, (vii) the WAC applicable to each dispensable unit, (ix) the Gross to Net Fraction for the applicable period, together with\n",
            "the details respecting the calculation thereof (including details regarding each of the categories of the deductions to gross sales for\n",
            "such Calendar Quarter). Within sixty (60)\n",
            "days after the end of each Calendar Quarter during the Term, Dova shall pay to Valeant\n",
            "the undisputed portion of the promotion fee payable in respect of such Net Sales in accordance with Section 6.1. If this Agreement\n",
            "terminates or expires during a Calendar Quarter, the promotion fee payable to Valeant under Section 6.1 will be calculated only on\n",
            "the Net Sales that occurred during such Calendar Quarter prior to the effective date of such termination or expiration.\n",
            "\n",
            "\n",
            "Doc2  4.4. Taxes and Withholding.  It is understood and agreed between the Parties that any payments made under this Agreement are exclusive\n",
            "of any value added or similar tax (\"\n",
            "\"), and that no such VAT shall apply to the payments made under this Agreement. In the\n",
            "event any payments made pursuant to this Agreement become subject to withholding taxes under the laws or regulation of any\n",
            "jurisdiction, the Party making such payment shall deduct and withhold the amount of such taxes for the account of the payee to\n",
            "the extent required by Applicable Law and such amounts payable to the payee shall be reduced by the amount of taxes deducted\n",
            "and withheld. Any such withholding taxes required under Applicable Law to be paid or withheld shall be an expense of, and\n",
            "borne solely by, the payee. To the extent that the Party making a payment is required to deduct and withhold taxes on any\n",
            "payments under this Agreement, the Party making such payment shall pay the amounts of such taxes to the proper Governmental\n",
            "Authority in a timely manner and promptly transmit to the payee an official tax certificate or other evidence of such withholding\n",
            "sufficient to enable the payee to claim such payments of taxes. The payee shall provide any tax forms to the Party making such\n",
            "payment that may be reasonably necessary in order for such Party not to withhold tax or to withhold tax at a reduced rate under\n",
            "an applicable bilateral income tax treaty. The payee shall use commercially reasonable efforts to provide any such tax forms to the\n",
            "Party making the payment at least thirty (30) days prior to the due date for any payments for which the payee desires that the\n",
            "Party making the payment apply a reduced withholding rate. Each Party shall provide the other with reasonable assistance to\n",
            "enable the recovery, as permitted by Law, of withholding taxes, VAT, or similar obligations resulting from payments made under\n",
            "this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or VAT. Notwithstanding anything\n",
            "in this Agreement to the contrary, (a) if an action (including any assignment or sublicense of its rights or obligations under this\n",
            "Agreement, or any failure to comply with Applicable Law or filing or record retention requirements) by a Party leads to the\n",
            "imposition of withholding tax liability or VAT on the other Party that would not have been imposed in the absence of such action\n",
            "or in an increase in such liability above the liability that would have been imposed in the absence of such action, then the sum\n",
            "payable by that Party (in respect of which such deduction or withholding is required to be made) shall be increased to the extent\n",
            "necessary to ensure that the other Party\n",
            "34\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "receives a sum equal to the sum which it would have received had no such action occurred, (b) otherwise, the sum payable by\n",
            "that Party (in respect of which such deduction or withholding is required to be made) shall be made to the other Party after\n",
            "deduction of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted in\n",
            "accordance with Applicable Law.\n",
            "Doc1  6.4. . To the extent Dova is required to deduct and withhold taxes from any payment to Valeant, Dova shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Valeant an official tax\n",
            "receipt or other evidence of timely payment sufficient to enable Valeant to claim the payment of such taxes as a deduction or tax\n",
            "credit. Valeant may provide to Dova any tax forms that may be reasonably necessary in order for Dova to not withhold tax and\n",
            "Dova shall dispense with withholding, as applicable. Dova shall provide Valeant with reasonable assistance to enable the recovery,\n",
            "as permitted by Applicable Laws, of withholding taxes.\n",
            "\n",
            "\n",
            "Doc2  4.5. No Partnership Provision.  It is expressly agreed that Pfizer and Exact shall be independent contractors and that the relationship\n",
            "between Pfizer and Exact shall not constitute a partnership, joint venture or agency. The Parties agree that the rights and\n",
            "obligations under this Agreement are not intended to constitute a partnership or similar arrangement that will require separate\n",
            "reporting for tax purposes consistent with the intent reflected in the foregoing sentence and agree that they shall not file any\n",
            "reports, documents or other item relating to taxes or state or acknowledge to any tax authority that such relationship is a\n",
            "partnership or similar arrangement unless required by Applicable Law.\n",
            "Doc1  13.10. . It is expressly agreed that Valeant and Dova shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Valeant nor Dova shall\n",
            "have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be\n",
            "binding on the other Party, without the prior written consent of the other Party.\n",
            "\n",
            "\n",
            "Doc2  4.6. Payments? Currency.  All payments due by one Party to the other Party hereunder shall be paid by wire transfer in immediately\n",
            "available funds from the account or accounts of a Party and/or its Affiliates to an account or accounts of the receiving Party\n",
            "and/or its Affiliates designated in writing by the receiving Party. All amounts payable and calculations hereunder shall be in\n",
            "United States dollars.\n",
            "Doc1  6.3.5. . All payments under this Agreement shall be made in US Dollars by wire transfer or Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "ACH to a bank account designated in writing by Valeant or Dova, as applicable, which shall be designated at least five (5)\n",
            "Business Days before such payment is due.\n",
            "\n",
            "\n",
            "Doc2  4.7. Maintenance of Records? Audits. (a)\n",
            "Doc1  7.1. .  Each Party shall maintain complete and accurate books and records in sufficient detail, in\n",
            "accordance with GAAP (to the extent applicable and in accordance with the Agreement) and all Applicable Law, to enable\n",
            "verification of the performance of such Party's obligations under this Agreement and any payments due to a Party under this\n",
            "Agreement. Unless otherwise specified herein, the books and records for a given Calendar Year of the Term shall be maintained\n",
            "for a period of [***] after the end of such Calendar Year or longer if required by Applicable Law.\n",
            "\n",
            "\n",
            "Doc2  Record Keeping.  Each Party shall keep and shall cause its Affiliates to keep accurate books and accounts of record in\n",
            "connection with (i) its Marketing and Promotion of the Product, (ii) (with respect to Exact) performance of Product\n",
            "Laboratory Services, and (iii) its activities under this Agreement and any Annual Marketing Plan, in sufficient detail to\n",
            "permit accurate determination of all figures necessary for verification of (A) amounts to be paid hereunder and (B)\n",
            "compliance with the terms of this Agreement. Each Party shall, and shall cause its Affiliates to, maintain such records for\n",
            "a period of at least three (3) years after the end of the Calendar Year to which they pertain.\n",
            "(b)\n",
            "Doc1  7.1. .  Each Party shall maintain complete and accurate books and records in sufficient detail, in\n",
            "accordance with GAAP (to the extent applicable and in accordance with the Agreement) and all Applicable Law, to enable\n",
            "verification of the performance of such Party's obligations under this Agreement and any payments due to a Party under this\n",
            "Agreement. Unless otherwise specified herein, the books and records for a given Calendar Year of the Term shall be maintained\n",
            "for a period of [***] after the end of such Calendar Year or longer if required by Applicable Law.\n",
            "\n",
            "\n",
            "Doc2  Financial Audits. (i)\n",
            "Doc1  5.10.  Manufacturing? Distribution? Marketing.. 25. ARTICLE 6 FINANCIAL PROVISIONS 26\n",
            "\n",
            "Doc2  Audit Right.  Upon thirty (30) days prior written notice from a Party (the \"\n",
            "\"), the other Party (the\n",
            "\"\n",
            "\") shall permit an independent certified public accounting firm of nationally recognized standing\n",
            "selected by the Auditing Party and reasonably acceptable to the Audited Party, to examine, at the Auditing\n",
            "Party's sole expense, the relevant books and records of the Audited Party and its Affiliates as may be\n",
            "reasonably necessary to verify the accuracy of the reports submitted by the Audited Party in accordance with\n",
            "Sections 3.4(d), 4.1(c) and 4.3(a) and the payment of Promotion Fees hereunder. An examination by the\n",
            "Auditing Party under this Section 4.6(b) shall occur not more than once in any Calendar Year and shall\n",
            "35\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "be limited to the pertinent books and records for any Calendar Year during the Term ending not more than\n",
            "twenty-four (24) months before the date of the request. The accounting firm shall be provided access to such\n",
            "books and records at the Audited Party's facility(ies) in the Territory where such books and records are\n",
            "normally kept and such examination shall be conducted during the Audited Party's normal business hours. The\n",
            "Audited Party may require the accounting firm to sign a standard non-disclosure agreement before providing\n",
            "the accounting firm access to the Audited Party's facilities or records. Upon completion of the audit, the\n",
            "accounting firm shall provide both Pfizer and Exact a written report disclosing whether the reports submitted by\n",
            "the Audited Party are correct or incorrect, whether the Promotion Fees paid during the audited period or\n",
            "Baseline M&P Expenses or Shared M&P Expenses incurred during the audited period are correct or incorrect,\n",
            "and, in each case, the specific details concerning any discrepancies. No other information shall be provided to\n",
            "the Auditing Party. The decision of the accounting firm will be final and unappealable absent manifest error.\n",
            "(ii)\n",
            "Underpayments/Overpayments.\n",
            " If such accounting firm concludes that additional Promotion Fees were due to Pfizer,\n",
            "Exact shall pay to Pfizer an amount equal to the actual Promotion Fee due minus the Promotion Fee paid within\n",
            "thirty (30) days of the date Exact receives such accountant's written report so concluding. If such accounting\n",
            "firm correctly concludes that Promotion Fees paid to Pfizer were in excess of the amount properly due, Pfizer\n",
            "shall pay or refund to Exact an amount equal to the Promotion Fee paid minus the actual Promotion Fee due\n",
            "within thirty (30) days of the date Exact receives such accountant's written report so concluding.\n",
            "(c)\n",
            "Doc1  7.2. . Valeant shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through certified public accounting firm or other auditor selected by Valeant and reasonably acceptable to Dova and\n",
            "upon execution of a confidentiality agreement reasonably satisfactory to Dova in form and substance, to inspect and audit the\n",
            "applicable records and books maintained by Dova for purposes of verifying Dova's payment obligations within this Agreement,\n",
            "including the applicable records and books of account maintained by Dova, or any Affiliate, as applicable, with respect to Net\n",
            "Sales in order to confirm the accuracy and completeness of such records and books of account and all payments hereunder?\n",
            "provided, however, that (i) such examination shall not take place more often than once per every twelve (12) months during the\n",
            "Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of\n",
            "time that has previously been audited? provided that Valeant shall have the right to conduct additional \"for cause\" audits to the\n",
            "extent necessary to address significant problems relating to Dova's payment obligations hereunder. Dova shall reasonably\n",
            "cooperate in any such inspection or audit conducted by Valeant. Any undisputed adjustments required as a result of overpayments\n",
            "or underpayments identified through the exercise of audit rights shall be made by payment to the Party owed such adjustment\n",
            "within [***] after identification of such adjustment. Valeant shall bear the out-of-pocket costs and expenses incurred by the Parties\n",
            "in connection with any such inspection or audit, unless the audit shows an undisputed under-reporting or underpayment for that\n",
            "audited period in excess of [***] of the amounts properly determined, in which case, Dova shall reimburse Valeant for its audit\n",
            "fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within\n",
            "[***] of receiving appropriate invoices and other support for such audit-related costs.\n",
            "\n",
            "\n",
            "Doc2  Compliance Audit.  Upon thirty (30) days prior written notice from an Auditing Party, the Audited Party shall permit the\n",
            "Auditing Party's external auditors access to any relevant books documents, papers, and records of the Party involving\n",
            "any report delivered pursuant to Sections 3.2(d), 3.4(d) and 4.3(a) of this Agreement and the activities performed under\n",
            "this Agreement, if the other Party has credible evidence that the other Party violated terms of this Agreement, including\n",
            "with respect to Product Training under Section 3(e). An examination by a Party under this Section 4.6(c) shall (i) occur\n",
            "not more than once in any Calendar Year, (ii) be limited to the pertinent books and records for any Calendar Year during\n",
            "the Term ending not more than twenty-four (24) months before the date of the request and (iii) be at the sole expense of\n",
            "the Auditing Party. The external auditors of the Auditing Party shall be provided access to such books and records at\n",
            "the Audited Party's facility(ies) in the Territory where such books and records are normally kept and such examination\n",
            "shall be conducted during the Audited Party's normal business hours. The Audited Party may require any external\n",
            "auditors to sign a standard non-disclosure agreement before providing the accounting firm access to the Audited\n",
            "Party's facilities or records.\n",
            "36\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(d)\n",
            "Doc1  7.1. .  Each Party shall maintain complete and accurate books and records in sufficient detail, in\n",
            "accordance with GAAP (to the extent applicable and in accordance with the Agreement) and all Applicable Law, to enable\n",
            "verification of the performance of such Party's obligations under this Agreement and any payments due to a Party under this\n",
            "Agreement. Unless otherwise specified herein, the books and records for a given Calendar Year of the Term shall be maintained\n",
            "for a period of [***] after the end of such Calendar Year or longer if required by Applicable Law.\n",
            "\n",
            "\n",
            "Doc2  Confidentiality.  All financial and other confidential information of the Audited Party which is subject to review under this\n",
            "Section 4.6 shall be deemed to be the Audited Party's Confidential Information and, subject to the provisions of Article 6\n",
            "hereof, the Auditing Party shall not disclose such Confidential Information to any Third Party or use such Confidential\n",
            "Information for any purpose other than verifying compliance with this Agreement.\n",
            "REPRESENTATIONS, WARRANTIES AND COVENANTS.\n",
            "Doc1  9.1. .. 9.1.1. . Each Party agrees that, during the Term and for a period of [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in\n",
            "this Agreement (which includes the exercise of its rights or performance of any obligations hereunder) any Confidential Information\n",
            "furnished to it by or on behalf of the other Party pursuant to this Agreement, except to the extent expressly authorized by this\n",
            "Agreement or otherwise agreed in writing by the Parties. Without limiting the foregoing, each Party will use at least the same\n",
            "standard of care as it uses to protect its own Confidential Information to ensure that its employees, agents, consultants and\n",
            "contractors do not disclose or make any unauthorized use of such Confidential Information. Each Party will promptly notify the\n",
            "other upon discovery of any unauthorized use or disclosure of the other's Confidential Information. Any and all information and\n",
            "materials disclosed by a Party pursuant to the Confidentiality Agreement between the Parties dated [***] (the \"Confidentiality\n",
            "\n",
            "\") shall be deemed Confidential Information disclosed pursuant to this Agreement. The foregoing confidentiality and\n",
            "non-use obligations shall not apply to any portion of the other Party's Confidential Information that the receiving Party can\n",
            "demonstrate by competent tangible evidence:\n",
            "(a)\n",
            "was already known to the receiving Party or its Affiliate, other than under an obligation of\n",
            "confidentiality, at the time of disclosure by the other Party?\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "(b)\n",
            "was generally available to the public or otherwise part of the public domain at the time of its disclosure\n",
            "to the receiving Party?\n",
            "(c)\n",
            "became generally available to the public or otherwise part of the public domain after its disclosure and\n",
            "other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement?\n",
            "(d)\n",
            "was disclosed to the receiving Party or its Affiliate by a Third Party who has a legal right to make such\n",
            "disclosure and who did not obtain such information directly or indirectly from the other Party (or its Affiliate)? or\n",
            "(e)\n",
            "was independently discovered or developed by the receiving Party or its Affiliate without access to or\n",
            "aid, application, use of the other Party's Confidential Information, as evidenced by a contemporaneous writing.\n",
            "\n",
            "Doc2  5.1. Mutual Representations and Warranties.  Each of Exact and Pfizer hereby represents and warrants to the other Party as of the Effective\n",
            "Date that:\n",
            "(a)\n",
            "it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization?\n",
            "(b)\n",
            "the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite action\n",
            "under the provisions of its certificate of incorporation, bylaws and other organizational documents, and does not require\n",
            "any action or approval by any of its shareholders or other holders of its voting securities or voting interests that has not\n",
            "been taken?\n",
            "(c)\n",
            "it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder?\n",
            "(d)\n",
            "this Agreement has been duly executed by an appropriate representative of such Party and is a legal, valid and enforceable\n",
            "against such Party in accordance with its terms?\n",
            "(e)\n",
            "the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions\n",
            "hereof does not and will not conflict with or result in a breach of or default under (i) any oral or written agreement that\n",
            "binds such Party's operations or property, including any assignment, license agreement, loan agreement, guaranty or\n",
            "financing agreement, (ii) the provisions of such Party's certificate of incorporation, bylaws or other organizational\n",
            "documents, or (iii) any order, writ, injunction, decree or judgment of any court or Governmental Authority entered\n",
            "against such Party or by which any of such Party's operations or property are bound?\n",
            "(f)\n",
            "all material written information provided by each Party in the virtual data room maintained for the purposes of the proposed\n",
            "transactions under this Agreement is complete, truthful and accurate in all material respects? and\n",
            "(g)\n",
            "neither it, nor any of its Affiliates, nor, to such Party's knowledge, any of their respective Representatives has been debarred\n",
            "or suspended under 21 U.S.C. SS 335(a) or (b), excluded from a federal health care program, debarred from federal\n",
            "contracting, or convicted of or pled nolo contendere to any felony, or to any federal or state legal violation (including\n",
            "misdemeanors) relating to medical devices or fraud (\"\n",
            "Debarred/Excluded\n",
            "\").\n",
            "37\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Doc1  10.1.2 the execution, delivery and performance of this Agreement by it has been duly authorized by all requisite\n",
            "corporate action?\n",
            "\n",
            "\n",
            "Doc2  5.2. Representations and Warranties of Exact.  Exact hereby represents and warrants to Pfizer as of the Effective Date that:\n",
            "(a)\n",
            "no consent is required from any Third Party for Exact to enter into, or to exercise its rights and perform its obligations under,\n",
            "this Agreement?\n",
            "(b)\n",
            "in connection with the development, manufacturing and Promotion of the Product, except as would not reasonably be\n",
            "expected to have a material adverse effect on the Promotion of the Product in the Territory, Exact has complied and will\n",
            "continue to comply in all material respects with Applicable Law, including the FD&C Act, the Anti-Kickback Statute (42\n",
            "U.S.C. SS 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. SS 1320a-7a), the False Claims Act (31 U.S.C. SS 3729 et seq.),\n",
            "comparable state statutes, the regulations promulgated under all such statutes, and the regulations issued by the FDA?\n",
            "(c)\n",
            "with respect to the development, manufacturing and Promotion of the Product, Exact has not taken and will not take any\n",
            "action directly or indirectly to offer, promise or pay, or authorize the offer or payment of, any money or anything of value\n",
            "in order to improperly or corruptly seek to influence any Government Official in order to gain an improper advantage?\n",
            "(d)\n",
            "in connection with Exact's manufacturing and Promotion of Product or Exact's performance of the Product Laboratory Service\n",
            "in the Territory or directly relating to the transactions contemplated by this Agreement, except as would not reasonably\n",
            "be expected to have a material adverse effect on the Promotion of the Product in the Territory, (i) no written claim,\n",
            "demand, suit, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, has been filed and\n",
            "received by Exact, and is pending in any court, arbitration or government agency proceeding nor, to the knowledge of\n",
            "Exact, has any claim, demand, suit, investigation or other legal action of any nature, civil, criminal, regulatory or\n",
            "otherwise been threatened in writing, to be filed against Exact in any court, arbitration or government agency\n",
            "proceeding? and (ii) there is no judgment or settlement against or owed by Exact?\n",
            "(e)\n",
            "Exact has not received written notice from any Third Party claiming that the manufacture, use, sale or importation by or on\n",
            "behalf of Exact of the Product in the Territory or the performance of any Product Laboratory Service by or on behalf of\n",
            "Exact (i) infringes any issued patent or intellectual property right of such Third Party in the Territory or (ii) will infringe\n",
            "any claim of any published patent application of such Third Party in the Territory when and if such claim issues?\n",
            "(f)\n",
            "to Exact's knowledge, the manufacture, use, sale or importation by or on behalf of Exact of the Product in the Territory or the\n",
            "performance of any Product Laboratory Service by or on behalf of Exact (i) does not infringe any issued patent or\n",
            "intellectual property right of any Third Party in the Territory\n",
            "38\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "or (ii) will not infringe any claim of any published patent application of any Third Party in the Territory when and if such\n",
            "claim issues? and\n",
            "(g)\n",
            "Exact is not presently engaged in any discussions with any Third Party with respect to the grant to any Third Party of and\n",
            "does not currently have any agreement with any Third Party to grant any right or license to make, use, import, offer for\n",
            "sale or sell any Product, in the Territory, in each case, which would constitute a grant of Ex-US Commercial Rights or\n",
            "OB/Gyn Commercial Rights.\n",
            "Doc1  10.1.6 there is no action, suit or proceeding pending or, to the knowledge of Dova, threatened, against Dova or\n",
            "any of its Affiliates, or to the knowledge of Dova, any Third Party acting on their behalf, which would be reasonably expected to\n",
            "impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement?\n",
            "\n",
            "\n",
            "Doc2  5.3. Covenants. (a)\n",
            "Each Party hereby covenants to the other Party that, during the Term in the Territory:\n",
            "(i)\n",
            "it will immediately remove any Sales Representative from having any responsibilities relating to Promotion of the\n",
            "Product under this Agreement if required by Applicable Laws, including if such Party determines that such\n",
            "Sales Representative is Debarred/Excluded?\n",
            "(ii)\n",
            "it will promptly remove any Sales Representative from having any responsibilities relating to the Promotion of the\n",
            "Product under this Agreement if, following an investigation, it is determined that there has been a significant\n",
            "violation of any Applicable Laws, or the Party's Applicable Compliance/Review Policies by such Sales\n",
            "Representative? and\n",
            "(iii)\n",
            "it will not knowingly make any untrue or misleading statements or comments about the Product.\n",
            "(b)\n",
            "Pfizer hereby covenants to Exact that, during the Term in the Territory, it, its Affiliates and its Sales Representatives will not (i)\n",
            "Promote the Product outside of the Territory or the Co-Promote Field? or (ii) disparage or present in a negative light the\n",
            "Product in the performance of its obligations hereunder? \n",
            "provided\n",
            " that nothing herein shall be interpreted to preclude\n",
            "Pfizer from (A) describing any risks of a Product set forth in the Product Label or (B) making truthful statements about\n",
            "the Products to the extent required by Applicable Laws, in connection with any litigation or in response to any question,\n",
            "inquiry or request for information when required by legal process (\n",
            "e.g.\n",
            ", a valid subpoena or other similar compulsion of\n",
            "law) or as part of a government investigation.\n",
            "(c)\n",
            "Exact hereby covenants that neither Exact nor its Affiliates shall sue Pfizer and its Affiliates under any Exact Patent Rights\n",
            "solely with respect to any activities carried out by Pfizer or its Affiliates under, and to the extent in compliance with, this\n",
            "Agreement, including its and their activities to Promote and Detail the Product in the Co-Promote Field in the Territory\n",
            "during the Term of this Agreement and in compliance with this Agreement.\n",
            "39\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Doc1  2.1. . During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product\n",
            "in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account\n",
            "management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance\n",
            "with the terms and conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the right for Dova and\n",
            "its Affiliates to promote the Product in the Territory including in the Specialty. Valeant shall have no other rights relating to the\n",
            "Product, except as specifically set forth in this Agreement and, without limiting the foregoing, except as set out in Section 4.1.5, if\n",
            "agreed upon, Valeant shall have no right to, and shall not, conduct the Valeant Activities for the Product outside the Specialty or\n",
            "outside the Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant's rights and obligations under this Section\n",
            "\n",
            "\n",
            "Doc2  5.4. Compliance with Law and Ethical Business Practices.  In addition to the other representations, warranties and covenants made by\n",
            "each Party under this Agreement, each Party hereby represents, warrants and covenants to the other Party that, during the Term\n",
            "in the Territory:\n",
            "(a)\n",
            "it is, and will remain during the Term, licensed, registered and/or qualified under Applicable Law to do business, and has\n",
            "obtained such licenses, consents, authorizations or completed such registration or made such notifications as may be\n",
            "necessary or required by Applicable Law to perform its obligations under this Agreement?\n",
            "(b)\n",
            "it will perform its obligations under this Agreement in material compliance with this Agreement and any applicable Annual\n",
            "Marketing Plan, its Applicable Compliance/Review Policies and Applicable Laws (including the FD&C Act, the Anti-\n",
            "Kickback Statute (42 U.S.C. SS 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. SS 1320a-7a), the False Claims Act (31\n",
            "U.S.C. SS 3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes, and the\n",
            "regulations issued by the FDA)?\n",
            "(c)\n",
            "in connection with the activities contemplated by this Agreement, to each Party's knowledge, it has been, and during the Term\n",
            "will be, in compliance with all applicable U.S. trade laws, including those related to, import controls, export controls, or\n",
            "economic sanctions?\n",
            "(d)\n",
            "it will ensure its own compliance with all Applicable Laws?\n",
            "(e)\n",
            "with respect to the Product and any payments or services provided under this Agreement, such Party has not taken, and\n",
            "during the Term will not take, any action, directly or indirectly, to offer, promise or pay, or authorize the offer or payment\n",
            "of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official in order\n",
            "to gain an improper advantage, and has not accepted, and will not accept in the future such payment?\n",
            "(f)\n",
            "each Party hereby certifies that it has implemented and will maintain and enforce a compliance and ethics program designed to\n",
            "prevent and detect violations of Applicable Laws throughout its operations (including Affiliates) and the operations of\n",
            "its Representatives that have responsibility for Product, payments, or services provided under the Agreement, including\n",
            "by implementing policies and procedures setting out rules governing interactions with healthcare professionals and\n",
            "Government Officials? the engagement of third parties, and where appropriate, due diligence? and the investigation,\n",
            "documentation, and remediation of any allegations, findings, or reports related to a potential violation of its Applicable\n",
            "Compliance/Review Policies. Such compliance program shall include at a minimum, compliance officer, compliance\n",
            "committee(s), policies and procedures relating to (i) sales, medical, Promotional and Marketing activities for the Product,\n",
            "(ii) regular auditing and monitoring, (iii) training\n",
            "40\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "on sales, medical, Promotional and Marketing activities and the relevant legal requirements regarding such activities, (iv)\n",
            "methods to raise questions or concerns internally (e.g., via a hotline) without fear of retribution or retaliation, (v)\n",
            "processes for investigating and documenting any compliance concerns or allegations raised, findings or reports related\n",
            "to a potential violation of Applicable Laws, and (vi) taking remedial, corrective action and/or disciplinary action, as\n",
            "appropriate?\n",
            "(g)\n",
            "has implemented, and will maintain and enforce, a system of internal accounting controls designed to ensure the making and\n",
            "keeping of fair and accurate books, records, and accounts with respect to products, payments, or services provided\n",
            "under this Agreement, and regularly monitors and audits its business activities to ensure compliance with its Applicable\n",
            "Compliance/Review Policies and the adequacy of internal controls, and implements remediation in response to identified\n",
            "issues?\n",
            "(h)\n",
            "it will (A) maintain truthful and complete documentation supporting, in reasonable detail, the work performed and any\n",
            "expenses incurred in connection with this Agreement and any products, payments, or services provided under this\n",
            "Agreement and (B) maintain financial books and records that timely, fairly, accurately, and completely reflect all financial\n",
            "transactions, in accordance with all Applicable Laws (for example, invoices, reports, statements, books, and other\n",
            "records), and shall maintain such books and records during the Term of the Agreement and for three years after final\n",
            "payment has been made under the Agreement?\n",
            "(i)\n",
            "it provides, and during the Term will provide, training to Representatives providing services in connection with this\n",
            "Agreement?\n",
            "(j)\n",
            "every year of this Agreement that coincides with the term of the Corporate Integrity Agreement (\"\n",
            "\") entered into on May\n",
            "23, 2018 between Pfizer and the United States Department of Health and Human Services, Office of Inspector General,\n",
            "Pfizer will send a letter to Exact that: (A) summarizes Pfizer's obligations under the CIA, (B) expresses Pfizer's\n",
            "commitment to full compliance with all federal health care program requirements, (C) describes the Pfizer Compliance\n",
            "Program and (D) includes a copy of (or includes a link to) Pfizer's code of conduct (referred to as the Blue Book). Within\n",
            "thirty (30) days of receipt of this letter, Exact shall respond in writing to the contact information included in Pfizer's letter\n",
            "that Exact shall: (1) make Pfizer's code of conduct and a description of the Pfizer Compliance Program available to its\n",
            "employees engaged in activities related to the Agreement or (2) represent to Pfizer that it has and enforces a\n",
            "substantially comparable code of conduct and compliance program for its employees who have responsibilities related\n",
            "to the Agreement? and\n",
            "(k)\n",
            "with respect to the Product and any payments made or services provided under this Agreement:\n",
            "41\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(i)\n",
            "in the event that such Party receives a report of or otherwise becomes aware of a potential violation of its Applicable\n",
            "Compliance/Review Policies, the Party will perform an investigation in accordance with its established policies\n",
            "and procedures and will take all necessary and appropriate responsive, and corrective actions, including\n",
            "disciplinary actions (up to and including termination of any employee, contractor, agent, sub-contractor,\n",
            "customer, vendor or other Person that the Party believes was responsible)?\n",
            "(ii)\n",
            "such Party has implemented, and will at all times during the Term maintain, adequate policies and procedures\n",
            "describing the materials and information that may be distributed or discussed by the Party's Sales\n",
            "Representatives related to the Product and the manner in which such Persons should handle unsolicited\n",
            "requests for information related to off-label uses of the Product, which policies and procedures shall be\n",
            "designed to ensure compliance with Applicable Laws and regulations?\n",
            "(iii)\n",
            "such Party regularly reviews its Applicable Compliance/Review Policies as part of its internal processes of\n",
            "improvement, and, from time to time, benchmarks them against the standards of the industry?\n",
            "(iv)\n",
            "such Party has implemented, and will at all times during the Term maintain, adequate systems, policies, and\n",
            "procedures to screen before hire and annually thereafter all prospective and current Representatives\n",
            "conducting activities with respect to the Product against (A) the List of Excluded Individuals/Entities compiled\n",
            "by the Office of the Inspector General in the Department of Health and Human Services and (B) the General\n",
            "Services Administration's List of Parties Excluded from Federal Programs, which policies and procedures\n",
            "require each Party's prospective and current Representatives conducting activities with respect to the Product\n",
            "to disclose immediately to the Party that such Representative is or may become Debarred/Excluded?\n",
            "(v)\n",
            "neither Party shall provide funding to the other Party for charitable donations to independent charities that provide\n",
            "financial assistance to patients, including sharing costs associated with such donations? provide information\n",
            "to the other Party concerning its own such donations? or seek to obtain information about such donations from\n",
            "the other Party. Each Party shall have appropriate policies and procedures to ensure that such donations\n",
            "comply with Applicable Law and current government guidance, including without limitation guidance issued\n",
            "by the U.S. Department of Health and Human Services, Office of Inspector General, and shall operate\n",
            "consistent with those policies and procedures. Unless a Party does not and will not make such donations\n",
            "during the Term of the Agreement, if a Party does not have appropriate policies and procedures in place on\n",
            "42\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "the Effective Date, the Party must implement such policies and procedures within thirty (30) days of the\n",
            "Effective Date. Either Party may request copies of such policies and procedures of the other Party in order to\n",
            "confirm compliance with the requirements of this Section?\n",
            "(vi)\n",
            "certifies that in connection with this Agreement, such Party's compensation system for its Representatives that\n",
            "perform any Marketing, Promotion, or sales activities related to the Product is designed to ensure that financial\n",
            "incentives do not inappropriately motivate such Representative to engage in improper or illegal Promotion,\n",
            "sales or Marketing of the Product (including off-label Promotion of the Product), and excludes from Incentive\n",
            "Compensation sales that may be attributable to the off-label use of the Product? and\n",
            "(vii)\n",
            "in connection with this Agreement, each Party's call planning system for its Sales Representatives that call upon\n",
            "health care professionals or health care institutions for any Promotional or sales activities related to the\n",
            "Product is designed to ensure that such Sales Representatives do not call upon health care professionals or\n",
            "health care institutions that are not likely to prescribe or use the Product for an on-label use.\n",
            "Doc1  Applicable Laws \" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind\n",
            "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this\n",
            "Agreement, including, as applicable, the Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. SS 335a et seq.), the Anti-\n",
            "Kickback Statute (42 U.S.C. SS 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal\n",
            "False Claims Act (31 U.S.C. SSSS 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the\n",
            "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for\n",
            "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the\n",
            "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by\n",
            "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)\n",
            "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (iii) governing consumer\n",
            "2\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time\n",
            "to time.\n",
            "\n",
            "Doc2  5.5. Notice of Investigations.  Each Party shall promptly notify the other Party in the event that it becomes subject to or aware of any FDA\n",
            "or other Governmental Authority inspection, investigation, or other inquiry or a FDA warning letter, untitled letter, or other\n",
            "material governmental notice or communication relating to the services or products covered by this Agreement promptly after the\n",
            "Party becomes aware of such inspection, investigation, inquiry, letter, notice, or communication, except to the extent that the\n",
            "disclosing Party's counsel reasonably believes that such disclosure to the other Party could violate Applicable Laws (including\n",
            "privacy laws) or have a significant adverse impact on the disclosing Party's legal position or defense (including the loss of\n",
            "attorney-client privilege) with respect to any such inspection, investigation or other inquiry. In the event that the Party\n",
            "determines that disclosure could violate Applicable Laws (including privacy laws) or have a significant adverse impact on the\n",
            "disclosing Party's legal position or defense (including the loss of attorney-client privilege), the Party shall promptly notify the\n",
            "other Party that it is exercising its right not to make such disclosure.\n",
            "Doc1  9.1.2. . Notwithstanding the obligations set forth in Section 9.1.1, a Party may disclose the other Party's Confidential Information and the terms of this Agreement to the extent:\n",
            "(a)\n",
            "such disclosure is reasonably necessary (x) to comply with the requirements of Governmental\n",
            "Authorities? or (y) for the prosecuting or defending litigation as contemplated by this Agreement?\n",
            "(b)\n",
            "such disclosure is reasonably necessary to its Affiliates, employees, agents, consultants and contractors\n",
            "on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement? provided\n",
            "that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this\n",
            "Agreement and the disclosing Party shall be liable for any failures of such disclosees to abide by such obligations of confidentiality\n",
            "and non-use? or\n",
            "(c)\n",
            "such disclosure is reasonably necessary to comply with Applicable Laws, including regulations\n",
            "promulgated by applicable securities exchanges, court order, administrative subpoena or order.\n",
            "Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party's\n",
            "Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of\n",
            "such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party's cost) in obtaining, a\n",
            "protective order preventing or limiting the required disclosure.\n",
            "\n",
            "\n",
            "Doc2  5.6. Representation by Legal Counsel.  Each Party hereto represents that it has been represented by legal counsel in connection with this\n",
            "Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions\n",
            "of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party which drafted such terms and\n",
            "provisions.\n",
            "Doc1  13.14. . Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement\n",
            "shall be construed against the drafting Party shall not apply.\n",
            "\n",
            "\n",
            "Doc2  5.7. No Inconsistent Agreements.  Neither Party shall enter into any oral or written agreement or arrangement that would be inconsistent\n",
            "with its obligations under this Agreement.\n",
            "43\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Doc1  12.6.  Survival.. 43. ARTICLE 13 MISCELLANEOUS 43\n",
            "\n",
            "Doc2  5.8. Disclaimer.  THE FOREGOING WARRANTIES OF EACH PARTY ARE IN LIEU OF ANY OTHER WARRANTIES, EXPRESS OR\n",
            "IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF NONINFRINGEMENT, ANY IMPLIED WARRANTIES OF\n",
            "MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE ALL OF WHICH ARE\n",
            "Doc1  10.3. Disclaimer of Warranty. . EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, DOVA (AND ITS AFFILIATES) AND VALEANT (AND ITS AFFILIATES) MAKE NO\n",
            "REPRESENTATIONS AND NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF\n",
            "LAW, BY STATUTE OR OTHERWISE, AND DOVA (AND ITS AFFILIATES) AND VALEANT (AND ITS AFFILIATES)\n",
            "EACH SPECIFICALLY DISCLAIM ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN\n",
            "OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY,\n",
            "MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE\n",
            "VALIDITY OF ANY INTELLECTUAL PROPERTY OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL\n",
            "\n",
            "Doc2  HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED.. 6.. INDEMNIFICATION? LIMITATION OF LIABILITY AND INSURANCE.. 6.1. Indemnification. (a)\n",
            "Doc1  11.1.  Indemnification by Dova.. 39. 11.2.  Indemnification by Valeant.. 39. 11.3.  Indemnification Procedures.. 40. 11.4.  Limitation of Liability.. 40. 11.5.  Insurance.. 40. ARTICLE 12 TERM AND TERMINATION 41\n",
            "\n",
            "Doc2  Indemnification by Exact.  Exact shall indemnify, defend and hold Pfizer, its Affiliates and their respective Representatives (the\n",
            "\"\n",
            "Doc1  11.2. . Valeant shall defend, indemnify and hold harmless Dova and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims and all\n",
            "associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any\n",
            "misrepresentation or breach of any representations, warranties, agreements or covenants of Valeant under this Agreement, or (b)\n",
            "the negligence, willful misconduct, or violation of Applicable Laws by Valeant (or any of its Affiliates or its and their respective\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "officers, directors, employees, agents or representatives)? except in each case to the extent any such Claims, and all associated\n",
            "Losses, are caused by an item for which Dova is obligated to indemnify Valeant pursuant to Section 11.1.\n",
            "\n",
            "\n",
            "Doc2  Pfizer Indemnitees \") harmless from any claims, damages, actions, liabilities, losses, costs and expenses, including\n",
            "attorneys' fees incurred in defending against them, (hereinafter \"\n",
            "\") of a Third Party arising out of (A) the\n",
            "manufacture, Marketing, education, Promotion, importation or use of the Product or the performance of the Product\n",
            "Laboratory Service by Exact or its Representatives? (B) any breach by Exact of any of its representations, warranties or\n",
            "obligations under this Agreement? or (C) any negligent or wrongful act or omission of Exact? and (D) any alleged patent\n",
            "infringement, regardless of direct, contributory or inducement, by Pfizer, its Affiliates or their respective Representatives,\n",
            "as a result of the performance of Pfizer's obligations under this Agreement? except, in each case (A) - (D), to the extent\n",
            "such Claims arise out of any breach by any Pfizer Indemnitee of any of its obligations under this Agreement, or any\n",
            "negligent or wrongful act or omission of any Pfizer Indemnitee.\n",
            "(b)\n",
            "Doc1  11.1. . Dova shall defend, indemnify and hold harmless Valeant and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims, and all\n",
            "associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any\n",
            "misrepresentation or breach of any representations, warranties, agreements or covenants of Dova under this Agreement, (b) the\n",
            "negligence, willful misconduct or violation of Applicable Laws by Dova (or any of its Affiliates or its or their respective officers,\n",
            "directors, employees, agents or representatives), (c) the infringement of the intellectual property rights of any Third Party in\n",
            "connection with the Product, including from the use of the Dova Trademarks and Copyrights on Product Labeling or Product\n",
            "Materials in accordance with this Agreement, (d) death or personal injury to any person related to use of the Product, or (e) the\n",
            "failure to comply with Applicable Laws by the Specialty Pharmacies, applicable reimbursement hub or any 501(c)(3) charitable\n",
            "foundation used in connection with the Product? except in each case to the extent any such Claims, and all associated Losses, are\n",
            "caused by an item for which Valeant is obligated to indemnify Dova pursuant to Section 11.2.\n",
            "\n",
            "\n",
            "Doc2  Indemnification by Pfizer.  Pfizer shall indemnify, defend and hold Exact, its Affiliates and their respective Representatives (the\n",
            "\"\n",
            "Doc1  11.2. . Valeant shall defend, indemnify and hold harmless Dova and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims and all\n",
            "associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any\n",
            "misrepresentation or breach of any representations, warranties, agreements or covenants of Valeant under this Agreement, or (b)\n",
            "the negligence, willful misconduct, or violation of Applicable Laws by Valeant (or any of its Affiliates or its and their respective\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "officers, directors, employees, agents or representatives)? except in each case to the extent any such Claims, and all associated\n",
            "Losses, are caused by an item for which Dova is obligated to indemnify Valeant pursuant to Section 11.1.\n",
            "\n",
            "\n",
            "Doc2  Exact Indemnitees \"), harmless from any Claims of a Third Party, to the extent arising out of (i) any breach by Pfizer of\n",
            "any of its representations, warranties, or obligations under this Agreement or (ii) any negligent or wrongful act or\n",
            "omission of Pfizer, except to the extent such Claims arise out of any breach by any Exact Indemnitee of any of its\n",
            "obligations under this Agreement, or any negligent or wrongful act or omission of any Exact Indemnitee? \n",
            "provided\n",
            " that\n",
            "in no event shall Pfizer have any obligation to indemnify Exact for any product liability claim arising out of bodily injury\n",
            "or death arising from the use of the Product.\n",
            "(c)\n",
            "Doc1  11.1. . Dova shall defend, indemnify and hold harmless Valeant and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims, and all\n",
            "associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any\n",
            "misrepresentation or breach of any representations, warranties, agreements or covenants of Dova under this Agreement, (b) the\n",
            "negligence, willful misconduct or violation of Applicable Laws by Dova (or any of its Affiliates or its or their respective officers,\n",
            "directors, employees, agents or representatives), (c) the infringement of the intellectual property rights of any Third Party in\n",
            "connection with the Product, including from the use of the Dova Trademarks and Copyrights on Product Labeling or Product\n",
            "Materials in accordance with this Agreement, (d) death or personal injury to any person related to use of the Product, or (e) the\n",
            "failure to comply with Applicable Laws by the Specialty Pharmacies, applicable reimbursement hub or any 501(c)(3) charitable\n",
            "foundation used in connection with the Product? except in each case to the extent any such Claims, and all associated Losses, are\n",
            "caused by an item for which Valeant is obligated to indemnify Dova pursuant to Section 11.2.\n",
            "\n",
            "\n",
            "Doc2  Procedure. (i)\n",
            "A Party believing that it is entitled to indemnification under Section 6.1 (an \"\n",
            "\") shall give prompt\n",
            "written notification to the other Party (the \"\n",
            "\") of the commencement of any Claim by a Third\n",
            "Party for which indemnification may be sought or, if earlier, upon the assertion of any such Claim by a Third\n",
            "Party (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a\n",
            "Third Party Claim as provided\n",
            "44\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "in this Section 6.1(c) shall not relieve the Indemnifying Party of its indemnification obligation under this\n",
            "Agreement except and only to the extent that such Indemnifying Party is actually materially prejudiced as a\n",
            "result of such failure to give notice). Within thirty (30) days after delivery of such notification, the Indemnifying\n",
            "Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Claim\n",
            "with counsel reasonably satisfactory to the Indemnified Party. If a Party believes that a Claim presented to it for\n",
            "indemnification is one as to which the Party seeking indemnification is not entitled to indemnification under\n",
            "Section 6.1, it shall so notify the Party seeking indemnification.\n",
            "(ii)\n",
            "If the Indemnifying Party elects to assume the defense of such Claim, the Indemnified Party may participate in such\n",
            "defense at its own expense? \n",
            "provided\n",
            " that if the Indemnified Party reasonably concludes, based on advice from\n",
            "counsel, that the Indemnifying Party and the Indemnified Party have conflicting interests with respect to such\n",
            "Claim, the Indemnifying Party shall be responsible for the reasonable fees and expenses of counsel to the\n",
            "Indemnified Party solely in connection therewith.\n",
            "(iii)\n",
            "The Indemnifying Party shall keep the Indemnified Party advised of the status of such Claim and the defense thereof\n",
            "and shall consider recommendations made by the Indemnified Party with respect thereto.\n",
            "(iv)\n",
            "The Indemnified Party shall not agree to any settlement of such Claim without the prior written consent of the\n",
            "Indemnifying Party, which shall not be unreasonably withheld. The Indemnifying Party shall not agree to any\n",
            "settlement of such Claim or consent to any judgment in respect thereof that does not include a complete and\n",
            "unconditional release of the Indemnified Party from all liability with respect thereto or that imposes any liability\n",
            "or obligation on the Indemnified Party or adversely affects the Indemnified Party without the prior written\n",
            "consent of the Indemnified Party, which shall not be unreasonably withheld.\n",
            "Doc1  11.3. . The Party seeking indemnification under Section 11.1 or 11.2, as applicable (the \"\n",
            "\n",
            "\") shall give prompt notice to the Party against whom indemnity is sought (the \"\n",
            "\") of the\n",
            "assertion or commencement of any Claim in respect of which indemnity may be sought under Section 11.1 or 11.2, as applicable,\n",
            "and will provide the Indemnifying Party such information with respect thereto that the Indemnifying Party may reasonably request.\n",
            "The failure to give such notice will relieve the Indemnifying Party of any liability hereunder only to the extent that the Indemnifying\n",
            "Party has suffered actual prejudice thereby. The Indemnifying Party shall assume and control the defense and settlement of any\n",
            "such action, suit or proceeding at its own expense. The Indemnified Party shall, if requested by the Indemnifying Party, cooperate\n",
            "in all reasonable respects in such defense, at the Indemnifying Party's expense. The Indemnified Party will be entitled at its own\n",
            "expense to participate in such defense and to employ separate counsel for such purpose. For so long as the Indemnifying Party is\n",
            "diligently defending any proceeding pursuant to this Section 11.3, the Indemnifying Party will not be liable under Section 11.1 or\n",
            "\n",
            "Doc2  6.2. Insurance Requirements.  Each Party agrees to obtain and maintain, during the Term and for five (5) years after the Term, commercial\n",
            "general liability insurance, including products liability insurance, with minimum \"A-\" AM Best rated insurance carriers, in each\n",
            "case with limits of not less than five million dollars ($5,000,000) per occurrence and in the aggregate. All deductibles/retentions\n",
            "will be the responsibility of the named insured. Pfizer and its Affiliates will be an additional insured on Exact's commercial general\n",
            "liability and products liability policies, and be provided with a waiver of subrogation. To the extent of its culpability, all coverages\n",
            "of Exact will be primary and non-contributing with any similar insurance carried by Pfizer. Notwithstanding any provision of this\n",
            "Section 6.2 to the contrary, Pfizer may meet its obligations under this Section 6.2 through self-insurance.\n",
            "45\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Neither Party's insurance will be construed to create a limit of liability with respect to its indemnification obligations under this\n",
            "Section 6.\n",
            "Doc1  11.5. . Each Party acknowledges and agrees that during the Term, it shall maintain, through purchase or self- insurance, adequate insurance, including products liability coverage and comprehensive general liability insurance, adequate to\n",
            "cover its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly\n",
            "situated. Each Party shall provide reasonable written proof of the existence of such insurance to the other Party upon request.\n",
            "Dova does not and will not maintain or procure any worker's compensation, healthcare, or other insurance for or on behalf of any\n",
            "Field Force Personnel, all of which shall be Valeant's sole responsibility. For clarity, the insurance requirements of this Section 11.5\n",
            "shall not be construed to create a limit of either Party's liability with respect to its indemnification obligations under this ARTICLE\n",
            "\n",
            "\n",
            "Doc2  6.3. Limitation of Liability.  NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, EXCEPT FOR (A)\n",
            "INDEMNIFICATION OBLIGATIONS OF A PARTY UNDER SECTION 6.1, (B) A BREACH OF SECTION 7 BY A PARTY OR (C)\n",
            "THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL\n",
            "BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR\n",
            "CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, LOST REVENUES OR PENALTIES ARISING FROM OR\n",
            "RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH\n",
            "Doc1  11.4. . NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN (OTHER THAN AS SET FORTH IN THE SECOND SENTENCE OF THIS SECTION 11.4), IN NO EVENT SHALL DOVA (OR\n",
            "ITS AFFILIATES) OR VALEANT (OR ITS AFFILIATES) BE LIABLE TO THE OTHER OR ANY OF THE OTHER\n",
            "PARTY'S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR\n",
            "EXEMPLARY DAMAGES (INCLUDING LOST PROFITS) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR\n",
            "ITS AFFILIATES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR IN CONNECTION WITH A\n",
            "BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT, STRICT LIABILITY\n",
            "OR OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE\n",
            "FOREGOING SENTENCE SHALL NOT LIMIT (1) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE\n",
            "OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER SECTION 11.1 OR 11.2, AS APPLICABLE,\n",
            "OR (2) DAMAGES AVAILABLE FOR A PARTY'S BREACH OF THE CONFIDENTIALITY AND NON-USE\n",
            "\n",
            "\n",
            "Doc2  DAMAGES.. 7.. CONFIDENTIALITY? PUBLICITY.. 7.1. Confidentiality.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, for\n",
            "the term of this Agreement and for five (5) years thereafter, each Party (the \"\n",
            "\"), receiving any Confidential\n",
            "Information of the other Party (the \"\n",
            "\") hereunder shall keep such Confidential Information confidential and shall\n",
            "not publish or otherwise disclose or use such Confidential Information for any purpose other than as provided for in this\n",
            "Agreement. \"\n",
            "\" means any technical, scientific, regulatory, commercial, business or other information\n",
            "provided by or on behalf of the Disclosing Party to the Receiving Party pursuant to this Agreement or otherwise relating to or\n",
            "disclosed during any transaction contemplated hereby (including information disclosed prior to the Effective Date under a\n",
            "confidentiality agreement in contemplation of this Agreement), including information relating to the terms of this Agreement or\n",
            "the Product, and the scientific, regulatory or business affairs or other activities of either Party? \n",
            "provided\n",
            " that, Confidential\n",
            "Information shall not include any information that the Receiving Party can establish:\n",
            "(a)\n",
            "was already known to the Receiving Party (other than under an obligation of confidentiality), at the time of disclosure by the\n",
            "Disclosing Party and such Receiving Party has documentary evidence to that effect?\n",
            "(b)\n",
            "was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party?\n",
            "(c)\n",
            "became generally available to the public or otherwise part of the public domain after its disclosure or development, as the case\n",
            "may be, and other than through any act or omission of a Party in breach of this confidentiality obligation?\n",
            "(d)\n",
            "was disclosed to that Party, other than under an obligation of confidentiality, by a Third Party who had no obligation, directly\n",
            "or indirectly, to the Disclosing Party, not to disclose such information to others? or\n",
            "46\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(e)\n",
            "was independently discovered or developed by or on behalf of the Receiving Party without the use of the Confidential\n",
            "Information belonging to the other Party and the Receiving Party has documentary evidence to that effect.\n",
            "Doc1  9.1. .. 9.1.1. . Each Party agrees that, during the Term and for a period of [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in\n",
            "this Agreement (which includes the exercise of its rights or performance of any obligations hereunder) any Confidential Information\n",
            "furnished to it by or on behalf of the other Party pursuant to this Agreement, except to the extent expressly authorized by this\n",
            "Agreement or otherwise agreed in writing by the Parties. Without limiting the foregoing, each Party will use at least the same\n",
            "standard of care as it uses to protect its own Confidential Information to ensure that its employees, agents, consultants and\n",
            "contractors do not disclose or make any unauthorized use of such Confidential Information. Each Party will promptly notify the\n",
            "other upon discovery of any unauthorized use or disclosure of the other's Confidential Information. Any and all information and\n",
            "materials disclosed by a Party pursuant to the Confidentiality Agreement between the Parties dated [***] (the \"Confidentiality\n",
            "\n",
            "\") shall be deemed Confidential Information disclosed pursuant to this Agreement. The foregoing confidentiality and\n",
            "non-use obligations shall not apply to any portion of the other Party's Confidential Information that the receiving Party can\n",
            "demonstrate by competent tangible evidence:\n",
            "(a)\n",
            "was already known to the receiving Party or its Affiliate, other than under an obligation of\n",
            "confidentiality, at the time of disclosure by the other Party?\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "(b)\n",
            "was generally available to the public or otherwise part of the public domain at the time of its disclosure\n",
            "to the receiving Party?\n",
            "(c)\n",
            "became generally available to the public or otherwise part of the public domain after its disclosure and\n",
            "other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement?\n",
            "(d)\n",
            "was disclosed to the receiving Party or its Affiliate by a Third Party who has a legal right to make such\n",
            "disclosure and who did not obtain such information directly or indirectly from the other Party (or its Affiliate)? or\n",
            "(e)\n",
            "was independently discovered or developed by the receiving Party or its Affiliate without access to or\n",
            "aid, application, use of the other Party's Confidential Information, as evidenced by a contemporaneous writing.\n",
            "\n",
            "Doc2  7.2. Authorized Disclosure and Use. (a)\n",
            "Doc1  9.1.2. . Notwithstanding the obligations set forth in Section 9.1.1, a Party may disclose the other Party's Confidential Information and the terms of this Agreement to the extent:\n",
            "(a)\n",
            "such disclosure is reasonably necessary (x) to comply with the requirements of Governmental\n",
            "Authorities? or (y) for the prosecuting or defending litigation as contemplated by this Agreement?\n",
            "(b)\n",
            "such disclosure is reasonably necessary to its Affiliates, employees, agents, consultants and contractors\n",
            "on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement? provided\n",
            "that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this\n",
            "Agreement and the disclosing Party shall be liable for any failures of such disclosees to abide by such obligations of confidentiality\n",
            "and non-use? or\n",
            "(c)\n",
            "such disclosure is reasonably necessary to comply with Applicable Laws, including regulations\n",
            "promulgated by applicable securities exchanges, court order, administrative subpoena or order.\n",
            "Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party's\n",
            "Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of\n",
            "such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party's cost) in obtaining, a\n",
            "protective order preventing or limiting the required disclosure.\n",
            "\n",
            "\n",
            "Doc2  Disclosure.  Notwithstanding the foregoing Section 7.1, each Party may disclose to Third Parties Confidential Information\n",
            "belonging to the other Party to the extent such disclosure is reasonably necessary to:\n",
            "(i)\n",
            "prosecute or defend litigation,\n",
            "(ii)\n",
            "exercise or enforce rights hereunder? \n",
            "provided\n",
            " that such disclosure is covered by terms of confidentiality no less\n",
            "stringent than those set forth herein, and\n",
            "(iii)\n",
            "comply with inquires by a Governmental Authority or subpoena issued by a Governmental Authority or a court of\n",
            "competent jurisdiction.\n",
            "In the event a Party shall deem it necessary to disclose pursuant to this Section 7.2 Confidential Information belonging\n",
            "to the other Party, the Disclosing Party shall to the extent possible give reasonable advance notice of such disclosure to\n",
            "the other Party and take reasonable measures to ensure confidential treatment of such information.\n",
            "(b)\n",
            "Doc1  9.1.2. . Notwithstanding the obligations set forth in Section 9.1.1, a Party may disclose the other Party's Confidential Information and the terms of this Agreement to the extent:\n",
            "(a)\n",
            "such disclosure is reasonably necessary (x) to comply with the requirements of Governmental\n",
            "Authorities? or (y) for the prosecuting or defending litigation as contemplated by this Agreement?\n",
            "(b)\n",
            "such disclosure is reasonably necessary to its Affiliates, employees, agents, consultants and contractors\n",
            "on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement? provided\n",
            "that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this\n",
            "Agreement and the disclosing Party shall be liable for any failures of such disclosees to abide by such obligations of confidentiality\n",
            "and non-use? or\n",
            "(c)\n",
            "such disclosure is reasonably necessary to comply with Applicable Laws, including regulations\n",
            "promulgated by applicable securities exchanges, court order, administrative subpoena or order.\n",
            "Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party's\n",
            "Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of\n",
            "such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party's cost) in obtaining, a\n",
            "protective order preventing or limiting the required disclosure.\n",
            "\n",
            "\n",
            "Doc2  Use.  Notwithstanding the foregoing Section 7.1, during the Term, each Party shall have the right to use the other Party's\n",
            "Confidential Information in carrying out its respective responsibilities under this Agreement.\n",
            "Doc1  9.1. .. 9.1.1. . Each Party agrees that, during the Term and for a period of [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in\n",
            "this Agreement (which includes the exercise of its rights or performance of any obligations hereunder) any Confidential Information\n",
            "furnished to it by or on behalf of the other Party pursuant to this Agreement, except to the extent expressly authorized by this\n",
            "Agreement or otherwise agreed in writing by the Parties. Without limiting the foregoing, each Party will use at least the same\n",
            "standard of care as it uses to protect its own Confidential Information to ensure that its employees, agents, consultants and\n",
            "contractors do not disclose or make any unauthorized use of such Confidential Information. Each Party will promptly notify the\n",
            "other upon discovery of any unauthorized use or disclosure of the other's Confidential Information. Any and all information and\n",
            "materials disclosed by a Party pursuant to the Confidentiality Agreement between the Parties dated [***] (the \"Confidentiality\n",
            "\n",
            "\") shall be deemed Confidential Information disclosed pursuant to this Agreement. The foregoing confidentiality and\n",
            "non-use obligations shall not apply to any portion of the other Party's Confidential Information that the receiving Party can\n",
            "demonstrate by competent tangible evidence:\n",
            "(a)\n",
            "was already known to the receiving Party or its Affiliate, other than under an obligation of\n",
            "confidentiality, at the time of disclosure by the other Party?\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "(b)\n",
            "was generally available to the public or otherwise part of the public domain at the time of its disclosure\n",
            "to the receiving Party?\n",
            "(c)\n",
            "became generally available to the public or otherwise part of the public domain after its disclosure and\n",
            "other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement?\n",
            "(d)\n",
            "was disclosed to the receiving Party or its Affiliate by a Third Party who has a legal right to make such\n",
            "disclosure and who did not obtain such information directly or indirectly from the other Party (or its Affiliate)? or\n",
            "(e)\n",
            "was independently discovered or developed by the receiving Party or its Affiliate without access to or\n",
            "aid, application, use of the other Party's Confidential Information, as evidenced by a contemporaneous writing.\n",
            "\n",
            "Doc2  7.3. Certain Regulatory Filings.  Either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of\n",
            "such Party's legal counsel, to comply with Applicable Laws, including the rules and regulations promulgated by the United\n",
            "States Securities and Exchange Commission or by any stock exchange or regulatory body to which the Party is subject. Before\n",
            "disclosing this Agreement or any of the terms hereof pursuant to this Section 7.3, the Parties will consult with one another\n",
            "regarding the terms in this Agreement to be redacted in making any such disclosure. If a Party discloses this Agreement or any of\n",
            "the terms hereof in accordance with this Section 7.3, such Party agrees, at its own expense, to seek confidential treatment of\n",
            "portions of this Agreement or such terms, as may be reasonably requested by the other Party.\n",
            "Doc1  9.1.2. . Notwithstanding the obligations set forth in Section 9.1.1, a Party may disclose the other Party's Confidential Information and the terms of this Agreement to the extent:\n",
            "(a)\n",
            "such disclosure is reasonably necessary (x) to comply with the requirements of Governmental\n",
            "Authorities? or (y) for the prosecuting or defending litigation as contemplated by this Agreement?\n",
            "(b)\n",
            "such disclosure is reasonably necessary to its Affiliates, employees, agents, consultants and contractors\n",
            "on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement? provided\n",
            "that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this\n",
            "Agreement and the disclosing Party shall be liable for any failures of such disclosees to abide by such obligations of confidentiality\n",
            "and non-use? or\n",
            "(c)\n",
            "such disclosure is reasonably necessary to comply with Applicable Laws, including regulations\n",
            "promulgated by applicable securities exchanges, court order, administrative subpoena or order.\n",
            "Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party's\n",
            "Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of\n",
            "such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party's cost) in obtaining, a\n",
            "protective order preventing or limiting the required disclosure.\n",
            "\n",
            "\n",
            "Doc2  7.4. Public Announcements.  The Parties shall agree upon a joint press release to announce the execution of this Agreement, a copy of\n",
            "which is attached as Exhibit 7.4.Neither Party shall issue any news release or other public announcement relating to this\n",
            "Agreement except as set forth in Exhibit 7.4, including any of its terms, or to the performance of either Party hereunder, without\n",
            "the prior written approval of the other Party? \n",
            "provided\n",
            " that nothing in this Agreement shall prohibit Exact from making required\n",
            "disclosures or filings required by Applicable Law or by the rules\n",
            "47\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "and regulations of any securities exchange. Once the text or substance of any announcement has been so approved, it may be\n",
            "repeated without further approval.\n",
            "Doc1  9.2. . The press release announcing the execution of this Agreement shall be issued in the form attached hereto as Exhibit A. No public announcement or statements (including presentations to investor meetings and customer\n",
            "updates) concerning the existence of or terms of this Agreement or incorporating the marks of the other Party or their respective\n",
            "Affiliates shall be made, either directly or indirectly, by either Party or a Party's Affiliates, without first obtaining the written\n",
            "approval of the other Party and agreement upon the nature, text and timing of such announcement or disclosure. Either Party shall\n",
            "have the right to make any such public announcement or other disclosure required by Applicable Law after such Party has\n",
            "provided to the other Party a copy of such announcement or disclosure and an opportunity to comment thereon and the disclosing\n",
            "Party shall reasonably consider the other Party's comments. Each Party agrees that it shall cooperate fully with the other with\n",
            "respect to all disclosures regarding this Agreement to the Securities Exchange Commission and any other Governmental\n",
            "Authorities, including requests for confidential treatment of proprietary information of either Party included in any such disclosure.\n",
            "Once any written statement is approved for disclosure by the Parties or information is otherwise made public in accordance with\n",
            "this Section 9.2, either Party may make a subsequent public disclosure of the same contents of such statement in the same context\n",
            "as such statement without further approval of the other Party. Notwithstanding anything to the contrary contained herein, in no\n",
            "event shall either Party disclose any financial information of the other without the prior written consent of such other Party, unless\n",
            "such financial information already has been publicly disclosed by the Party owning the financial information or otherwise has been\n",
            "made part of the public domain by no breach of a Party of its obligations under this ARTICLE 9.\n",
            "8\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "\n",
            "Doc2  7.5. Use of Names.  Except as described in this Agreement and as may be required by Applicable Law, neither Party shall distribute or have\n",
            "distributed any publicity or information which bears the name of the other without the prior written approval of the other.\n",
            "Doc1  13.15. . Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for\n",
            "any purpose in connection with the performance of this Agreement.\n",
            "\n",
            "\n",
            "Doc2  8.. TERM AND TERMINATION.. 8.1. Term.  This Agreement shall be effective as of the Effective Date and shall continue in effect through December 31, 2021 and any\n",
            "Renewal Term (the \"\n",
            "\"), unless terminated earlier as set forth herein.\n",
            "Doc1  11.. 12.1. . This Agreement shall become effective as of the Effective Date and, unless earlier terminated as provided in this ARTICLE 12, shall extend until the four (4) year anniversary of the Effective Date (the \"\n",
            "\n",
            "\").\n",
            "\n",
            "Doc2  8.2. Renewal.  This Agreement may be renewed for an additional one year term (\"\n",
            "\") upon mutual written agreement of the\n",
            "Parties. Ninety (90) days prior to the beginning of the Renewal Term, or as far in advance as practicable if the Parties agree to a\n",
            "Renewal Term less than ninety (90) days prior the commencement of such Renewal Term, the Parties shall agree to a Baseline\n",
            "Laboratory Service Revenue, Baseline M&P Expenses and Shared M&P Expenses for the Renewal Term. All other terms of this\n",
            "Agreement shall remain the same through the Renewal Term.\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  8.3. Termination for Cause.  This Agreement may be terminated at any time by either Party effective:\n",
            "(a)\n",
            "upon thirty (30) days prior written notice if the other Party fails to make the required investments pursuant to Sections 3.5 or\n",
            "Doc1  3.2. . Meetings of the JSC may be called by either Party on no less than thirty (30) days' notice during the Term. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to\n",
            "such proposed items at least ten (10) days in advance to the applicable meeting? provided that under exigent circumstances\n",
            "requiring input by the JSC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the\n",
            "meeting, or may propose that there not be a specific agenda for that particular meeting, so long as the other Party consents to such\n",
            "later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably\n",
            "withheld. The chairperson shall prepare and circulate for review and approval of the Parties minutes of each meeting within thirty\n",
            "(30) days after the meeting. Each Party shall bear its own costs for its members to attend such meetings.\n",
            "\n",
            "\n",
            "Doc2  3.6, as applicable, or pay any amount properly due under this Agreement?  provided\n",
            " that neither Party may terminate if\n",
            "the failure of the other Party to meet the investment requirements under Sections 3.5 or 3.6, as applicable, is \n",
            "de minimis\n",
            "or not material?\n",
            " provided, further, \n",
            "that any such termination shall only become effective if the allegedly breaching Party\n",
            "fails to remedy or cure such breach or default prior to the end of such thirty (30) day period. If, prior to the end of such\n",
            "thirty (30) day period, the allegedly breaching Party remedies or cures such breach or default to the reasonable\n",
            "satisfaction of the non-breaching Party, this Agreement shall remain in full force and effect?\n",
            "(b)\n",
            "upon sixty (60) days prior written notice if the other Party materially breaches its representations, warranties or obligations\n",
            "under this Agreement? \n",
            "provided, however, \n",
            "that any such termination shall only become effective if the allegedly\n",
            "breaching Party fails to remedy or cure such breach or default prior to the end of such sixty (60) day period. If, prior to\n",
            "the end of such sixty (60) day period, the allegedly breaching Party remedies or cures such breach or default to the\n",
            "reasonable satisfaction of the non-breaching Party, this Agreement shall remain in full force and effect?\n",
            "48\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "(c)\n",
            "immediately upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an\n",
            "assignment of a substantial portion of the assets for the benefit of creditors by the other Party? \n",
            "provided, however,\n",
            " that\n",
            "in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party\n",
            "consents to the involuntary bankruptcy? or\n",
            "(d)\n",
            "immediately upon notice to the other Party, if such Party (the \"\n",
            "\n",
            "\") is convicted of violating any Applicable Law,\n",
            "including applicable anti-corruption laws, bribery and corruption of public officials as well as private persons and\n",
            "entities, in connection with its activities under this Agreement and such violation materially adversely affects the ability\n",
            "of either Party to perform its obligations under this Agreement. The Violating Party shall be liable for damages or\n",
            "remedies as provided by law.\n",
            "Doc1  12.2.7 by a Party immediately upon written notice to the other Party upon the filing or institution of bankruptcy,\n",
            "reorganization, liquidation or receivership proceedings with respect to such other Party, or upon an assignment of a substantial\n",
            "portion of the assets for the benefit of creditors by such other Party, or in the event a receiver or custodian is appointed for such\n",
            "other Party's business or a substantial portion of such other Party's business is subject to attachment or similar process? provided,\n",
            "however, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the party\n",
            "consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof.\n",
            "\n",
            "\n",
            "Doc2  8.4. Termination Without Cause.  After the date that is eighteen (18) months after the Effective Date, either Party may terminate this\n",
            "Agreement upon six (6) months prior written notice to the other Party.\n",
            "Doc1  12.3. .. 12.3.1 Either Party shall have the right to terminate this Agreement before the end of the Term for its convenience\n",
            "upon [***] written notice to the other Party (and any such termination shall become effective at the end of such [***])? [***].\n",
            "\n",
            "\n",
            "Doc2  8.5. Mutual Termination.  This Agreement may be terminated at any time by mutual written consent of the Parties.\n",
            "Doc1  Parties \".\n",
            "\n",
            "Doc2  8.6. Termination for Change of Control.  This Agreement may be terminated by either Party upon six (6) months written notice following a\n",
            "Change of Control of Exact? \n",
            "provided\n",
            " that such notice is given within thirty (30) days of the consummation of such Change of\n",
            "Control.\n",
            "Doc1  3.2. . Meetings of the JSC may be called by either Party on no less than thirty (30) days' notice during the Term. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to\n",
            "such proposed items at least ten (10) days in advance to the applicable meeting? provided that under exigent circumstances\n",
            "requiring input by the JSC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the\n",
            "meeting, or may propose that there not be a specific agenda for that particular meeting, so long as the other Party consents to such\n",
            "later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably\n",
            "withheld. The chairperson shall prepare and circulate for review and approval of the Parties minutes of each meeting within thirty\n",
            "(30) days after the meeting. Each Party shall bear its own costs for its members to attend such meetings.\n",
            "\n",
            "\n",
            "Doc2  8.7. Royalty Upon Expiration.  After the expiration of the Term or termination pursuant to Section 8.4 by either Party or Section 8.6 by Exact,\n",
            "based on cumulative Incremental Laboratory Services Revenue achieved during the Term or up to the termination date, Exact\n",
            "agrees to pay Pfizer the applicable royalty payment set forth below for twelve (12) consecutive Calendar Quarters following the\n",
            "expiration of the Term (the \"\n",
            "\")? \n",
            "provided\n",
            ", \n",
            "however\n",
            ", the Tail Period shall be reduced to the number of full Calendar\n",
            "Quarters completed during the Term if less than twelve (12) Calendar Quarters if either Party terminates the Agreement without\n",
            "cause pursuant to Section 8.4 or Exact terminates as a result of a Change of Control pursuant to Section 8.6. Such royalty\n",
            "payment shall be payable to Pfizer within thirty (30) days of the end of each Calendar Quarter. Royalty payments shall be\n",
            "determined by multiplying the Laboratory Services Revenue and the applicable royalty rate from the chart below.\n",
            "Cumulative Incremental Laboratory\n",
            "Services Revenue during the Term\n",
            "Applicable Royalty Rate\n",
            "If < $200 million\n",
            "0%\n",
            "If > $200 million and < $400 million\n",
            "1%\n",
            "If > $400 million and < $600 million\n",
            "2%\n",
            "If > $600 million\n",
            "3%\n",
            "49\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "For example, if the cumulative Incremental Laboratory Services Revenue achieved during the Term is $500 million, the applicable\n",
            "royalty rate is 2%. The royalty payable by Exact to Pfizer at the end of each Calendar Quarter after the Term is 2% of Laboratory\n",
            "Service Revenues for the applicable Calendar Quarter.\n",
            "Doc1  6.2. . In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand\n",
            "Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the\n",
            "Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\n",
            "\n",
            "\n",
            "Doc2  8.8. Consequences of Termination. (a)\n",
            "In the event of any termination under this Agreement, (i) Pfizer shall have no obligation to invest Shared M&P Expenses\n",
            "pursuant to Section 3.5 as of the effective date of the termination (except as set forth below), (ii) Pfizer shall cease to\n",
            "make any commitments under Section 3.2(d) as of the date of notice of termination, unless Exact notifies Pfizer pursuant\n",
            "to Section 8.8(b) and (iii) neither Party shall have any obligation to reimburse the other Party for any expenses for\n",
            "activities conducted after the effective date of such termination unless such expenses were incurred prior to termination.\n",
            "Notwithstanding the above, Exact agrees to pay any financial commitment made by Pfizer pursuant to Section 3.2(d) and\n",
            "Exhibit 3.2(d) to Third Parties following the effective date of termination? \n",
            "provided\n",
            " that such amounts conform with the\n",
            "then-current Annual Marketing Plan, including the budget.\n",
            "(b)\n",
            "Exact shall use commercially reasonable efforts to provide six (6) month notice prior to the expiry of the Term, or in the case of\n",
            "termination by Pfizer under Section 8.4, within the applicable notice period in advance of the effective date of such\n",
            "termination, that Exact intends for Pfizer to continue providing Advertising services for the Product pursuant to Section\n",
            "Doc1  12.6. . Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Notwithstanding any expiration or termination of this Agreement,\n",
            "such expiration or termination shall not relieve any Party from obligations which are expressly or by implication intended to survive\n",
            "expiration or termination, including Sections 2.3, , 4.4.2, 5.7, 5.9, 6.3.6, 6.3.5, 11.1, 11.2, 11.3, 11.4, 12.4, 12.5 and 12.6,\n",
            "Articles 7, 8, 9 and 13 (to the extent applicable to implementation of the survival of the preceding Sections and Articles) and,\n",
            "solely as it relates to the last Calendar Quarter, Sections 6.1, 6.2 and 6.3, which shall survive and be in full force and effect.\n",
            "\n",
            "\n",
            "Doc2  3.2(d). Thereafter, the Parties will use good faith efforts to agree to the Advertising services that will be provided by Pfizer during the Tail Period in accordance with Section 3.2(d) and Exhibit 8.8(b). For clarity, Pfizer's obligation to provide\n",
            "Advertising services during the Tail Period is limited to the expiry of the Term or termination by Pfizer pursuant to\n",
            "Section 8.4, or termination by Exact pursuant to Section 8.3.\n",
            "(c)\n",
            "In the event Exact terminates this Agreement for cause pursuant to Section 8.3 or Pfizer terminates this Agreement without\n",
            "cause pursuant to Section 8.4, Exact shall not be obligated to pay Pfizer a supplemental Promotion Fee pursuant to\n",
            "Section 4.2(c) for the Calendar Year, or any portion of such Calendar Year in which such termination occurs.\n",
            "\n",
            "Doc1  12.5. . Solely in the event that Dova has terminated this Agreement pursuant to Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion services performed by Valeant during the Term, with respect\n",
            "to the Tail Period, Dova shall make payments to Valeant in an amount equal to [***] of the amounts that would have been payable\n",
            "by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had the Agreement not been so terminated. Such\n",
            "payments shall be made within [***] following the end of each calendar quarter in the Tail Period. Sections 6.3, 6.4 and 6.5 shall\n",
            "apply, \n",
            "mutatis mutandis\n",
            ", to such Tail Period payments. For clarity, no tail payment shall be due following any expiration or\n",
            "termination of this Agreement except as set forth in this Section 12.5.\n",
            "\n",
            "\n",
            "Doc2  8.9. Survival of Certain Obligations.  Expiration or termination of the Agreement shall not relieve the Parties of any obligation accruing\n",
            "before such expiration or termination, and the provisions of Sections 1 (Definitions), 2.5 (Alliance Managers), 3.2(d)\n",
            "(Advertising), 3.2(e)(iii) (Return of Training Materials), 3.2(j) (Customer Service Activities? Safety Reporting), 4.4 (Taxes and\n",
            "Withholding)? 4.7 (Maintenance of Records? Audits), 6 (Indemnification? Limitation of Liability? Insurance), 7 (Confidentiality?\n",
            "Publicity)? 8 (Term and Termination) and 9 (Miscellaneous) inclusive, shall survive the expiration of the Agreement. Any\n",
            "expiration or early termination of this Agreement shall be without prejudice to the\n",
            "50\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "rights of either Party against the other accrued or accruing under this Agreement before termination.\n",
            "Doc1  12.6. . Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Notwithstanding any expiration or termination of this Agreement,\n",
            "such expiration or termination shall not relieve any Party from obligations which are expressly or by implication intended to survive\n",
            "expiration or termination, including Sections 2.3, , 4.4.2, 5.7, 5.9, 6.3.6, 6.3.5, 11.1, 11.2, 11.3, 11.4, 12.4, 12.5 and 12.6,\n",
            "Articles 7, 8, 9 and 13 (to the extent applicable to implementation of the survival of the preceding Sections and Articles) and,\n",
            "solely as it relates to the last Calendar Quarter, Sections 6.1, 6.2 and 6.3, which shall survive and be in full force and effect.\n",
            "\n",
            "\n",
            "Doc2  9.. MISCELLANEOUS.. 9.1. Interpretation.  Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to encompass\n",
            "references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the\n",
            "words \"include\", \"includes\" and \"including\" will be deemed to be followed by the phrase \"without limitation\", (c) the word \"will\"\n",
            "will be construed to have the same meaning and effect as the word \"shall\", (d) any reference herein to any Person will be\n",
            "construed to include the Person's successors and assigns, (e) the words \"herein\", \"hereof\" and \"hereunder\", and words of\n",
            "similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (f) all\n",
            "references herein to Sections or Exhibits will be construed to refer to Sections or Exhibits of this Agreement, and references to\n",
            "this Agreement include all Exhibits hereto, (g) the word \"notice\" means notice in writing (whether or not specifically stated) and\n",
            "will include notices, consents, approvals and other written communications contemplated under this Agreement, (h) provisions\n",
            "that require a Party, the Parties or any committee hereunder to \"agree,\" \"consent\" or \"approve\" or the like will require that such\n",
            "agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise\n",
            "(but excluding text and instant messaging), (i) references to any specific law, rule or regulation, or article, section or other division\n",
            "thereof, will be deemed to include any amendments thereto or any replacement or successor law, rule or regulation thereof, and (j)\n",
            "the term \"or\" will be interpreted in the inclusive sense commonly associated with the term \"and/or.\"\n",
            "Doc1  13.17. . Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Exhibit, of or to, as the case\n",
            "may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words of any\n",
            "gender include each other gender, (b) words such as \"herein\", \"hereof\", and \"hereunder\" refer to this Agreement as a whole and\n",
            "not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice\n",
            "versa, (d) whenever any provision of this Agreement uses the term \"including\" (or \"includes\"), such term shall be deemed to mean\n",
            "\"including without limitation\" (or \"includes without limitations\"), and (e) references to any Articles or Sections include Sections and\n",
            "subsections that are part of the references' Article or Section (e.g., a section numbered \"Section 2.2.1\" would be part of \"Section\n",
            "\n",
            "\n",
            "Doc2  9.2. Assignment.  This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or\n",
            "transferred, by either Party without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may,\n",
            "without consent of the other Party, assign this Agreement and its rights and obligations hereunder in whole or in part to an\n",
            "Affiliate of such Party, or in whole to its successor in interest in connection with the sale of all or substantially all of its stock or\n",
            "its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction. Any attempted\n",
            "assignment not in accordance with the foregoing shall be null and void and of no legal effect. Any permitted assignee shall\n",
            "assume all assigned obligations of its assignor under this Agreement. The terms and conditions of this Agreement shall be\n",
            "binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns.\n",
            "Doc1  13.2. . Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other\n",
            "Party (such consent not to be unreasonably withheld)? provided that a merger, sale of stock or comparable transaction shall not\n",
            "constitute an assignment. In the event either Party desires to make such an assignment or other transfer of this Agreement or any\n",
            "rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party's written\n",
            "consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination\n",
            "whether to provide such written consent within [***] following its receipt of such written notice from such Party. Notwithstanding\n",
            "the foregoing, (a) either Party may, without the other Party's consent, assign this Agreement and its rights and obligations hereunder\n",
            "in whole or in part to an Affiliate? and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or\n",
            "other transfer of all or substantially all of Dova's assets or rights relating to the Product? provided that such assignee shall remain\n",
            "subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing\n",
            "before or after such assignment. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.\n",
            "Any attempted assignment not in accordance with this Section 13.2 shall be void. This Agreement shall be binding on, and inure to\n",
            "the benefit of, each Party, and its permitted successors and assigns.\n",
            "\n",
            "\n",
            "Doc2  9.3. Further Actions.  Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may\n",
            "be necessary or appropriate in order to carry out the purposes and intent of the Agreement.\n",
            "Doc1  13.16. . Each Party agrees to execute, acknowledge and deliver all such further Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "instruments, and to do all such further acts, as may be reasonably necessary or appropriate to carry out the intent and purposes of\n",
            "this Agreement.\n",
            "\n",
            "\n",
            "Doc2  9.4. Force Majeure.  Each Party will be excused from the performance of its obligations under this Agreement to the extent that such\n",
            "performance is prevented by force\n",
            "51\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse\n",
            "will be continued so long as the condition constituting force majeure continues and the nonperforming Party takes commercially\n",
            "reasonable efforts to remove the condition? \n",
            "provided\n",
            " that if any delay in performance due to force majeure continues for a period\n",
            "of six (6) months or more, then the other Party will have the right to terminate this Agreement immediately upon written notice.\n",
            "For purposes of this Agreement, \"force majeure\" will include conditions beyond the control of the Parties, including an act of\n",
            "God, voluntary or involuntary compliance with any regulation, law or order of any government, war, act of terror, civil commotion,\n",
            "labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or\n",
            "materials by fire, earthquake, storm or like catastrophe.\n",
            "Doc1  13.1. . Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "caused by or results from causes beyond the reasonable control of the affected Party, potentially including, embargoes, war, acts of\n",
            "war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor\n",
            "disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any Governmental Authority. The affected\n",
            "Party shall notify the other Party of such force majeure circumstances as soon as reasonably practicable, and shall promptly\n",
            "undertake all reasonable efforts necessary to cure such force majeure circumstances and re-commence its performance hereunder\n",
            "as soon as practicable.\n",
            "\n",
            "\n",
            "Doc2  9.5. Notices.  All notices and other communications required or permitted hereunder (including any notice of force majeure, breach,\n",
            "termination, change of address, etc.) shall be in writing and will be deemed given (a) upon receipt if delivered personally or by\n",
            "facsimile transmission (receipt verified), (b) five (5) days after being deposited in the mail if mailed by registered or certified mail\n",
            "(return receipt requested) postage prepaid or (c) on the next Business Day if sent by overnight delivery using a nationally\n",
            "recognized express courier service and specifying next Business Day delivery (receipt verified), and will be sent to the Parties at\n",
            "the following addresses or facsimile numbers, as applicable, (or at such other address or facsimile number for a Party as will be\n",
            "specified by like notice? \n",
            "provided\n",
            ", however, that notices of a change of address will be effective only upon receipt thereof):\n",
            "All correspondence to Pfizer shall be addressed as follows:\n",
            "Pfizer Inc.\n",
            "235 East 42nd Street\n",
            "New York, New York 10017 Attn: General Counsel\n",
            "Fax: (212) 309-0874\n",
            "With a copy to:\n",
            "Pfizer Inc.\n",
            "235 East 42  Street\n",
            "New York, New York 10017\n",
            "Attn: Regional President, North America, Internal Medicine\n",
            "And\n",
            "Pfizer Inc.\n",
            "235 East 42  Street\n",
            "New York, New York 10017\n",
            "Attn: Chief Counsel, Internal Medicine\n",
            "All correspondence to Exact shall be addressed as follows:\n",
            "52\n",
            "nd\n",
            "nd\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Exact Sciences Corporation\n",
            "441 Charmany Drive\n",
            "Madison, Wisconsin 53719\n",
            "Attn: General Counsel\n",
            "Fax: (608) 284-5701\n",
            "With a copy to:\n",
            "Exact Sciences Corporation\n",
            "441 Charmany Drive\n",
            "Madison, Wisconsin 53719\n",
            "Attn: CEO\n",
            "Doc1  Business Day \" means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in\n",
            "New York, New York, USA are closed.\n",
            "\n",
            "Doc2  9.6. Amendment.  No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in\n",
            "a writing signed by a duly authorized officer of each Party and delivered to each of the Parties.\n",
            "Doc1  Senior Officer \" shall mean, with respect to Dova, its President and Chief Executive Officer (or such officer's\n",
            "designee), and with respect to Valeant, its [***] (or such officer's designee). From time to time, each Party may change its Senior\n",
            "Officer by giving written notice to the other Party.\n",
            "\n",
            "Doc2  9.7. Waiver.  No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except\n",
            "by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The\n",
            "failure of either Party to require the performance of any term of this Agreement, or the waiver of either Party of any breach of this\n",
            "Agreement, shall not prevent a subsequent exercise or enforcement of such terms or be deemed a waiver of any subsequent\n",
            "breach of the same or any other term of this Agreement.\n",
            "Doc1  13.12. . The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of\n",
            "such other Party whether of a similar nature or otherwise.\n",
            "\n",
            "\n",
            "Doc2  9.8. Severability.  If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same\n",
            "shall not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in\n",
            "such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this\n",
            "Agreement shall be construed as if such clause of portion thereof had never been contained in this Agreement, and there shall be\n",
            "deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement\n",
            "to the fullest extent permitted by Applicable Law.\n",
            "Doc1  13.3. . If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected\n",
            "or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The\n",
            "Parties shall in such an instance use reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal\n",
            "and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.\n",
            "\n",
            "\n",
            "Doc2  9.9. Descriptive Headings.  The descriptive headings of this Agreement are for convenience and reference purposes only, and shall be of\n",
            "no force or effect in construing or interpreting any of the provisions of this Agreement.\n",
            "Doc1  3.3.16 perform such other responsibilities as may be mutually agreed upon by the Parties in writing from time to\n",
            "time? provided, however, for clarity the JSC shall have no authority to amend or modify any provisions of this Agreement and no\n",
            "authority to waive or definitively interpret the provisions of this Agreement.\n",
            "\n",
            "\n",
            "Doc2  9.10. Governing Law.  This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of New\n",
            "York, without regard to conflict of law principles thereof.\n",
            "Doc1  13.5. . This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with the internal laws of the [***] applicable to agreements made and to be performed\n",
            "entirely in such state, including its statutes of limitation but without giving effect to the conflict of law principles thereof.\n",
            "\n",
            "\n",
            "Doc2  9.11. Dispute Resolution.  The Parties recognize that a bona fide dispute as to certain matters may from time to time arise during the term of\n",
            "this Agreement that relate to any Party's rights or obligations hereunder. In the event of the occurrence of any dispute arising out\n",
            "of or relating to this Agreement (other than a Disputed JSC\n",
            "53\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Matter, which shall be resolved as provided in Section 2.1, a Disputed JOC Matter, which shall be resolved as provided in Section\n",
            "Doc1  13.6. .. 13.6.1. . Except for disputes resolved by the procedures set forth in Section. 3.4, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a \"\n",
            "\n",
            "\"), then either Party shall have the right to refer such dispute to the Senior Officers\n",
            "who shall confer within [***] after such Dispute was first referred to them to attempt to resolve the Dispute by good faith\n",
            "negotiations. Any final decision mutually agreed to by the Senior Officers in writing shall be conclusive and binding on the Parties. If\n",
            "such Senior Officers do not agree on the resolution of an issue within [***] after such issue was first referred to them, either Party\n",
            "may, by written notice to the other Party, initiate arbitration for resolution of such Dispute pursuant to Section 13.6.2.\n",
            "\n",
            "Doc2  2.2 and Disputed JRC Matter, which shall be resolved as provided in Section 2.3), including any question regarding its existence, validity or termination (a \"Dispute\"), any Party may, by written notice to the other, have such Dispute referred to their respective\n",
            "Senior Officer or such Senior Officer's designee, for attempted resolution by good faith negotiations within thirty (30) days after\n",
            "such notice is received. Any negotiations regarding a Dispute are confidential and shall be treated as compromise and settlement\n",
            "negotiations for purposes of the U.S. Federal Rules of Evidence and any similar rules of evidence.\n",
            "\n",
            "Doc1  13.6. .. 13.6.1. . Except for disputes resolved by the procedures set forth in Section. 3.4, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a \"\n",
            "\n",
            "\"), then either Party shall have the right to refer such dispute to the Senior Officers\n",
            "who shall confer within [***] after such Dispute was first referred to them to attempt to resolve the Dispute by good faith\n",
            "negotiations. Any final decision mutually agreed to by the Senior Officers in writing shall be conclusive and binding on the Parties. If\n",
            "such Senior Officers do not agree on the resolution of an issue within [***] after such issue was first referred to them, either Party\n",
            "may, by written notice to the other Party, initiate arbitration for resolution of such Dispute pursuant to Section 13.6.2.\n",
            "\n",
            "Doc2  9.12. Entire Agreement of the Parties.  This Agreement constitutes and contains the complete, final and exclusive understanding and\n",
            "agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and\n",
            "agreements, whether oral or written, among the Parties respecting the subject matter hereof and thereof.\n",
            "Doc1  13.8. . This Agreement, together with the Schedules and Exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and\n",
            "understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof (including the\n",
            "Confidentiality Agreement, but solely with respect to information which is deemed Confidential Information hereunder) are\n",
            "superseded by the terms of this Agreement. The Exhibits to this Agreement are incorporated herein by reference and shall be\n",
            "deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly\n",
            "executed by authorized representative(s) of both Parties hereto.\n",
            "\n",
            "\n",
            "Doc2  9.13. Independent Contractors.  Both Parties are independent contractors under this Agreement. Nothing herein contained shall be deemed\n",
            "to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or\n",
            "employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other\n",
            "Party. Neither Party shall have any express or implied power to enter into any contracts or commitments or to incur any liabilities\n",
            "in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. Neither Party shall have any\n",
            "responsibility for the hiring, termination, compensation or benefits of the other Party's employees.\n",
            "Doc1  13.10. . It is expressly agreed that Valeant and Dova shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Valeant nor Dova shall\n",
            "have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be\n",
            "binding on the other Party, without the prior written consent of the other Party.\n",
            "\n",
            "\n",
            "Doc2  9.14. No Legal Advice.  Each Party acknowledges and agrees that the other Party and the other Party's attorneys are not representing such\n",
            "Party during the course of or in connection with any activities under this Agreement and that, unless otherwise expressly agreed\n",
            "in writing by the other Party's attorneys, any opinions expressed by the other Party or the other Party's attorneys with respect to\n",
            "any marketing or promotional materials or the activities of either Party under this Agreement shall not be considered to be legal\n",
            "advice regardless of whether or not related to a legal or regulatory matter.\n",
            "Doc1  9.1. .. 9.1.1. . Each Party agrees that, during the Term and for a period of [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in\n",
            "this Agreement (which includes the exercise of its rights or performance of any obligations hereunder) any Confidential Information\n",
            "furnished to it by or on behalf of the other Party pursuant to this Agreement, except to the extent expressly authorized by this\n",
            "Agreement or otherwise agreed in writing by the Parties. Without limiting the foregoing, each Party will use at least the same\n",
            "standard of care as it uses to protect its own Confidential Information to ensure that its employees, agents, consultants and\n",
            "contractors do not disclose or make any unauthorized use of such Confidential Information. Each Party will promptly notify the\n",
            "other upon discovery of any unauthorized use or disclosure of the other's Confidential Information. Any and all information and\n",
            "materials disclosed by a Party pursuant to the Confidentiality Agreement between the Parties dated [***] (the \"Confidentiality\n",
            "\n",
            "\") shall be deemed Confidential Information disclosed pursuant to this Agreement. The foregoing confidentiality and\n",
            "non-use obligations shall not apply to any portion of the other Party's Confidential Information that the receiving Party can\n",
            "demonstrate by competent tangible evidence:\n",
            "(a)\n",
            "was already known to the receiving Party or its Affiliate, other than under an obligation of\n",
            "confidentiality, at the time of disclosure by the other Party?\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "(b)\n",
            "was generally available to the public or otherwise part of the public domain at the time of its disclosure\n",
            "to the receiving Party?\n",
            "(c)\n",
            "became generally available to the public or otherwise part of the public domain after its disclosure and\n",
            "other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement?\n",
            "(d)\n",
            "was disclosed to the receiving Party or its Affiliate by a Third Party who has a legal right to make such\n",
            "disclosure and who did not obtain such information directly or indirectly from the other Party (or its Affiliate)? or\n",
            "(e)\n",
            "was independently discovered or developed by the receiving Party or its Affiliate without access to or\n",
            "aid, application, use of the other Party's Confidential Information, as evidenced by a contemporaneous writing.\n",
            "\n",
            "Doc2  9.15. Counterparts.  This Agreement may be executed in two (2) counterparts, each of which will be an original and both of which will\n",
            "constitute together the same document. Counterparts may be signed and delivered by facsimile or digital file, each of which will\n",
            "be binding when received by the applicable Party.\n",
            "(remainder of page intentionally left blank)\n",
            "54\n",
            "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "IN WITNESS WHEREOF, \n",
            "duly authorized representatives of the Parties have duly executed this Agreement to be effective as of the\n",
            "Effective Date.\n",
            "Doc1  2.2\", and references to \"ARTICLE 2\" or \"Section 2.2\" would refer to material contained in the subsection described as \"Section. 2.2.1\").. 13.18. . This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile or\n",
            "electronic mail (including pdf) and any counterpart so delivered shall be deemed to have been duly and validly delivered and be\n",
            "valid and effective for all purposes and shall have the same force and effect as original signatures.\n",
            "[signature page follows]\n",
            "[\n",
            "Signature page to Co-Promotion Agreement\n",
            "]\n",
            "IN WITNESS WHEREOF, \n",
            "the Parties have executed this Agreement as of the Effective Date.\n",
            "DOVA PHARMACEUTICALS, INC.\n",
            "By: __/s/ Alex C. Sapir______________________\n",
            "Name: Alex C. Sapir\n",
            "Title: CEO\n",
            "\n",
            "\n",
            "Doc2  PFIZER INC.. EXACT SCIENCES CORPORATION By /s/ Michael Gladstone\n",
            "By /s/ Kevin Conroy\n",
            "Name: Michael Gladstone\n",
            "Name: Kevin Conroy\n",
            "Title: Global President, Internal Medicine\n",
            "Title: Chairman & Chief Executive Officer\n",
            "Pfizer Innovative Health\n",
            "Doc1  VALEANT PHARMACEUTICALS NORTH AMERICA LLC By: ___/s/ Joseph C. Papa_______________\n",
            "Name: Joseph C. Papa\n",
            "Title: Chief Executive Officer and President\n",
            "9\n",
            "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION\n",
            "SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED\n",
            "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n",
            "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n",
            "\n",
            "Doc2  Signature Page Source: EXACT SCIENCES CORP, 8-K, 8/22/2018\n",
            "Doc1  2.2\", and references to \"ARTICLE 2\" or \"Section 2.2\" would refer to material contained in the subsection described as \"Section. 2.2.1\").. 13.18. . This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile or\n",
            "electronic mail (including pdf) and any counterpart so delivered shall be deemed to have been duly and validly delivered and be\n",
            "valid and effective for all purposes and shall have the same force and effect as original signatures.\n",
            "[signature page follows]\n",
            "[\n",
            "Signature page to Co-Promotion Agreement\n",
            "]\n",
            "IN WITNESS WHEREOF, \n",
            "the Parties have executed this Agreement as of the Effective Date.\n",
            "DOVA PHARMACEUTICALS, INC.\n",
            "By: __/s/ Alex C. Sapir______________________\n",
            "Name: Alex C. Sapir\n",
            "Title: CEO\n",
            "\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "xd6ItUXkDL9V"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}